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Free radicals, such as superoxide, hydroxyl, nitric oxide and other reactive oxygen species, 
like hydrogen peroxide, are formed in vivo. Though nitric oxide, a multi-faceted bioregulatory 
agent produced by many types of cells, is known to play a critical role in both regulatory processes 
and cell defense, yet it also participates in collateral reactions, leading to DNA damage and cell 
death in both nitric oxide generating and neighbouring cells. 
Though many human genetic diseases and cancer are thought to arise from deamination of 
DNA, yet spontaneous (hydrorytic) deamination is extremely unfavourable energenticafly. Certain 
toxic agents may catalyze this reaction and increase the incidence of the genetic disorders. One 
candidate is nitric oxide, a cigarette constituent and environmental pollutant, produced in numerous 
cell types in amounts that can total to 200 millimoles per day per person. This bioregulatory molecule 
can accelerate base deamination, DNA strand breaks, and cause deamination-induced genetic 
changes in the hviug cells. 
Nitric oxide is an imp ort ant mediator ofthe inflammatory reponse. It is a strong proinflammatory 
substance that may increase vascular permeability in inflamed tissues. There is extensive suggestive 
evidence that nitric oxide can participate as mediator of tissue damage in autoimmune diseases. 
Elevated nitric oxide biosynthesis has been associated with chronic inflammatory autoimmune diseases 
including rheumatoid arthritis, inflammatory bowel diseases, glomerulonephritis, vasculitis, multiple 
sclerosis and systemic hipus erythematosus. 
Systemic lupus erythematosus (SLE) is a multisystem, autoimmune disease ofunknown etiology, 
characterised by a broad diversity of clinical features and serum autoantibodies, including antibodies 
to DNA, RNA, ribonucleoproteins, phospholipids, cytoskeletal proteins and histones. The 
mechanisms, whereby these autoantibodies are triggered, remain elusive. The trtre of anti-DNA 
autoantibodies in SLE patients correlate with the disease activity. 
Although antibodies that react with B-conformation are found in sera of patients witi SLE. 
yet B-DNA per se\sa poor immunogen. Ou the other hand, various other conformations of DNA 
such as right-handed A-forai and left-handed Z-form are potentially immunogenic. Also DNA 
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modified with ROS, certain chemicals, in conjugation with the female sex hormone (estradiol) and 
photo-crosslinked with 8-methoxy psoralen have been found to result in production of antibodies. 
The hypothesis that ROS-modification ofDNA is involved in the development of autoantibodies in 
SLE has been supported by the enhanced reactivity of SLE anti-DNA autoantibodies to ROS-
DNA. 
In the preseut study plasmid Bhiescript DH5a"KS" DNA and native calf thymus DNA 
fragments of approximately 200 bp were isolated and subjected to modification with nitric oxide 
radical, generated by reduction of sodium nitrite with sodiurn dithionite. The nitric oxide induced 
modifications in 200 bp DNA were analysed by UV spectroscopic and thermal denaturation studies. 
The modified DNA showed hypochromicity at 260 run as well as shifts in A. and X ., as compared 
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to native 200 bp DNA. The data reflects the presence of single-stranded regions in the modified 
DNA. The Tin of NO-200 bp DNA was found to be 74"C, whereas, native 200 bp DNA showed 
a Tm of 80°C. A net decrease of 6"C in the Tm value of NO-200 bp DNA indicates a partiiil 
destruction of its secondary structure. The single strand breaks, induced in the 200 bp DNA as a 
result of nitric oxide modification, were detected by agarose gel electrophoresis and nuclease S1 
sensitivity assay. The NO-200 bp DNA fragments were employed in competitive assays to delineate 
the epitope recognition of induced antibodies against NO-plasmid DNA. 
The nitric oxide induced modifications in plasmid DNA were analysed by UV and CD 
spectroscopic techniques. The modified plasmid DNA showed hypochromicity as well as shifts in 
k ^ and X as compared to plasmid DNA. thereby reflecting the presence of single-stranded 
regions in the modified plasmid DNA. The single strand breaks induced in the plasmid DNA upon 
nitric oxide modification were further ascertained by agarose gel electrophoresis, nuclease SI 
sensitivity assay and alkaline sucrose density gradient ultracentrifugation. 
The antigenicity ofuitric oxide modified plasmid DNA was probed by inducing antibodies hi 
rabbits. The repertoire of specificities of induced antibodies were evaluated by direct binding and 
competition ELISA. The induced antibodies exhibited poryspecificity. a property commonly associated 
with SLE anti-DNA autoantibodies. Anti-NO plasmid DNA antibo]dies showed preferential 
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recognition ofNO-modified conformers of DNA, nucleic acid polymers and nitrogenous bases in a 
competitive inhibition assay. 
A group of SLE sera were investigated for the evaluation ofauti-DNA autoantibody titre. 
SLE IgGs isolated from sera of twelve patients showing high titre auti-DNA autoantibodies, were 
analysed for their specificity towards native calf thymus DNA by inhibition ELISA. The binding 
specificity of SLE IgGs with NO-modified and native plasmid DNA was analysed by ELISA, gel 
retardation assay and quantitative precipitin titration. Direct binding ELISA results show preferential 
binding of SLE autoantibodies to NO-plasmid DNA in comparison to native plasmid DNA. Inhbkion 
ELISA reiterates the direct buiding results. Gel retardation assay further substantiated die binding of 
native and modified plasmid DNA with anti-DNA autoantibodies. The binding affinity of modified 
and unmodified plasmid DNA with one of the SLE IgGs was calculated, using Langmuir plot. The 
association constant (Ka) for NO-plasmid DNA was found to be higliest, followed by native calf 
thymus DNA and native plasmid DNA, respectively. The antigen binding chract eristics of SLE IgGs 
obtained from different patients were remarkably similar, including their binding to plasmid and N O 
plasmid DNA. The results suggest that the nitric oxide modification of plasmid DNA causes 
perturbations, resulting in die generation ofneo-epitopes, thus making it a potential immuuogen. 
In conclusion, the nitric oxide radical causes extensive damage to plasmid DNA and renders 
it immunogenic. The antibodies against modified plasmid DNA are poryspecific in nature, resembling 
the antigen binding characteristics of SLE anti-DNA autoantibodies. The possibility of nitric oxide 
modified plasmid DNA in the production of SLE anti-DNA autoantibodies has been probed in the 
present study. 
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In 1879, Friedrich Meischer, a Swiss biologist, carried out the first systematic 
chemical studies of cell nuclei. Since then DNA has occupied a centre stage in various 
biochemical investigations. Watson and Crick in 1953 described the right handed double 
helical structure of DNA. In a fully hydrated medium, DNA is found in B form (Langridge 
et al., 1960) which is the most accepted structure of DNA molecule in solution. X-ray 
diffraction studies have shown that a number of variations in conformation of this basic 
structure can occur (Adams et al., 1981). It is well known that the right handed double 
helical DNA can exist in A, B, C and D conformations, whereas the left handed 
polynucleotide can adopt the Z structure (Saenger, 1984), so called because phosphate 
groups in the backbone are zig-zagged (Rich et al.. 1984). Triple stranded nucleic acids 
have been found to exist in DNA using a variety of hydrogen bonding arrangements in the 
major groove of B-DNA(Camerini-Otero andHseih, 1993). Rich in 1958 gave the idea of 
quadruple stranded nucleic acids. The importance of DNA lies in its unique property to 
adopt multiple conformations depending on its bioenvironment. The DNA double helix is 
both deformed and made deformable by its local base sequence, whereas other regions 
may be made especially susceptible to a change in conformation when the helix interacts 
with protein, drug or an adjacent DNA helix in a crystal lattice. The different conformations 
adopted by DNA reflect the enormous versatility that is inherent in the molecule. 
Antigenicity of DNA 
The antigenic property of nucleic acids has received considerable attention 
since 1957, when DNA was identified as a reactant for systemic lupus erythematosus 
(SLE) autoantibodies (Cepellini e/«/.. 1957; Meischer and Strassie, 1957; Kohb'ms et al. 
1957). In the early 1960s, methods were developed for the experimental induction of 
antibodies to nucleic acids (Levine etal., 1960; Erlanger and Beiser, 1964;Plescia eta/.. 
1964; Halloran and Parker, 1966) which until then had been considered widely to be non-
immunogenic. Studies on the antigenic specificity of anti-DNA antibodies have enforced 
the view that DNA is immunologically 'simple and bland'. Exogenous native B-DNA has 
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not been found immunogenic in experimental animals. Immunization of experimental 
animals with denatured DNA, synthetic nucleic acid polymers like poly(dT), poly(dC). 
poly(A), poly(l), poly(G), dsRNA, left-handed Z-DNA, chemically modified DNA, and 
certain helical synthetic polynucleotides with the notable exception of native B-DNA, 
induced antibodies that react selectively with the immunogen and do not crossreact with 
native DNA (Stollar, 1986; Anderson et al., 1988). 
The unique features of the DNA molecule have a direct bearing on its immune 
reactions. In nature it exists in different helical forms, including both right handed (A- and 
B-DNA) and left-handed (Z-DNA) helix (Setlow, 1992). Another feature of DNA antigen 
which distinguishes it from most protein antigens is its multideterminant nature and 
polyanionic character. The helical polymer has hydrophobic core of stacked heterocyclic 
bases and a soluble sugar phosphate backbone with highly acidic phosphate residues. The 
phosphate residues make DNA a notoriously sticky antigen. 
The notion that DNA is immunologically inactive derives primarily from efforts to 
mimic SLE by immunization of normal animals with DNA (Messina et al., 1993). 
Mammalian DNA elicit poor responses to single stranded DNA and fails to induce antibodies 
against native or double stranded DNA, the serologic hallmark of SLE (Madaio et al.. 
1984). However, recent studies have shown that DNA complexes with synthetic peptide 
Fus-I can induce anti-dsDNA response in mice (Desai et al.. 1993). This led to the 
conclusion that antigen drive in lupus involves either a substance other than DNA or DNA 
in a form (e.g., nucleosomes) that is not readily mimicked by artificial complexes 
(Burlingame etal.. 1993; Mohan et al.. 1993). Since the antibody reactivity to both single 
and double stranded forms appears independent of DNA species origin, these findings 
suggest recognition of conserved conformational determinants (e.g., helical backbone of 
B-DNA) aud a lack of DNA sequence microheterogeneity on antigenicity (Stollar, 1975; 
Pisetsky, 1993). Anti-DNA antibodies may also result by autoimmunizatiou with chromatin, 
rather than native DNA (Theofilopoulos, 1995). 
3 
The left handed Z-DNA is an example of a helical DNA that is a much more potent 
immunogen than native B-helical DNA (Lafer et al., 1981; Madaio et al., 1984). The 
antibodies induced by Z-DNA have high degree of selectivity and specificity as they react 
with immunogen but not with B-DNA or ssDNA (Zarling et al., 1984). Chemically or 
physically niodifiad DNA or helical structures that differ significantly from B-DNA are 
much stronger immunologic stimuli than nDNA, and most of the antibodies induced by 
modified nDNA do not react with the unmodified DNA (Anderson et al., 1988a). Calf 
thymus DNA modified with drugs, hormones, free radicals etc, has been reported to induce 
antibodies against the modified polymer (Moinuddin and Ali, 1994; Ara and Ali, 1995; 
Arjumand et al., 1995). Several polynucleotides including poly(A), poly(I), poly(G) and 
poly(C) that differ from the B-helical conformation are much stronger immunogens than 
native B-DNA (Braun and Lee, 1988). Polynucleotides in B-conformation become 
immunogenic after modification with furocoumarins (Arif and Ali, 1996). 
There is a compelling evidence that bacterial DNA, in contrast to mammalian DNA. 
which is poorly immunogenic (Isenberg et al., 1994). induces a variety of responses in 
both normal humans and animals (Pisetsky, 1997). In contrast to the normal dogma that 
anti-DNA antibodies are prevalent in lupus alone, a surprising finding was the recognition 
of bacterial DNA from two species. Micrococcus lysodeikticus and Staphylococcus 
epidermidis and DNA from BK polyoma virus as well, by normal human sera (Karounos 
et al., 1988; Fredriksen et al., 1994; Rekvig et al., 1995). These antibodies had a high 
affinity and did not crossreact with other types of DNA. Antibodies to bacterial DNA in 
human sera are of IgG2 isotype quite distinct from SLE autoantibodies which are 
predominantly IgGl and IgG3 (Zouali et al., 1984; Kay et al., 1988; Pisetsky, 1997; 
Pisetsky and Drayton, 1997; Tsujimura et al., 1997). This pattern of isotype expression 
suggests that the responses to foreign DNA are distinct from the lupus anti-DNA response, 
which appears T cell dependent (Robertson etal., 1992). Studies have also demonstrated 
that complexes of bacterial DNA and MBSA are immunogenic in normal mice (Gilkeson 
et al., 1989) and the induced antibodies show negligible cross reactivity with mammalian 
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DNA(Gilkesone/a/., 1991). Recently, it has been found that sera from normal human subjects 
showed binding to highly purified bacterial dsDNA. A plausible explanation is that bacterial 
DNA can induce antibody production during infection because of sequences rarely present in 
host DNA and. therefore, recognised as foreign (Pisetsky etal.. 1990). In contrast to normal 
mice, autoimmune mice (NZB/NZW), immunized with bacterial or viral DNA. produce 
crossreactive antibodies to mammalian DNA (Fredriksen etal.. 1994;Gilkeson etal.. 1995) 
These antibodies have specificities comparable to spontaneous lupus anti-DNA antibodies 
(Gilkeson etal.. 1993). Thus, the presence ofbacterial DNA sequences in immune complexes 
in lupus sera indicate the possibility of foreign DNA driven immune response. Low molecular 
weight DNA was found in the DNA-anti-DNA complexes of lupus patients and is enriched in 
CG contents (Sauo et al.. 1983). The CG rich DNA regions has the tendency to form 7-
DNA, which is highly immunogenic. 
The immunologic potential of DNA has immediate relevance in the therapeutic 
arena. Both gene therapy and DNA vaccination can entail the administration of large 
quantities of naked DNA. often containing plasmid DNA sequences (Crystal. 1995; Pardoll 
and Beckonleg. 1995). Administration of plasmid DNA expression vectors has been shown 
to result in protein expression in vivo, the generation of humoral and cell mediated immune 
responses and protective efficacy in animal models of infectious diseases (Donnelly etal.. 
1994). DNA vaccine seems to be a broadly applicable technique for generating proteeti\ e 
immune response against viral, parasitic and tumour antigens in animals ranging from 
mice to non-human primates. 
Bacterial DNA has an immunostimulatory property due to the presence of nucleotide 
hexamers contaming unmethylated CpG motifs (Krieg etal., 1995; Sato et al., 1996) and 
it has been recently demonstrated that the amount of unmethylated CpG motifs directly 
correlates with the immunogenicity of DNA vaccines (Klinman et al.. 1997) 
Immunostimulatory sequence (ISS) includes the following CpG containing hexamers 
5'-GACGTC-3\ 5'-AGCGCT-3' and 5'-AACGTT-3\ Plasmid DNA can be divided 
conceptually into two distinct units: a transcription unit that directs antigen synthesis and an 
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adjuvant unit in the plasmid backbone that elicits the production of type-1 IFN and IL-12 in 
transfected skin keratinocytes and antigen presenting cells. Hence manipulation of the 
transcription unit to yield higher levels of antigen expression does not necessarily produce 
stronger immune response. Both the localization and precise sequence of the ISS within 
the plasmid backbone are also important for DNA vaccination (Sato et al.. 1996). 
DNA immunization is also a very promising approach to the formulation of 
multivalent vaccines in which multivalent immunization against several antigens is required 
for protection. However, very little information is available on multiplasmid injections 
In particular, it is not known whether immune responses to individual antigens are 
qualitatively and quantitatively influenced by multiplasmid formulation. Recently, it ha.s 
been reported that multiplasmid DNA vaccination avoids antigenic competition and enhances 
immunogenicity of a poorly immunogenic plasmid vaccine (Grifantini et al.. 1998) . The 
antibody response appears to be strongly potentiated by the presence of additional plasmids. 
indicating an adjuvant effect of DNA. 
Nitric Oxide : A Novel Biological Messenger 
Nitric oxide is an auoxious unstable free radical gas which is an unlikely candidate 
to act as a biological messenger. Space shuttles (Vierecke/ al., 1991 ), jet planes (Johnson 
etai, 1992), automobile exhaust (Ulfvarson etal., 1991), electric power stations, lightening, 
cigarette smoke (Pryor et al., 1985; Bortland and Higenbottam, 1987), Achromobacto 
cycloclastes. Alcaligetis faecales and Bacillus halodenitrificans (Godden et al., 199 I) 
generate oxides of nitrogen. Initially, these compounds had little interest beyond their 
ability to aggravate lung diseases or cure meat. However, in the last few years nitric oxide 
was discovered in the body where it participates in various functions, including supression 
of pathogens, vasodilation and neurotransmission (Marietta, 1989; Ignarro, 1990; Luscher. 
1990;Moncadae/a/., 1991; Luscher, 1992; Lowenstein and Snyder, 1992; Nathan, 1992; 
Stamler *>/«/., 1992). 
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Nitric oxide is formed by nitric oxide synthase (NOS) in an unusual reaction that converts 
arginineand oxygen into citrulline and nitric oxide (White and Marietta. 1992; McMillan era!.. 
1992). Three enzyme isoforms produce nitric oxide (Fostermann et al.. 1990): a neuronal 
nitric oxide synthase (NOS 1) and endothelial NOS (NOS2 and NOS3). The inducible form 
NOS2 is found in many cell types, including mononuclear phagocytes, hepatocytes and 
chondrocytes (Bredt et al.. 1991; Marsdeu etal.. 1992). Hie constitutive isoforms release 
small amounts of nitric oxide for brief periods to signal adjacent cells, whereas the inducible 
isoform releases large amounts of nitric oxide continuously to eliminate bacteria and parasites 
Nitric oxide diffuses out of the cell that generates it and into target cells, where it interacts with 
specific molecular targets (Table 1). 
(a) Nitric oxide in cardiovascular and pulmonary systems 
In 1980. Furchgott and Zawadski discovered that the section of the aorta would 
relax in response to agonists only if the inner lining of endothelial cells were intact. Howev er 
aortic rings with no endothelial cells could not relax. Endothelial cells, thus released an 
agent and this "endothelial-derived relaxation factor" was discovered to be nitric oxide 
(Palmer et al.. 1987). Nitric oxide binds to heme group of guanylate cyclase and hence 
changes the activity of guanylate cyclase which in turn induces smooth muscle relaxation 
Nitric oxide acts as an endogenous autoregulator of blood flow. Ischemia and 
reperfusion cause vasodilation in the affected tissue, which is mediated by nitric oxide 
(WennmalniW al.. 1990, Schror etal.. 1991; Mathies etal., 1992). Shear stress is another 
physical stimulus to which endothelial cells respond by increasing nitric oxide production 
(Buga et al., 1991; Kelm etal., 1991). Nitric oxide not only regulates the systemic blood 
pressure but also the local flow to specific vascular beds (Faraci and Heistad, 1992) including 
the brain (Toda and Okamura, 1990; Tanaka etal., 1991; Faraci and Breese, 1993), kidney 
(Baumanne/a/. , 1992; Ribeiro etal., 1992; Yukimura et al., 1992; Deng and Baylis, 1993). 
luug(Fineman etal., 1991), heart (Amezcua et al., 1989; Chu etal., 1990; Richard etal.. 
1991; Broten et al., 1992; Jones and Brody, 1992) and gastrointestinal tract (Iwata etal.. 
TABLE 1 
Molecular Targets of Nitric Oxide 
Nitric Oxide Target Mechanism 
Molecules 
Targets 
Proteins Binding to heme iron Guanylate cyclase, hemoglobin. 
NADPH-ubiquinone oxido-
reductase, succinate-ubiquinone 
oxidoreductase 
Binding to iron-sulfur Cis-acouitase. ribonucleotide 
reductase 
ADP ribosvlation Glyceraldehyde-3-phosphate 
dehydrogenase 
Nucleic acids 
Radical molecule 
Deamination DNA 
Superoxide 
ADP = adenosine diphosphate; N ADPH = nicotinamide adenine dinucleotide phosphate 
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1992). A local defect in nitric oxide production could cause vasospasm in particular organs 
Endothelial generation of nitric oxide also regulates blood clotting. Nitric oxide 
synthase has been found inside platelets (Radomski et al., 1990a). It reduces clotting by 
inhibiting platelet aggregation ( Radomski et al., 1990b; Pasqui et al., 1991; Vallance et 
al., 1992; Varela et al., 1992; Ivanova et al., 1993) and adhesion (Radomski et al.. 
1987a, b and c; Sneddon and Vane, 1988; Siney and Lewis, 1992; de Graaf et al., 1992) 
The possible molecular basis of this mechanism includes nitric oxide activating platelet 
guanylate cyclase and adenylate cyclase (Yamakado et al., 1982; Gryglewski et al., 1989a. 
Maurice and Haslam, 1990; Bowen and Haslam, 1991; Nolte et al., 1991), inhibiting 
platelet phospholipase C (Durante et al., 1992) or attaching ADP-ribose to platelet 
glyceraldehyde-3-phosphate dehydrogenase (Brune et al., 1990). Excessive amounts of 
nitric oxide due to endotoxin shock during bacterial infection is expected to be responsible 
for hypotension associated with sepsis which can be reversed by treatment with inhibitors 
of inducible form of NOS (Gryglewski etal, 1989b; Kilbourn etal, 1990a and b).Cardiac 
dysfunction of dilated cardiomyopathy is also associated with increased production of 
nitric oxide (de Belder and Radomski, 1993; Winlaw et al., 1994) by venous smooth cells 
(Vallance and Moncada, 1993), myocardium and endocardium (Schulz et al. 1992) and 
due to the activation of the inducible form of NOS by endotoxin. The hyperdynamic state 
of cirrhosis is also associated with vasodilation, hyporesponsiveuess to vasoconstrictors 
and high circulating concentrations of endotoxin (Vallance and Moncada, 1991). Nitric 
oxide has also been reported to play a role in pathophysiology of hypovolemic hemorrhagic 
shock (Zingarelli et al., 1992). 
(b) Nitric oxide as a neurotransmitter 
Abundant evidence indicates that nitric oxide is a neurotransmitter in the peripheral 
and central nervous systems, where it contributes to sensory transmission (Duarte et al., 
1990 ) and may also be the transmitter or a modulator in non-adrenergic and non-cholinergic 
nerves (Rand, 1992). Immunohistochemical studies have localised NOS to discrete neuronal 
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population, such as those in the myentric plexus throughout the gastronitestinal tract (Bredt et 
al., 1990; Saffrey et al., 1992; Young et al., 1992). Nitric oxide has been indicated as a 
neurotransmitter of neurons of the gut segments (Gustafsson et a!., 1990; Sanders er al.. 
1992) and causes gastric relaxation in response to a food bolus as well as relaxation of the 
ileocolonic junction and sphincter (Bult et al., 1990; Desai et al., 1991; Tottrup et al., 
1992). NOS has been detected in varying amounts in all the areas of animal and human 
brain (Forstermaim et al., 1990; Springall et al., 1992). Accumulating evidence indicates 
that nitric oxide plays a part in the formation of memory (Bohme et al., 1991; O'Dell et 
al., 1991; Schuman and Madison, 1991; Shibuki and Okada, 1991). Nitric oxide may also 
have physiological role in vision (Venturini et al., 1991), feeding behaviour (Morley and 
Flood, 1991), nociception (Moore etal., 1991) and olfaction (Breer and Shepherd, 1993) 
in animals. 
Evidence to support the hypothesis that overproduction of nitric oxide might be 
involved in conditions such as cerebral ischemia, epilepsy and cerebral infarction (Dawson 
etal., 1991; Mollace etal., 1991; Nowicki et al., 1991) is still controversial. Microglial 
cells can express the inducible form of NOS (Zielasek et al., 1992) and these cells have 
been implicated in pathogenesis of multiple sclerosis, Alzheimer's disease, Parkinson's 
disease and the dementia of the acquired immunodeficiency syndrome. Nitric oxide appears 
to elicit neurotoxicity by activating poly (adenosine 5'-diphosphoribose) synthase (Zhang 
etal., 1994). 
(c) Nitric oxide as an immune effector 
Monocyte derived macrophages (Denis, 1991a), alveolar macrophages (Sherman 
et al., 1991) and neutrophils (Moncada, 1992) can generate nitric oxide by inducible form 
of NOS. In large quantities nitric oxide kills or inhibits the growth of many pathogens, 
including bacteria (Adams etal., 1991; Denis, 1991b; Fortiere/a/., 1992; Beckermane/o/.. 
1993; Mayer etal., 1993), fungi (Alspaugh and Granger, 1991) and parasites (Green t>M/, 
1990; Liew <?/«/., 1990; Mauele/a/., 1991; Vincendeau and Daulouede, 199I;Gazzinellit>/ 
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al., 1992; Lin and Chadee, 1992; Munoz-Fernandez *>/«/., 1992; Rockett etal., 1992). In 
particular, nitric oxide eliminates intracellular pathogens such as Mycobacteria tuberculosis 
(Denis, 1991b) and recent studies also suggest that it blocks viral replication (Croen, 1993; 
Karupiah etal., 1 993). Rockett etal. (1994) have suggested possible role of nitric oxide in 
malarial immunosuppression. It also kills tumour cells (Hibbse/ al.. 1988). Nitric oxide induced 
apoptosis (Tews and Goebel, 1998) is mediated by p53 expression in macrophages and 
pancreatic cells (Messmer etal., 1994). Nitric oxide generating compound, S-nitro so glutathione 
induces apoptosis in human chondrocytes and causes necrosis like cell death in human epithelial 
CaOv cell line (Turpaev et al., 1997). It has been reported (Hortelano et al., 1997) that 
induction of apoptosis by nitric oxide is mediated via triggering mitochondrial permeability 
transition. The biochemical basis of the cytotoxicity induced by nitric oxide is its combination 
with iron-containing enzymes of the respiratory cycle and the inactivation of ribonucleotide 
reductase (Hibbs?/ al., 1990; Ignarro, 1991; Lepoivre etal., 1991; Kwon etal., 1991). 
Nitric Oxide as a Free Radical 
A free radical is any species capable of independent existence (for however brief a 
period) that contains one or more unpaired electrons (Halliwell and Gutteridge. 1989) 
They can be positively or negatively charged or electrically neutral. Examples are superoxide 
(O , an oxygen-centered radical), thiyl (RS, a sulphur-centered radical), trichloromethyl 
(CC13, a carbon-centered radical) and nitric oxide (NO) in which the unpaired electron is 
delocalised between both atoms. Nitric oxide is a paramagnetic, diatomic and uncharged 
molecule with an unpaired electron. These characteristics of nitric oxide make it an ideal 
messenger molecule which can difiuse freely across membranes. Having an unpaired 
electron, it is called a radical molecule, which is highly reactive, having a half life of 2 to 
30 seconds (Lowensteiner al., 1994). 
DNA Damage 
Both attenuation of nitric oxide pathway and excess production of nitric oxide have 
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been linked to certain human diseases (Collier and Vallance. 1991). It has been proposed that 
uitric oxide could be a candidate for endogenous human carcinogenesis, as a result of mutations 
in DNA arising following nitric oxide induced deamination (Cooper and Krawczak. 1990; 
Hirschbornf/a/. . 1990;Perutz. 1990; Reefer etai. 1991; Nguyen et ai. 1992). Saturated 
solutions of nitric oxide have been demonstrated to deaminate deoxyribonucleousides. 
nucleotides and calf thymus DNA under aerobic environment m vitro (Keefer et al.. 1991) 
Nitric oxide and its progenitors have been shown to be mutagenic to Salmonella typhimuriiim 
TA1535 (Keefer tVa/., 1991; Arroyo etai. 1992), rat lung cells following in vivo exposure 
(Isomura etai. 1984) and human TK 6 lymphoblastoid cells in culture (Nguyen etai, 1992) 
The prediction that uitric oxide might damage DNA followed from the recognition that it can 
diazotize primary arylamines (ArNTL.) nitrosatively in an oxidizing environment (Ji and Bellocher. 
1988; Rait etai. 1988; Kosaka etai. 1989) (Eq. 1). Since hydrolysis of the diazouium ion 
product replace the nitrogen substituent by oxygeu (Eq. 2) it was reasoned that diazotization 
and hydrolysis of cytosine aud other DNA bases as in Eq. 3-6 /// vivo might lead to heritable 
genetic alterations. 
-e" 
ArNH, + NO > ArN + + H,0 (1) 
(ox) 
ArN/ + H 2 0 > ArOH + N, + H+ (2) 
-e" 
dC + NO dU + N + H* (3) 
pH 7.4 
-e" 
nf dC + NO > dT + N + H+ (4) 
pH 7.4 
-e" 
dG + NO > dX + N + H+ (5) 
p H 7 . 4 
-e" 
dA + NO dl + N + H+ (6) 
p H 7 . 4 
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Observed DNA sequence changes found (Reefer et al., 1991) on treating Salmonella 
typhimiinum TA1535 /'// vivo with nitric oxide, were > 99% C—>T transitions, consistent 
with a cytosine deamination mechanism. The vast majority (99%) of mutations found 
were CG— TA transitions. Similarly, deamination of guanine and adenine to xanthine 
and hypoxanthine respectively on exposure of human cells to nitric oxide /// vitro lead 
to GC—>AT transitions (Nguyen et al.. 1992). The GC—>AT transition arises as a result 
of insertion of dA opposite dU, following deamination of dC (Duncan and Miller, 1980) 
or by the insertion of dT opposite dX, following deamination of dG (Eritja et al.. 1986) 
Two direct acting mutagens namely N-nitroso-2-fluronylacetamide and N-nitroso-3.5-
dinitro-acetaminophen develop their genetoxicity by release of nitric oxide free radical 
(Lin et al.. 1993a). Purines were more readily deaminated than pyrimidines. Moreover, 
some unexpected bases like 8-hydroxyadenine and 8-hydroxyguanine were also found 
8-hydroxyderivatives. products of hydroxyl radical or single oxygen attack on a DNA 
base (Kasai et al.. 1986; Kuchino et al.. 1987; Floyd et al., 1988) have been reported to 
cause misreading of DNA templates not only at that site but also at adjacent sites, suggesting 
its involvement in mutation and carcinogenesis. Nitric oxide attacks guanine bases, as the 
most preferential cleaving sites and the frequency of the nitric oxide induced cutting 
decreases in the order G>OA>T The preferred cleavage at GC sequences by nitric 
oxide may correlate to predominant mutagenicity at GC sites by nitric oxide (Sugiura and 
Matsumoto, 1995). 
Another possible route of nitric oxide toxicity is its interaction with superoxide 
anion (02") to form secondary species which make a greater contribution to DNA damage 
The secondary species can react with other cellular constituents to form tertiary species which 
may also cause DNA damage (Fig. I). Biosynthesis of nitric oxide may lead to the production 
of reactive oxymtrogen intermediates such asnitrosonhim(NO+), nitroxyl ions (NO), nitrogen 
dioxide (N02), peroxynitrite(ONOO') and S-nitrosothiols(StamIere/fl/., 1992). Theone 
electron reduction product of nitric oxide, nitroxyl ion (NO) has been proposed to contribute 
to the cytotoxicity associated with an enhanced expression of L arginine: nitric oxide pathway 
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Primary 
species 
Nitric oxide 
Secondary 
species 
Tertiary species 
Fig. 1. Nitric oxide as a primary, secondary or tertiary mutagen. Possible DNA-damaging 
species are highlighted. 
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under different biological conditions and these nhroxyl ions have been reported to cause double 
strand breaks in whole cells (Wink eta/., 1998a). Simultaneous generation of 02" and nitric 
oxide can lead to the production of ONOO" and hydroxyl ion which can cause considerable 
damage to host cells (Beckman?/ al., 1990; hioueand Kawanishi, 1995) as well as antioxidant 
depletion in human body fluids (vander-Vliet etal., 1994). Peroxynitrite can oxidize variety of 
biomolecules including both protein and non-protein thiols (Radi et al., 1991), protein sulfides 
(Moreno and Pryor, 1992; Pryor etal., 1994), lipids (Moncada etal., 1991) and deoxyribose 
(Beckmanef al., 1990). It can also cause nicks in the supercoiled plasmid DNA (Pryor etal. 
1995). Cigarette tar and nitric oxide act synergisticalry to induce DNA strand breakage (Ohshima 
and Yoshie, 1997). Cigarette tar contains quinoue/hydroquinoue complex, catechol and 1, 4-
hydroquinone which on auto-oxidation generate 02~. Peroxynitrite when protonated 
decomposes rapidly resulting in the formation of hydroxyl radical and nitrogen dioxide, 
both of which are tissue damaging agents and cause DNA strand breaks (Moncada et al. 
1987; Beckman et a!., 1990; Moncada et al., 1991; Wang et al.. 1991; Ischiropoulos et 
al., 1992; Felley-Bosco, 1998; Thomas et al., 1998). 
The major candidates for the DNA-damaging activity of uitric oxide in cells are 
nitrous anhydride and peroxynitrite (Koppenel et al.. 1992; Tannenbaum et al.. 1994) 
Nitrous anhydride can cause nitrosative deamination of bases. N-nitrosamines can be 
formed from reaction of nitrous anhydride with primary amines (Lewis et al., 1995; Liu 
and Hotchkiss, 1995). These are well known chemical carcinogens that are metabolised to 
strongly alkylating electrophiles, reacting with DNA at several nucleophilic sites. The 
chemistry of nitric oxide in the gas phase is different from that in solution (Pires et al., 1994; 
Wink and Ford, 1995). Nitric oxide in the gas phase may lead to biological effects that differ 
from those of endogenous nitric oxide. Aerobic gaseous nitric oxide generates a different set of 
mutations in DNA than does nitric oxide released in aerobic solution (Routledge etal., 1993; 
1994). Aerobic gaseous nitric oxide was shown to generate primarily AT—>GC transitions 
whereas aqueous nitric oxide derived from nitric oxide donor compounds, generate largely 
GC—>AT transitions. Aerobic nitric oxide gas undergoes two reactions to generate species 
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(NO,, N204. N,Os) that react with DNA. N02 has been shown to generate single-strand 
breaks in DNA (Gorsdorf et a/., 1990; Bittrich et a/., 1993) but does not alter DNA bases 
By exposing DNA to two gas preparations (i.e. to NO,/ N,04 or to N,0}). as well as air 
alone. Dipple et al. (1997). obtained results that were consistent wiui the proposed mutagenicity 
of N,0 , and indicate that N,0. is responsible for the AT—>GC mutations observed earlier 
(Routledge etal., 1993) when plasmid pSP189 was exposed in aqueous buffer to bubbles of 
nitric oxide gas. Nitric oxide exposure also leads to DNA single strand breaks (Kolb etal.. 
1993). 
In addition to DNA damage it has been reported that nitric oxide also causes 
inhibition of various DNA repair enzymes (Park and Aust, 1998) namely: Fpg protein 
(formamidop>Timidine-DNA-glycosylase) (Wink and Laval, 1994) and Oh-methyl guanine-
DNA-uiethyl transferase (Laval and Wink, 1994). Nitric oxide also inhibits DNA ligase 
activity (Graziewicz et al., 1996). The inhibition of DNA ligase may explain the increase 
in strand breaks reported for cells exposed to nitric oxide and provide a mechanism to 
increase DNA lesions without direct chemical modification of DNA by nitric oxide. 
Repair of DNA Damage 
/// vivo, the DNA repair systems that comprise a variety of enzymes are the key 
lines of defense that prevent or limit the biological effects of DNA damage. Strand breaks 
are annealed and modified bases and deoxyribose sugars are excised as such or as nucleotides 
(Ramotar and Demple, 1993; Demple and Harrison, 1994). DNA glycosylases excise bases 
and subsequently endonucleases incise the phosphodiester bond on each site of abasic sites 
allowing insertion of an intact nucleotide. Endonuclease III possesses both glycosylase and 
endonuclease activities for the repair of oxidised pyrimidines. The repair product of this 
excision include thymidine, thymine glycol and hydroxyuracil which are excreted into the urine 
The formamidopyrimidine-DNA-glycosylase (Fpg; mut M) in E. coli repairs 8-oxo-dG and 
2,6-diamino-4-hydroxy-5-formamidopyrirnidine and to a lesser extent the corresponding 
adenine derivatives by base excision (Boiteux etal., 1992). The Fpg protein appears to repair 
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8-oxo-dG in non-coding and actively transcribed mammalian DNA sequences with equal 
efficiency (Bohr et al., 1995). Exonucleases incise the apurinic site for insertion of a new 
nucleotide. In humans, a similar two step pathway yielding 8-oxo-G have been identified in 
addition to repair of 8-oxo-dG by single step excision of the complete nucleotide (Bessho t't 
ai. 1993). In E. coli the mut M and mut T repair enzymes co-operate functionally with mut Y. 
an enzyme which removes adenine misinserted opposite 8-oxo-G in DNA (Tajiri etai, 1995) 
Lack of DNA repair mechanisms would lead to increased mutation frequencies in the early 
steps of carcinogenesis (Freidberg, 1985). Unrepaired DNA or inaccurate repair of damage 
can lead to cell death (Jackson, 1996). 
Autoimmunity 
Under certain conditions, immunological disbalance results in discrimination between 
'self and 'nonself leading to antibody production against various cellular components 
and tissue injury, resulting in clinical disease. Disruption of self-nonself discrimination 
leads to autoimmunity (Deodhar, 1992). Normally, immunologic attack is directed against 
agents which are foreign like bacteria, viruses, parasites and some internal changes such as 
cancer, while not responding to one's own self antigens. According to Burnet (1959), 
immune system must generate a diversity of lymphocyte antigen receptors through rapid 
somatic mutation in order to develop responsiveness to an enormous variety of antigens 
that has relevance to host defense. He also predicted that autoimmune clones are deleted 
during embryonic life and synthesis of autoantibodies reacting with self-components does not 
correspond to physiological process, but is the result of pathological situations. 
It has long been hypothesised that the development of the immune system is triadic in 
nature: useless cells are discarded, useful cells retained, and dangerous cells are destroyed or 
inactivated. Specifically, it appears that as T cells mature in thymus, those that rearrange and 
display self major histocompatibility complex (MHC) and peptide reactive T cell receptor of 
certain affinity/avidity are maintained and propagated within the thymus (positive selection) but 
prior to export to the periphery, those with receptors of dangerously high affinity/avidity are 
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eliminated or inactivated (negative selection) (Aston-Rickardt and Touegawa, 1994; Nossal. 
1994; von Boehiner. 1994). Through these and other editing processes a state of self-tolerance 
is achieved (Goodnow, 1992). 
Autoimmune diseases are those which result from immunologic reactions, humoral 
and/or cellular or a combination of both. Autoimmune diseases may be classified in different 
ways, it may be organ/tissue specific such as Hashimoto's syndrome, thyrotoxicosis, 
pernicious auemia or non-organ/tissue specific (systemic) such as progressive systemic 
sclerosis (PSS) or systemic lupus erythematosus (SLE). There is no single theory or 
mechanism that can adequately explain all the features of autoimmune diseases. However, 
three models have been proposed for the induction of a productive autoimmune process 
The first is the autoimmune response to a cross-reacting antigen, i.e. cross-reactivity between 
host and foreign antigens or modification of host proteins due to infection, drug 
administration and inflammation etc. (Theofilopoulos and Dixon. 1985; Huang et a/.. 
1988). The second is the genetic predisposition for autoimmunity through regulatory failure, 
and the third is the triggering with bacterial mitogen of potentially autoimmune B cells, 
normally held in check by suppressor cells. 
It is well known that autoimmune diseases show a highly significant familial 
predisposition (Hochberg, 1987; Arnett, 1992). The HLA genes function as secondary 
genes to allow expression of specific autoantibody. Most of the MHC association with SLE. 
the prototype of autoimmune diseases, involves class II (HLA-DR and DQ alleles) and class 
III alleles especially null or deficiency alleles of the fourth component (CJ of complement (Bias 
etal., 1986; Goldstein and Arnett, 1987; Braun and Zachary, 1988; Arnett and Moulds, 
1991;Deodhar, 1992). 
In a wide variety of autoimmune diseases like SLE, Sjogren's syndrome, progressive 
systemic sclerosis, rheumatoid arthiritis and pernicious anemia, the regulatory failure results 
in a significant decrease in T-suppressor cell numbers and activity, thereby unbalancing 
the T-helper/T-suppressor cell ratio. The increased T-helper/T-suppressor ratio has been 
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noted in the above cited examples (Krakauer e/a/., 1981). Various foreign organisms may 
also upset the balance of immunoregulation, for example switch from TH' like lymphokine 
pattern to TH2 type pattern seen in HIV infection is paralleled by an increased number of 
B cells and hypergammaglobulinemia and the switch is commonly seen in autoimmune 
diseases (Levinson, 1994). 
Polyclonal B and/or T cell activation has been proposed as a possible mechanism 
that may be responsible for the over-activation of B cells and production of autoantibodies 
in certain autoimmune diseases, particularly SLE (Dziarski, 1988; KJinman et al., 1990; 
Steinberg, 1992). In autoimmune prone individuals, B cells are hyper-responsive to 
polyclonal activators and undergo initial activation, followed by expansion of autoreactive 
clones, under the influence of exogenous or endogenous polyclonal activators. A large 
number of molecules, particularly of microbial origin, have been found to act as polyclon.il 
B cell activators and induce autoantibodies(Theofilopoulos, 1993). Among the well known 
polyclonal B cell activators are Epstein Barr Virus (EBV) and its components, endotoxin 
or lipopolysaccharides (LPS), certain bacterial agents and drugs may function by bypassing 
T cell regulatory mechanisms and activating B cells directly. 
Viruses are frequently associated with autoimmune diseases of humans and animals 
(KriegeM/., 1989; 1991; Krieg and Steinberg, 1990; Steinbergs ai, 1990). The mechanism 
by which viruses and other infectious agents initiate autoimmunity are complex and may include 
structural similarity, increased HLA expression, polyclonal B cell activation and alteration of 
self antigens (Shoenfeld and Isenberg, 1989). It is well established that human immunodeficienc\ 
virus (HIV) associated to immune dysregulation results in autoimmune phenomenon or inversely 
some type of autoimmune mechanism may contribute to the immunopathogenesis of the HIV 
infection itself (Calabrese, 1988). The autoantibodies associated with HIV infection include 
antinuclear antibodies, rheumatoid factor, auti-cardiolipin antibodies, anti-platelet, anti-red blood 
cell and anti-lymphocyte antibodies. Other viral agents involved in initiating autoimmune 
phenomenon include hepatitis B infection associated with chronic active hepatitis and polyarthritis 
nodosa, EB virus in polymyositis, HTLV-1 virus in multiple sclerosis, and related neurologic 
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diseases (Weetman and Borysiewicz, 1990). Autoimmune diseases occur far more commonly 
in females than in males, with a ratio of 10:1 or greater in certain diseases. Hormonal factors 
such as sex hormones, thymic hormones and corticosteroids play a significant role (TalaL 1989; 
Counihanefa/.. 1991;Lahita, 1992; Moinuddin and Ali, 1994). 
Tolerance is accomplished through three mechanisms, which are thymic education, 
thymic deletion and peripheral tolerance. Thymus is the major site for self/non-self 
discrimination. It is here that the T cell repertoire is determined. Some cells are programmed 
to die (negative selection) while others are not (positive selection) (Adorini, 1993). Those 
with a high affinity for self ligands are negatively selected. It has also been suggested 
(Rose and Pittsbury, 1994) that thymus is the critical time keeper with aging process with 
respect to immune response. Errors in central or peripheral tolerance at the T or B cell 
level have also been suggested as probable causes for autoimmunity. 
Immunological crossreactivity and molecular mimicry have been an important 
phenomenon in autoimmune diseases. It has been suggested that the degree of sequence 
conservation between the host and a given infectious agent, heat shock proteins, because 
of molecular mimicry, may provide the link between infection and subsequent autoimmunity. In 
responding to the virus, the immune system may become activated to attack the self molecule, 
since only a few residues are needed to stimulate the immune response. For example, adenovirus 
type II has sequences very much like those of myelin basic protein (Steinman, 1993). The 
reason that some persons may mount an immune response against self and others do not may 
be because HLA molecules from different individuals display different portions of the antigen 
to T cells. Thus, one person's HLA molecule may bind a self-mimicking portion while another's 
may not. 
Role of Nitric Oxide in Autoimmunity 
Nitric oxide is an important mediator of the inflammatory response. It is a strong 
proinflammatory substance (Kiechle and Malinski, 1993; Lowenstein t?/a/., 1994) that may 
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increase vascular permeability in inflammed tissue (Mayhan, 1992) and increase the potential 
of cells to produce hydrogen peroxide (Margrinat et al., 1992). Nitric oxide augments the 
inflammatory responses in sepsis by increasing the production of cytokines (Van Dervort etal. 
1994), e.g., tumor necrosis factor and interleukin-1 (Lander et al., 1993). Cytokine induces 
nitric oxide synthase in macrophages which in turn produces nitric oxide and the role of cytokines 
in autoimmune inflammation and diseases is well known (Kroemer and Martinez, 199 I) 
Cytokine combination of IL-1. TNF-a and IFN-y induced formation of nitric oxide by human 
islets (Corbett et al., 1993). Furthermore, immune complexes may play a pathogenic role as 
it has been reported that immune complex deposition can lead to nitric oxide release (Mulling an 
et al., 1991). Nitric oxide can also be a mediator of an inflammatory attack against normal 
syngeneic cells (Kroncke ?/«/., 1991), and is involved in chemotaxis of polymorphonuclear 
(PMN) leukocytes (Kaplan et al., 1989). 
There has been extensive suggestive evidence that nitric oxide can participate as a 
mediator of tissue damage in autoimmune diseases (Table 2). Elevated nitric oxide 
biosynthesis has been associated with chronic inflammatory autoimmune diseases including 
rheumatoid arthritis, inflammatory bowel diseases and multiple sclerosis (Cook and Cattell. 
1996; Huang et al.. 1996; Parkinson et al., 1997; van deer Veen et al., 1997; Fenyk-
Melody et al., 1998). Nitric oxide mediated mitochondrial damage in brain has been 
implicated in neurodegenerative diseases (Bolanos et al., 1997). Nitric oxide may be a 
candidate for the "toxin" that can be responsible for the cell damage in multiple sclerosis 
(Koprowski etal., 1993). Nitric oxide has been imp heated to be involved both in the induction 
of autoimmunity as well as in the effector phase of tissue injury in the HgCl2-treated Brown 
Norway rat (Woolfson etal., 1995). Patients with rheumatoid arthritis overexpressNOS and 
overproduce nitric oxide (FarrelUf a/., 1992; Sakurai etal., 1995; St. Clair et al., 1996). 
Devlin et al. (1994) have reported nitric oxide generation as a predictive parameter of acute 
allograft rejection. Genetically determined overexpression of nitric oxide plays a role in etiology 
of autoimmunity and may also serve as a barrier to transplantation - cellular or otherwise (Mills 
etal., 1994). 
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TABLE 2 
Implication of Nitric Oxide in Some Autoimmune Diseases 
Disease Species Treatment 
with NOS 
inhibitor 
Nitric Oxide 
or nitrite 
production 
References 
Experimental allergic 
encephalomyelitis (EAE) 
Mouse 
Rat 
Yes Yes MacMicking t7«/., 1992; 
Lin <?/«/.. 1993b; Ludou\k.7 
al.. 1993; Koprowski et«//. 
1993; C r o s s e al.. 1994 
Hooper et al.. 1995; Zhao et 
al.. 1996; Dinger al.. 1997; 
1998;Okudaf/fl/„ 1998; 
Sahrbacher et al.. 1998 
Experimental neuritis 
(adoptive) 
Diabetes, spontaneous 
Diabetes, induced by 
streptozotocin 
Lupus-like syndrome 
Arthritis 
Rat 
Mouse 
Rat 
Mouse 
Mouse 
(MRL-lpr/lpr) 
Mouse 
Rat 
Yes 
Yes 
Yes 
Yes 
Yes 
Liew, 1994. 
Yes CoxbeXl etal., 1993; 
Kleenman et al.. 1993; Lee. 
1994; Stevens et al.. 1994 
Yes Kolbefo/.. 1991: Luku etui.. 
1991; Catanzaroff <:;/.. 1994 
Yes Weinberg et al.. 1994; Kuhn 
etai., 1998. 
Yes Ialentiera/.. 1993; McCartney 
etai, 1993; Connor et al.. 
1995. 
Rheumatoid arthritis Man No Yes Farrellertf/., 1992. 
Ulcerative colitis Man No Yes Lundberg et al., 1994; Oudker 
etai, 1995. 
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(a) Cells that produce nitric oxide in autoimmune diseases 
Macrophages and PMN cells, which are known to produce relatively large amounts 
of nitric oxide after induction of NOS via lymphokines. release nitric oxide at the 
inflammatory lesions of autoimmune diseases. Macrophages are known to participate in 
the pathogenesis of autoimmune diseases in the experimental models of these diseases 
(Kolb and Kolb-Bachofen. 1992) and they are the first immune cells that infiltrate the 
islets early in the process of insulin in rodents (Lee et al.. 1988a and b; Hanenberg et al.. 
1989; Kolb et al.. 1990). Cells of monocyte-macrophage lineage are a component of the 
effector cells in the expression of an inflammatory demyelinating disease (Brosnan et al.. 
1981). MRL lpr/lpr mice have increased number of peritoneal macrophages as compared 
to mice of other strains and these macrophages show features of activation and seem to 
potentiate inflammatory manifestations that characterise the lupus-like syndrome in the>e 
mice (Dang-Vu et al.. 1987). There is over production of nitric oxide (Cohen and 
Eisenberg. 1991) and this over production parallels the development of clinical disease 
manifestations in mice (Weinberg etal.. 1994). Compared with control mice, MRL-lpr lpr 
mice have enhanced expression of nitric oxide synthase type 2 (NOS2) in their spleens and 
kidneys. In addition, they have increased levels of nitrosylated proteins in kidneys, indicating 
enhanced nitric oxide production within diseased organs (Privallee/o/., 1996). Enhanced 
NOS2 expression with increased nitric oxide production plays an important role in various 
forms of inflammation seen in SJL mice (Clancy etai, 1995; Tamir etal., 1995; Huang et al.. 
1996). The importance of nitric oxide in disease manifestations is further supported by 
observations that treatment of these mice with N°-monomethyl-L-arginine inhibits nitric oxide 
production and prevents glomerulonephritis, arthritis and vasculitis (Weinberg et al.. 1994; 
Oatese/a/., 1997). Furthermore, it is not clear whether human macrophages produce nitric 
oxide (Schneenmanne/fl/., 1993). A poteutial source of nitric oxide is Th 1 lymphocytes, as 
has been shown by Taylor - Robinson et al. (1993) in experimental malaria infection. In 
addition to lymphocytes (Kirk et al.. 1990), human neutrophils (Moncada, 1992) and 
chondrocytes (Bianco et al., 1995) can generate nitric oxide after induction of NOS. Another 
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possible source of nitric oxide is endothelial cells, and a common early feature of the autoimmune 
lesion is endothelial cell swelling, leading to the formation ofhigh endothelium venules (Miossec, 
1993). Infiltrating macrophages, resident endothelial cells, astrocytes (Hewett etal., 1993) or 
microglial cells (Zielasek et ai, 1992) in the central nervous system of animals with EAE may 
secrete nitric oxide (Lin etal., 1993b). 
(b) Action of nitric oxide in autoimmune diseases 
The effect of nitric oxide in autoimmune inflammatory reaction is its direct toxicin 
on cells. The basis of cytotoxicity depends on combination of nitric oxide with iron 
containing moieties in key enzymes of the respiratory chain and of DNA synthesis. The 
nitrosatioo leads to inhibition of mitochondrial electron transport complexes I and II (Stadler 
etal., 1991), inhibition ofacouitase activity (Welsh and Sandler, 1992)and ofribonucleotide 
reductase, the rate limiting step in DNA synthesis (Nussler and Billiar. 1993). Nitric oxide can 
also damage DNA directly by deaminatiou of purine and pyrimidine bases resulting in mutations 
and strand breaks (Loweustein era!., 1994). Apoptosis is an important mechanisms of cell 
destruction by nitric oxide. Nitric oxide induced formation of DNA strand breaks which are 
repaired by poly (adenosine diphosphoribose) polymerase lead to a depletion of the NAD' 
pool in the cells to lethally low levels and hence death of different cell types (Bukart etal.. 
1994; Zettl et al., 1997). Interaction of nitric oxide with other radicals seems to be important 
for cell destruction. It is likely that nitric oxide is necessary but not sufficient to produce 
apoptosis in many cells, and for this to occur oxygen radicals are also needed (Bianco etal.. 
1995). Nitric oxide and superoxide seem to be associated with apoptotic and/or necrotic cell 
death in diseases such as mesangioproliferative glomerulonephritis in which early phase of 
mesangiolysis is linked to significant nitric oxide production (Sandau et al., 1997; Cuzzocrea 
etal., 1998; Maruyama etal., 1998). Nitric oxide forms peroxynitrite through interaction with 
superoxide and peroxynitrite, may spontaneously produce hydroxyl radical which is highly 
damaging to the cells (Beckmau etal., 1990). Peroxynitrite induces cytotoxicity by generating 
DNA strand breakage, which is an obligatory stimulus for the activation ofpoly(ADP-ribose) 
synthetase (PARS), a nuclear enzyme that consumes oxidized nicotinamide adenine dinucleotide 
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(NAD+) and deplete cellular ATP which is consumed in regeneration of NAD. leading to cell 
death by energy depletion (Eliasson et al., 1997; Cookson et al., 1998; Kennedy et al.. 
1998). Peroxynitrite - PARS pathway by leading to cell necrosis or apoptosis contributes to 
cellular injury in a number of conditions including shock and inflammation, pancreatic islet cell 
destruction, diabetic stroke and neurodegenerative disorders (Szabo, 1996). Nitric oxide does 
not participate in the inducing phase but in the effector phase of the autoimmune response. It 
does not effect production of autoantibodies and, indeed, treatment of MRL-lpr/lpr mice with 
NOS inhibitor did not alter the amount of anti-DNA antibodies in their serum (Weinberg et al. 
1994). 
Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is an autoimmune, multisystem. inflammatoi \ 
disease, manifested by the production of autoantibodies, which leads to an array of clinical 
symptoms. These autoantibodies have multiple specificities, especially antibodies reactive 
with nuclear ligands. including native DNA (Andrews et al., 1978; Smith and Steinberg. 
1983; Tan, 1985; Steinberg et al., 1990; 1991; Steinberg. 1992; Harada et al.. 1994) 
Major orgau system involvement may occur in the heart, lungs, kidneys and central nervous 
system and is responsible for most of the mortality and morbidity caused by the disease 
(Klippel, 1997). The clinical manifestation includes fever, an erythematous 'butterfly' rash 
across the face, lesions of discoid lupus or a vasculitis rash, polyarthralgia and arthritis, 
polyserositis (especially pleurisy and pericarditis), anemia, thrombocytopenia, renal, neurologic 
and cardiac abuormalites. One of the impediments to understanding human systemic lupus has 
been its marked heterogeniety (Steinberg et al., 1991; Steinberg, 1992). 
SLE is episodic in its activity and variable in severity, although, a clinically similar 
syndrome can be induced by a variety of environmental agents (eg. certain drugs, microorganisms 
and immune stimulants). The etiology of the spontaneously occurring disorder is incompletely 
understood (Steinberg etal., 1990 and 1991). Interplay of both genetic and environmental 
factors plays an important role in the pathogenesis of SLE and assessing the role of anti-DNA 
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antibodies(Gourleyff a/., 1992; Satoheta!., 1995; Isenberg, 1997; Schwartz, 1997). Antigen 
specific and nonspecific factors and polyclonal cell activation may be responsible for creating 
an environment that facilitates the expansion of autoautigen-specific clones (Schlomchik eta/.. 
1987; Marion etal., 1989; Klinman etal., 1990; Steinberg etal., 1990). Polyoma T antigen 
binds with high avidity to mammalian DNA and the complex can be an immunogeu in individuals 
with a genetic susceptibility to SLE (Rekvig etal., 1995). The complexes consisting of DNA 
and a variety of microbial DNA binding peptides inducing anti-DNA antibodies have been 
suggested (Schwartz. 1997). Undigested DNA, DNA-protein or DNA-peptide complexes 
might accumulate in lupus due to failure to phagocytose the detritus of apoptotic cells and thus, 
provide a source of lupus provoking immmiogeus (Schwartz, 1997). Pathogenic anti-DNA 
antibodies might originate from bacterial antigens and DNA (Kalden and Marion. 1997) 
Alongwith the importance of somatic mutations, polymorphisms of Ig Vka locus and genetic 
predispositions, the failure of receptor editing may contribute to the development of pathogenic 
anti-DNA responses in humans (Suzuki etal., 1997). 
The major serological marker for diagnosis and prognosis of SLE. antibodies to double 
stranded DNA (Cepellini etal.. l957;Seligmaun, 1957) is of paramount interest. The main 
reason for this are the relationships seen in many, though not all, patients with SLE. between 
levels of anti-dsDNA antibodies and clinical activity and the elution of these antibodies from 
the kidneys of lupus patients and lupus-prone mouse models. In addition, these antibodies 
target conserved sites on both single stranded and double stranded DNA (Pisetsky. 1997) 
The preseuce of anti-DNA autoantibodies in the sera of SLE patients has long been considered 
both as a marker and pathologic factor in renal disease (Andres etal., 1970; Koffler, 1974). 
There are reports of serum anti-dsDNA antibody levels correlating with the severity of the 
renal disease in SLE (Wallace etal., 1993). Various serological findings suggest that lupus 
nephritis results from the deposition of DNA-anti-DNA complexes and subsequent complement 
mediated tissue damage (Emlen et al., 1986; Pisetsky, 1992). 
Anti-DNA antibodies are polyspecific showing enormous crossreactivity. Range of 
specificities to these antibodies, monoclonal antibodies and sera from SLE patients and lupus 
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prone animal models show that reactivity may be greater towards denatured forms of DN A 
(Stollar et al., 1986). These anti-DNA antibodies have been shown to recognise epitopes that 
occur not only in nucleic acids (native DNA, ssRNA. dsRNA. tRNA. rRNA. viral RNA) 
(Andrzejewski etal.. 1980; Swanson etal., 1996), but also on nucleoproteins (DNA-histone. 
nuclear ribonucleoproteins like Sm and Mo, cytoplasmic ribouucleoproteins like Ro=SSA and 
La=SSB,ribosome)(Stollar, 1981), proteins (Pistesky^al.. 1985; Wong etal.. 1995;Tsuzaka 
etal., 1996), cell membrane structures (Jacob etal., 1986), polysaccahrides(Kashihara et 
al., 1993), phospholipids (Tiikainem etal., 1991), erythrocytes, leucocytes, platelets and 
neurons. High levels of auti-DNA antibodies coupled with depressed total haemolytic 
complements (CH,() activity (Nishiya and Hashimoto, 1997) and low C3 andC4 complement 
component suggest that there is activation of the classical complement padiway in active immune 
complex disease. 
Additional specificities include other forms, such as RNA-DNA hybrid, triple helical 
RNA (Karanous et al.. 1988), poly(A), poly(U). poly(I) and poly(C). Multiple 
conformations of DNA are also found to be recognized by SLE autoantibodies. For 
example, left handed DNA Z-DNA, DNA-psoralen photoadduct, DNA-lysine photoadduct. 
hydroxyl radical modified DNA, estradiol-albumin-DNA conjugate and DNA-8-
methoxypsoralen photoadduct (Hasan and Ali, 1990; Sehgal and Ali. 1990; Ali et al.. 
1991; Hasan et al.. 1991; Alam and Ali, 1992; Alam et al., 1992; Ara et al., 1992; Ara 
and Ali 1992; 1993; Arjumand and Ali, 1994; Moinuddin and Ali, 1994). This 
polyspecificity of auti-DNA antibodies could be due to variable binding sites in individual 
immunoglobulin or to reccureut epitopes in different antigens. The polyreactivity of anti-DNA 
autoantibodies suggests that DNA itself may not be the immunogen responsible for the induction 
of anti-DNA antibodies. 
Mammalian DNA is non- immunogenic in a variety of animal species tested (Schwartz 
and Stollar, 1985), whereas bacterial DNA is able to induce a strong antibody response in 
mice (Gilkeson etal., 1989). It has been noted that anti-DNA antibodies may be structurally 
very similar to auti-bacterial antibodies (Halin and Tsao, 1993). Rekvig etal. (1995), exploring 
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the reaction to polyoma virus BK, have found that infection to this virus into young lupus prone 
mice, prior to the natural onset of the disease, induced a strong persistent anti-dsDNA response 
more typical of lupus (Frederikson etol., 1994). This suggests that anti-dsDNA might arise 
from stimulation with foreign rather than self DNA. Monoclonal antibodies raised against a 
complex of native DNA and synthetic DNA binding protein shared DNA specificities and V 
region structure with anti-DNA monoclonal derived from lupus prone NZB/NZW mice 
(Krishnanand Marion, 1993). It was thus hypothesized that the likely stimulus to anti-DNA 
antibody production is the possibility that nucleosome material, i.e DNA-linked to histone. is 
the key immunogen (Ehrenstein et al., 1993). Blount et al. (1989) postulated that DNA 
damaged by ROS may effect the development of autoimmune diseases, such as SLE. It has 
been suggested that activated phagocytic cells capable of releasing ROS could penetrate cell 
membranes, interact with nuclear DNA causing the release of altered DNA. in turn stimulating 
anti-DNA antibody production (Gordon etol., 1990; Alametal., 1993). The hypothesis that 
ROS modification of DNA is involved in the development of autoantibodies in SLE has been 
supported by the enhanced reactivity of SLE anti-DNA antibodies to ROS-modified DNA 
(Blount et al., 1990; Ara and Ah. 1993). 
Lupus is considered to be the prototype of a spontaneous immune complex disease in 
which anti-DNA antibody-DNA complexes deposit in the tissues and induce inflammation 
Although anti-double stranded DNA antibodies are considered to be the hallmarks of human 
lupus nephritis (van Bruggen etal., 1996). most of the anti-DNA antibodies in the murine renal 
lesions also bind single stranded DNA (Theofilopoulos and Dixon, 1985; Gavalchin and Dutta. 
1987). Recently, the interaction ofuucleosome/antibody complexes to heparan sulphate in the 
kidney, for the initiation of nephritis, has been reported (Neparstek and Madaio, 1997). A 
novel subset of murine monoclonal anti-DNA antibodies that deposit in cells and cross both 
cellular and nuclear membranes to deposit in nuclei in vivo has been described (Foster et al., 
1994;Kieber-Emmons<?/a/., 1994; Yanase etal., 1994). Another monoclonal anti-DNA 
antibody, termed JE10, has been reported to penetrate murine renal tubular cells and localize 
in the nucleus. 
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Hybridoma technology and antibody sequencing have facilitated enormously the 
dissection of auti-DNA antibodies into features which may impart pathogenicity and/or 
allow DNA recognition. Anti-DNA antibodies of IgG classes, especially those having 
high basic charge (cationic antibodies), show a tendency to form immune complex and hence 
participate in the pathogenesis of tissue injury. It has been reported (Sagawa, 1992; Putt ermann 
et al., 1996) that charge and affinity may not predict potential for tissue damage. 
Studies have indicated that auti-ssDNA antibody may, on occassions be a more 
potent immunogeu compared to a dsDNA antibody (Swansone/ al., 1996). In addition, it 
has been suggested that it is not the positive charges which allow pathogenicity, but the 
number of charged (positive and negative) residues within the V-region which influences 
this property (Ohnishi et al., 1994). Anti-DNA antibodies bind to endothelial cells which 
have pathogenic significance, as the expression of adhesion molecules and haemostatic 
factors by endothelial cells is modified following their binding (Chan et al., 1995). 
The process of apoptosis may provide a source of extracellular nuclear antigens to 
drive the autoantibody response and provide antigen in SLE (Emlen et al., 1994; Nagata 
and Sudo, 1995; Casciola-Rosen and Rosen, 1997). This suggestion can be further 
emphasised by studies which demonstrate that clearance of apoptotic cell material by 
phagocytosis is described in SLE patients, leading to accumulation and presentation of 
autoangitens and thus triggering an autoantibody response (Herrmann et al., 1996). Reports 
have suggested that apoptosis may be abnormal in an autoimmune disease and may play a role 
in the induction of autoimmunity (Cohen and Eisenberg, 1992;Fukunga etal., 1992). 
No single mechanism can fully explain the origin of human lupus in general, or anti-
dsDNA antibodies, in particular. From the various experiments performed, the main concept 
is that the systemic autoimmune disease is the result of polyclonal B cell activation (Klinman 
and Steinberg, 1987) and that auto-reactive clones are the result of antigen driven specific 
stimulation (Hardin, 1986). Last, but not the least, one envisages a two stage development, 
incorporating elements of both polyclonal activation and an antigen driven response (Zouali, 
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1992). Based on the evidence available from human studies, the third view is considered to be 
the most valid explanation (Isenberg etal., 1994). 
Autoantibodies and B cells have been in the lupus limelight for decades, but now T cells 
have been studied extensively in SLE (Spronk et ai, 1996). T cells have been cloned from 
lupus-prone mice and these were found to stimulate the production of anti-DNA antibodies 
and renal lesions when injected /'// vivo. In mice and humans with lupus, the histone/DNA-
binding T cells are activated, express the CD40 ligand, and have the potential to trigger B cell> 
to produce antibodies. A finding that T cells from MRL-lpr/lpr mice recognise DNA-binding 
peptide from a parasite underlines the relevance of Rekvig's report implicating a viral DNA-
binding protein (the polyoma T antigen) in human SLE. Perhaps many different DNA-binding 
peptides of microbial origin can be immunological carriers of nucleic acid or polynucleotide 
haptens. It is possible that the lupus patients' collective experience with microbial DNA-
binding proteins builds up a repertoire of carrier-specific memory T cells, members of which 
participate in triggering, enhancing or modifying the activation of B cells with the capacity to 
produce anti-DNA antibodies. 
Nitric Oxide in SLE 
There is an evidence for a pathological role of nitric oxide in human diseases, such 
as multiple sclerosis (Bagasra et al., 1995), artherosclerosis (Buttery eta/., 1996), and in 
carcinogenesis linked to chronic infection (Tamir and Tannenbaum, 1996). Studies using N"-
monomethyl-L-arginine in MRL-lpr/lpr mice indicate that nitric oxide is important in the 
pathogenesis of glomerulonephritis, arthritis and vasculitis (Weinberg etal., 1994; Oates et 
al., 1997). However, the work of Gilkesou et al. (1997), studying inflammation in MRL-lpr/ 
lpr mice with genetically disrupted NOS2, highlights the heterogeneity and complexity of the 
role of NOS2 and nitric oxide. Nitric oxide is an important mediator of the inflammatory 
response. MRL-lpr/lpr mice overexpress NOS2 and overproduce nitric oxide, parallel with 
the development of autoimmune syndrome with a variety of inflammatory manifestations. Previous 
studies have shown that nitric oxide production with nonselective NOS inhibitor N' -
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monomethyl-arginine reduced glomerulonephritis, arthritis and vasculitis. To further define the 
role of nitric oxide and NOS2 in disease, mice with targetted disruption of NOS2 were 
produced by homologous recombination. Measures of nitric oxide production were markedly 
decreased in the MRL-lpr/lpr (-/-) mice (homozygous for disrupted NOS2), compared with 
MRL-lpr/lpr (+/+) (wild type), with intermediate production by the MRL-lpr/lpr (-/-) mice 
(heterozygous for disrupted NOS2). There was no detectable NOS2 protein in the spleen, 
kidney, liver and peritoneal macrophages of the (-/-) animals, whereas that of (+/+) was high 
and (+/-) intermediate. The (-/-) mice developed glomerular and synovial pathology similar to 
that of the (+/-) and (+/+) mice. However, (-/-) mice and (+/-) mice had significantly less 
vasculitis of medium-sized renal vessels than (+/+) mice. IgG rheumatoid factor levels were 
significantly lower in the (-/-) mice as compared with (+/+) mice but levels of anti-DNA 
antibodies were comparable in all groups. Thus, nitric oxide from NOS2 has a variable impact 
on disease manifestations in the MRL-lpr/lpr mice. 
Nitric oxide production is increased in patients with SLE and two potential sources of 
excessive nitric oxide are activated endothelial cells and keratinocytes via up regulated NOS2 
(Belmont et al., 1997), Serum nitrite level, which is an index of nitric oxide production, was 
found to be correlated with the disease activity and with the levels of antibodies to dsDNA 
Wigand et al. (1997), reported that NOS activity or expression, or both, is upregulated in 
rheumatoid arthritis patients with high disease activity and in patients with SLE. Serum N' -
hydroxy-L-arginine seems to be a more specific and reliable index of an increased activity of 
this enzyme in patients with acute or chronic inflammatory disease than nitrate, and is the major 
circulating metabolite of nitric oxide whose concentration is influenced by dietary intake. The 
significance of oxidative stress, nitric oxide and antioxidants in SLE has also been reported 
(Mohan and Das, 1997). Eicosapentaenoic acid and docosahexaenoic acid (essential fatty 
acids) can modulate oxidative stress and nitric oxide synthesis and may have a regulatory role 
in the synthesis of antioxidant enzymes, such as superoxide disrnutase and glutathione peroxidase 
They have also suggested that measurement of Upid peroxides, nitric oxide and anti-oxidants 
can be used as markers to predict prognosis in patients with SLE. 
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Objective of the Present Study 
Nitric oxide shows an unusual divergence of action, being utilised both as a physiological 
signalling molecule and as a toxic mediator. Genotoxicity of nitric oxide follows its reaction 
with oxygen and superoxide. It be due either to direct or indirect DNA damage. Nitric oxide 
deaminates deoxynucleosides, deoxynucleotides and intact DNA at physiological pH and causes 
nucleotide selective DNA cleavage. It is well known that many human diseases and cancer are 
thought to arise from deamination of bases. 
In the present work, plasmid Bluescript DNA was isolated free of chromosomal 
DNA, proteins and RNA from E. coli DH,(X cells. The purified plasmid DNA was modified 
with nitric oxide radical generated by reduction of sodium nitrite with sodium dithionite 
Native calf thymus DNA fragments of approximately 200 bp were also isolated and subjected 
to nitric oxide modification. The NO-modified DNA fragments were characterised by 
various physio-chemical techniques and employed in competitive assay to delineate the 
epitope recognition of induced antibodies against NO-modified plasmid DNA. The 
modifications on DNA were studied by LTV spectroscopy, thermal denaturation studies, 
sedimentation in alkaline sucrose density gradient, nuclease SI digestibility and circular 
dichroism spectroscopy. The antigenicity of nitric oxide modified plasmid DNA was probed 
by inducing polyclonal antibodies in experimental animals. The repertoire of specificities 
of induced antibodies was evaluated by their binding to various nucleic acid polymers using 
direct binding and competition ELISA. Naturally occurring human anti-DNA antibodies in the 
sera ofvarious SLE patients were also studied for their recognition of native and nitric oxide 
modified plasmid DNA. 
cZxfiEximzntaL 
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MATERIALS 
Calf thymus DNA. nuclease SI, bovine serum albumin, methylated bovine serum albu-
min, anti-human/anti-rabbit-IgG-alkaliue phosphatase conjugate, p-nitrophenyl phosphate, 
ethidium bromide. Coomassie Brilliant Blue G 250 and R 250, sodium dodecyl sulphate. Tween-
20, Millipore filter (0.45 um pore size), Freund's complete and incomplete adjuvants, lysozyme. 
polydeoxyribouucleotides. ampicillin were purchased from Sigma Chemical Company, U.S.A. 
Synthetic polynucleotides. Protein A-Sepharose CL-4B, agarose, Ficoll 400. xylene cyanole 
FF were purchased from Pharmacia Fine Chemicals, Sweden. Folin-Ciocalteau reagent and 
Blue Dextran 2000 were purchased from Centre for Biochemical Technology, New Delhi 
Gentamycin, restriction enzymes, RNase A (DNase free) were obtained from Boehringei 
Manheim, Germany. pBR322/Hinf III digest was from Genei, India. Tryptone, yeast extract, 
bacto-agar were procured from Difco, U.S.A. Absolute ethanol was obtained from BDH Labo-
ratory Supplies, England. 
Polystyrene microtitre flat bottom ELISA plates having 96 wells (7 mm diameter) 
were purchased from Nunc, Denmark. Acrylamide, ammonium persulphate, bisacrylamide, 
N,N,N',N'-tetramethylethylene diamine(TEMED) were from Bio-Rad Laboratories, U.S.A 
EDTA(disodium salt), sodium nitrite, chloroform, isoamyl alcohol, methanol, glacial acetic-
acid were from Qualigeus, India. Sodium dithionite was from S.D. Fine Chemicals, India 
Diphenylamine was chemically pure. All other reagents/chemicals were of the highest 
analytical grade available. 
Equipment 
ELISA microplate reader MR-600 (Dynatech, U.S.A.), ELISA microplate washer 
(Denley, England), Elico pH meter model LI-120, Shimadzu UV-240 spectrophotometer 
equipped with thermo-programmer and controller unit, JASCO J-710 spectropolarimeter. 
UV-transilluminator (Vilber Lourmat, France), agarose gel electrophoresis assembly GNA-
100 and gradient mixer GM-1 (Pharmacia, Sweden), Avanti 30 table top high speed 
refrigerated centrifuge (Beckman, U.S.A.), power supply model PAC 300 and polyacrylamide 
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gel electrophoresis assembly (Bio-Rad, U.S.A.) were the major equipments used in this study. 
Serum Specimens 
Normal human sera were obtained from healthy subjects. SLE sera were obtained 
from outdoor and indoor patients of the Department of Medicine, All India Institute of 
Medical Sciences. New Delhi and J.N. Medical College Hospital, A.M.U., Aligarh. The 
SLE sera showed high titre anti-DNA antibodies and fulfilled the American College of 
Rheumatology (formerly American Rheumatism Association) revised criteria for the 
classification of SLE (Araett etal.. 1988). Serum samples were decomplemented at 56°C 
for 30 nun and stored in aliquots at -20°C with 0.1% sodium azide as preservative. 
METHODS 
Determination of DNA Concentration 
DNA concentration was estimated colorimetrically by the method of Burton (1956) 
using diphenylamine reagent. 
(a) Crystallization of diphenylamine 
Diphenylamine (2g) was dissolved in 200 ml boiling hexane. After adding 0.5 g of 
activated charcoal, the hot mixture was filtered through Whatman No. 1 filter paper and 
the filtrate was kept overnight at 4°C and dried at room temperature before use. 
(b) Preparation of diphenylamine reagent 
750 mg of recrystallized diphenylamine was mixed with 50 ml of glacial acetic acid 
and 0.75 ml concentrated sulphuric acid. The reagent was prepared fresh before use. 
(c) Procedure 
One ml of DNA sample was mixed with 1.0 ml of 1 N perchloric acid and incubated at 
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70°C for 15 min. One hundred uL of 5.43 mM acetaldehvde was added followed by 2.0 ml of 
freshly prepared diphettylamine reagent. The contents were mixed and incubated at room tem-
perature for 16-20 hr. Absorbance was read at 600 nm and the concentration of DNA in 
unknown samples was determined from a standard plot of calf thymus DNA purified free ot 
RNA and proteins. 
Determination of Protein Concentration 
Protein was estimated by the methods of LOWTV et al. (195 1) and Bradford (197b) 
Protein estimation by Folin 's-phenol reagent 
The protein estimation by this method utilizes alkali (to keep the pH high), Cir* ion> 
(to chelate proteins) and tartarate (to keep the Cu2" ions in solution at high pH) 
(a) Folin-Ciocalteau reagent 
The reagent was purchased from Centre for Biochemical Technology. New Delhi 
and diluted 1:4 with distilled water before use. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(i) Two percent sodium carbonate in 100 mM sodium hydroxide 
(ii) 0.5 per cent copper sulphate in 1 percent sodium potassium tartarate 
The working reagent was prepared fresh before use by mixing components (i) and 
(ii) in the ratio of 50:1. 
(c) Procedure 
To one ml of protein sample was added 5 ml of alkaline copper reagent and incubated 
for 10 min at room temperature. One ml of working Folin-Ciocalteau reagent was added 
and the tubes were read at 660 nm after 30 min. The concentration of protein in unknown 
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sample was determined from a standard plot ofbovine serum albumin. 
Protein estimation by dye-binding method 
This assay is based on colour change when Coomassie Brilliant Blue G 250 in acidic 
medium, binds strongly to protein hydrophobically and at positively charged groups 
(Bradford, 1976). In the environment of these positively charged groups, protonation is 
suppressed and a blue colour is observed (X - 595 nm). 
(a) Dye preparation 
One hundred mg Coomassie Brilliant Blue G 250 was dissolved in 50 ml of 95% 
ethanol and 100 ml of 85% (v/v) orthophosphoric acid was added. The resulting solution 
was diluted to a final volume of 1 litre and filtered through Whatman No. 1 filter paper to 
remove undissolved particles. 
(b) Protein assay 
To one ml of solutions containing 10-100 ug protein was added 5 ml of dye solution 
and contents mixed by vortexing. The absorbance was read at 595 nm after 5 min against 
a reagent blank. 
Isolation of Plasmid Bluescript DH5 a "KS" 
Plasmid DNA (2,958 base pairs) was isolated using the alkali lysis method as described 
by Maniatis et al. (1989). 
(a) Materials used 
(i) Cell strains and Media: E. coli strain DH,a and Luria broth was used throughout 
the study. Ampicillin was added in the growth medium at a concentration of 
100 ug/ml. 
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(ii) Solution I: 80 mM Glucose. 10 mM EDTA. 25 mM Tris-HCl. pH 7.0. 
(in) Solution II: Alkaline SDS solution (0.2 N NaOH, 1% SDS). 
(iv) A stock solution of RNase A (10 mg7ml in 10 mM Tris-HCl, pH 7.5 containing 
15 mM NaCl) was made DNase free by boiling at 100"C for 15 min. 
(b) Preparation of Plasmid DNA 
Plasmid containing E. co/i cells were grown in 250 ml Luria broth containing 100 
ug/ml Ampicillin. After 16 hr incubation at 37°C the culture was transferred to 2 L Luria 
broth containing 100 (.ig/ml ampicillin and further incubated for 16 hr at 37"C. Cells were 
harvested by centrifugation at 6000 rpm for 20 min at 4°C. The supernatant was discarded 
and open centrifuge bottle was left in an inverted position to allow all of the supernatant to 
drain away. The bacterial cell pellet was resuspended in 400 ml of STE (0.1 M NaCl, 10 
mM Tris-HCl. pH 8.0. 1 mM EDTA. pH 8.0). The cells were again centrifuged at 6000 
rpm for 20 min at 4°C. The supernatant was carefully removed and the cell pellet was 
suspended in 72 ml of solution I. 80 mg/ml of freshly prepared lysozyme in 10 mM Tris-
HCl, pH 8.0 was added. After a 10 min period of incubation at 0°C, 160 ml of solution II 
was added and the bottle was gently shaken up and down. The bottle was maintained for 
5 min at 0"C and then 80 ml of solution III was added. The contents of the bottle were 
gently mixed by inversion for a few seconds during which time a clot of chromosomal 
DNA forms. The bottle was maintained at 0°C for 15-20 min to allow most of the proteins, 
high mol.wt. RNA and chromosomal DNA to precipitate. Centrifugation for 30 min at 
4°C yields an almost clear supernatant. The supernatant was filtered through a Whatman No. 1 
filter paper. The plasmid DNA was precipitated with 0.7 volume of isopropanol at room 
temperature. The precipitate was collected by centrifugation at 16,000 rpm for 30 min at 
room temperature and the supernatant was removed by aspiration. The pellet was washed 
with 70% ethanol and again ceutrifiiged at 16,000 rpm for 10 min. The pellet was air dried for 
about 45 min and was dissolved in minimal volume of TE buffer (10 mM Tris-HCl, pH 8.0, 1 
mM EDTA). 
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The plasmid DNA was treated with pancreatic RNase A at a concentration of 20 ug/ml 
and kept at 37°C for 2 hr. It was then extracted with equal volume of phenol: chloroform: 
isoamyl alcohol (25:24:1). To the aqueous layer was added one-tenth volume of 3N sodium 
acetate buffer, pH 5.2 and two volumes of cold absolute alcohol. The DNA was collected 
by centrifugatiou, washed once with 70% etbanol and allowed to dry. It was then dissolved 
in TE bufifer, pH 8.0. 
Purification of Calf Thymus DNA 
Commercially obtained calf thymus DNA was purified free of proteins and single 
stranded regions as described by Ali et al. (1985). DNA (2 mg/ml) was dissolved in 0.1 X 
SSC (15 mM sodium citrate and 150 mM sodium chloride, pH 7.3) and then mixed with 
an equal volume of chloroform-isoamyl alcohol (24:1) in a stoppered container and shaken 
for 1 hr. The aqueous layer containing DNA was separated from the organic layer and re-
extracted with chloroform-isoamyl alcohol. The DNA was precipitated with two volumes 
of cold absolute ethanol and collected on a glass rod. After drying in air, the DNA was 
dissolved in acetate buffer (30 mM sodium acetate containing 30 mM zinc chloride, pH 
5.0) and treated with nuclease SI (150 units/mg DNA) at 37°C for 30 min to remove 
single stranded regions. The reaction was stopped by adding one-tenth volume of 200 mM 
EDTA, pH 8.0. The nuclease S1 treated DNA was extracted twice with chloroform-isoamyl 
alcohol and finally precipitated with two volumes of cold ethanol. The precipitate was 
dissolved in phosphate-buffered saline (PBS) (10 mM sodium phosphate containing 150 
mM sodium chloride, pH 7.4). 
Fragmentation of Purified DNA 
Micrococcal nuclease was used to digest purified DNA to obtain smaller fragments (Ali 
eta/., 1985). Purified DNA (2 mg/ml) in 6 mM Tris, lOOmMNaCland 2 mM CaCl^, pH 8 0 
was treated with 0.25 units micrococcal nuclease per mg DNA at 37°C for 6 min. The reac-
tion was stopped by adding oue-teuth volume of 200 mM EDTA, pH 8.0. The mixture was 
extracted twice with chloroform-isoamyl alcohol and fragmented DNA was precipitated with 
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cold absolute ethanol and dissolved in 30 mM acetate buffer, pH 5.0 containing 30 mM ZnCI,. 
The DNA was digested with nuclease SI (150 units/mg DNA) at 37"C for 30 min. The 
reactiou was stopped with oue-tenth volume of 200 mM EDTA. pH 8.0. The digested DNA 
fragments were extracted twice with chloroform-isoamyl alcohol and precipitated with cold 
absolute ethanol. The DNA fragments were then dissolved in Tris-buffered saline (TBS). pH 
8.0 and separated on the basis of size by gel filtration on a Sepharose 4B column (46.0 cm \ 
1.2 cm) equilibrated with TBS and fractions of 4 ml were collected. The size of the DNA 
fragments was determined by polyacrylamide gel electrophoresis (PAGE). 
Polyacrylamide Gel Electrophoresis 
Nucleic acid samples were subjected to PAGE under non-denaturing conditions as de-
scribed by Laemmli( 1970). The following stock solutions were prepared: 
(a) Acrylamide-bisacrylamide (30:0.8) 
Thirty gm acrylamide and 0.8 gm bisacrylamide was dissolved in distilled water to a final 
volume of 100 ml. The solution was filtered and stored at 4°C in an amber coloured bottle. 
(b) Resolving gel buffer 
Thirty six gm Tris was dissolved in 48 ml of 1 N HC1, pH adjusted to 8.8 and final 
volume made upto 100 ml with distilled water. 
(c) Stacking gel buffer 
Six gm Tris was dissolved in 40 ml distilled water, pH adjusted to 6.8 with 1 N HC1 and 
final volume made upto 100 ml with distilled water. 
(d) Electrode buffer 
The electrophoretic buffer used was TAE, pH 7.9 (40 mM Tris, 1.14 ml glacial acetic 
acid and 1 mM EDTA). 
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(e) Procedure 
The PAGE assembly was set up and the glass plates separated by 15 mm thick spacer 
were sealed with l°o agarose from the sides and bottom. The non-denaturing gel was prepared 
and poured between the glass plates and allowed to polymerize at room temperature. Nucleic 
acid samples were mixed with one-tenth volume of'stop mix' (30% Ficoll. 0.025% xylene 
cyanole FF and 500 mM EDTA in 10 times concentrated TAE buffer) and applied onto the gel 
The gel was electi oplioresed for 8-10 lvr at room temperature at 80 volts, stained with ethidiuni 
bromide (0.5 ug/ml) and visualized under UV light. 
Recipe for 7.5 % non-denaturing PAGE 
Acrylamide-bisacrylamide 10.0 ml 
Resolving gel buffer 5.0 nil 
1.5% Ammonium persulphate 1.5 ml 
Distilled water 23.5 ml 
TEMED 20.0 uL 
PAGE For Proteins 
A 7.5% resolving gel was layered with 2.5% stacking gel according to the composition 
given below. 
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Solutions Stacking gel Resolving gel 
Acrylamide-bisacrylaniide 
Stacking ael buffer 
Resolving gel buffer 
Distilled water 
I0%SDS 
1.5% Ammonium persulphate 
TEMED 
2.5 ml 
5.0 ml 
11.3 ml 
0.2 ml 
1.0 ml 
15 uL 
7.5 ml 
3.75 ml 
16 95 ml 
0.3 ml 
1.5 ml 
15 uL 
Protein samples were mixed with one-fourth volume of sample buffer (10% glycerol 
and 0.002% bromophenol blue in 10 times concentrated 0.5 M Tris-HCl. pH 6.8) and 
applied onto the gel and electrophoresed at 70 volts for 6-8 hr using Tris-glycine bulla 
(25 mMTris. 192 mM glycine containing 1% SDS), pH 8.3. The gels were stained overnight 
with 0.1% Coomassie Brilliant Blue R 250 (in 25% isopropanol and 10% glacial acetic 
acid). Destaining was carried out with a mixture of 10% methanol and 10% glacial acetic 
acid. 
Nitric Oxide Modification of Plasmid DNA 
Plasmid DNA (pBS DH;a "KS") was modified with nitric oxide by the method of Sugiura 
and Matsumoto (1995). A standard reaction of DNA (0.4 ug) with nitric oxide, which was 
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generated by reduction of sodium nitrite with sodium dithionite. was performed for 3 hi in a 
volume of 20 \.i\ containing 20 mM Tris-HClbuffer, pH 7.5. The reaction sample contained 
sodium nitrite (100 uM)and sodium dithionite at a concentration of 10 mM. After incubation, 
ethanol precipitation of modified and native DNA was performed twice. Plasmid DNA incu-
bated with 100 (.tM sodium nitrite or 10 mM sodium dithionite alone served as controls. 
Linearisation of Plasmid DNA 
(a) EcoRI digestion buffer 
10mMTris-HCl lOOmMNaCL lOmMMgCl,. 10mM2-mercaptoethanoLpH8.0. 
(b) Storage buffer 
10 mM Tris-HCl, 200 mM NaCl, 0.1 mM EDTA, 7 mM 2-mercaptoethanol. 
50% glycerol, 200 ug/rnl BSA and 0.2% Triton X-100, pH 7.4. 
(c) Procedure 
One microgram of both native and nitric oxide modified plasmid DNA was digested 
with 5 units of EcoRI at 37°C for 3 hr. The reaction was stopped by adding one-tenth 
volume of 'stop mix' dye and the samples were loaded in the wells of the submerged 
agarose gel and electrophoresed for 2 hr at 30 mA. 
Spectroscopic Analysis 
The ultraviolet spectra of native and nitric oxide modified plasmid DNA sample 
were recorded between 200-400 um on Shimadzu UV-240 spectrophotometer. 
Circular Dichroism Measurements 
Circular dichroism (CD) measurements of native and nitric oxide modified plasmid in 
PBS, pH 7.4 were performed in 1 nmpath length cells at a constant temperature of 25°C. The 
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wavelengths chosen ranged from 220 nm to 350 nm. Scans were recorded at 0.2 nm intervals, 
and three spectra of each sample were recorded and average determined. A scan of buffer 
alone was recorded to adjust the base line. The concentration of the plasmid DNA used was 
0.15 mM base pair Molar ellipticities [9] were calculated in terms of the base pair concentra-
tion according to the following equation 
™- u£r 
where. 0 is the measured ellipticity (mdeg), c is the molar concentration of plasmid DNA 
per base pair, and 1 is the path length in cm. 
Absorption-Temperature Scan 
Thermal denaturation analysis of nucleic acids was performed in order to ascertain 
the degree of modification incurred on the nucleic acids by determining mid point melting 
temperature (Tm). Native and modified samples were subjected to heat denaturation on a 
Shimadzu UV-240 spectrophotometer coupled with a temperature programmer and 
controller assembly (Hasan and Ali, 1990). All the samples were melted from 30"C to 
95°C at a rate of 1.5"C/min after 10 min equilibration at 30°C. The change in absorbance 
at 260 nm was recorded with increasing temperature. Percent denaturation was calculated 
as follows: 
Percent denaturation = x 100 
A
 -
 A
, o 
mix 30 
where, \ - Absorbance at a temperature T°C 
A = Final maximum absorbance on the completion of 
ma \ * 
denaturation (95°C) 
A = Initial absorbance at 30"C 
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Detection of Strand Breaks 
The damage to plasmid-DNA mediated by nitric oxide radical was characterized by the 
presence of strani breaks. The strand breaks in plasmid-DNA was ascertained by alkaline 
sucrose density gradient ultracentrifugation, agarose gel electrophoresis and nuclease S1 di-
gestibility. 
(a) Alkaline Sucrose Density Gradient Ultracentr if ligation 
EcoR.1 linearised, native and nitric oxide modified DNA (0.2 ml) were treated by the 
addition of an equal volume of 0.2 N NaOH. After 10 mm to allow denaturatiou of DNA. 
0.4 ml sample was layered on top of a linear 4.6 ml alkaline sucrose gradient (5-20°o 
sucrose in 0.1 N NaOH and 10 mM EDTA) (Ali and Sauerbier, 1978). The gradients were 
centrifuged at 30,000 rpm for 1 hr at room temperature in swinging bucket rotor of Beckman 
ultraceutrifuge. The bottom of the tubes were pierced and six drop fractions were collected. 
diluted to about 0.5 ml with distilled water and their absorbance were recorded at 260 urn. 
(b) Nuclease SI Digestibility 
Native and nitric oxide modified DNA were characterized by nuclease S 1 digestibility 
(Matsuo and Ross. 1987). One microgram each of native and modified DNA in acetate 
buffer (30 mM each of sodium acetate and zinc chloride, pH 5.0) were treated with nuclease 
SI (20 units/ug DNA) for 30 min at 37°C. The reaction was stopped by adding one tenth 
volume of 200 mM EDTA, pH 8.0. The digested and control samples were subjected to 
agarose gel electrophoresis. 
(i) Gel preparation 
Agarose (1%) in TAE buffer (40 mM Tris acetate, pH 8.0 containing 2 mM EDTA) 
was dissolved by heating. The solution was cooled to about 50°C and then poured into the 
gel tray and allowed to solidify at room temperature. 
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(ii) Sample preparation and loading 
Native and nitric oxide modified DNA samples treated with nuclease S1 were mixed 
with one-tenth volume of sample buffer (0.125% bromophenol blue, 30% Ficoll 400. 
500 mM EDTA in 10X electrophoresis buffer). The samples were loaded in the wells and 
electrophoresed for 2 hr at 30 mA. The gels were stained with ethidium bromide (0.5 ug 
ml), viewed by illumination under UV light and photographed. 
Immunization Schedule 
Female rabbits (8-12 months, weight 1-1.5 kg) were immunized with native and NO 
plasmid DNA. The immunizing antigen (50 ug/rabbit was complexed with methylated 
BSA in the ratio of 1:1 (w/w) and emulsified with an equal volume of Freund's complete 
adjuvant and injected subcutaneously at multiple sites in rabbits (Hasan et al.. 1991). 
Subsequent injections were given intramuscularly in Freund's incomplete adjuvant at weekly 
intervals. A total of 300 ug of native and NO-plasmid were injected during the course of 
six injections. Animals were bled by cardiac puncture and serum separated was 
decomplemented at 56°C for 30 min. Pre-immuue serum was collected prior to 
immunization. The sera were stored in small aliquots at -20°C with 0.1% sodium azide as 
preservative. 
Isolation of Serum IgG by Protein A-Sepharose CL-4B 
Serum IgG was isolated by affinity chromatography on Protein A-Sepharose CL-4B 
column. Diluted serum (0.5 ml) with equal volume of PBS, pH 7.4 was applied to column 
(0.9 cm X 15 cm) equilibrated with PBS, pH 7.4. The wash through was recycled 2-3 times 
and finally the column was washed extensively with PBS to remove unbound material. The 
bound IgG was eluted with 0.58% acetic acid in 0.85% sodium chloride (Goding, 1978) and 
neutralized with 1 ml of 1 M Tris-HCL, pH 8.5. Three ml fractions were collected and absorb-
ance recorded at 278 nm. IgG concentration was determined considering 1.4 0.D -
1.0 mg IgG/ml. The isolated IgG was dialyzed against PBS, pH 7.4 and stored at -20°C with 
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0.1% sodium azide. 
Immunological Detection of Antibodies 
Immune and SLE sera were tested for antibodies by immunodiffusion, 
counterimmunoelectrophoresis. enzyme linked immunosorbent and gel retardation assays 
(a) Immunodiffusion 
Immunodiffusion (ID) was carried out by Ouchterlony double diffusion system using 
glass petri dishes as described by Tan et ol. (1966). Six ml of 0.4% agarose solution in 
PBS, pH 7.4 was brought into molten state, allowed to cool to 50-60"C and subsequently 
poured onto glass petri dishes. Wells each 5 mm in diameter, separated by 8 mm distance 
were cut onto hardened gel. Appropriate amount of antibody and antigen was placed in 
the wells and the reaction was allowed to proceed for 48-72 hr in a moist chamber at room 
temperature. The gels were washed with 5% sodium citrate to remove non-specific precipitin 
lines. The preciptin lines were analyzed visually and photographed. 
(b) Counterimmunoelectrophoresis 
Counterimmunoelectrophoresis (CIE) was performed as described by Kurata and 
Tan( 1976) with slight modifications. Three ml of 0.6% molten agarose solution in 
25 mM barbital buffer, pH 8.4 was poured onto microscopic slides (7.5 x 2.5 cm) and 
allowed to solidify at room temperature. Wells 4 mm in diameter were cut at a distance of 
5 mm between the two opposite wells. Antigen was placed in cathodal well and antibodies in 
the anodal well, electrophoresed for 45-60 min in 50 mM barbital buffer, pH 8.4 with a current 
of 3-4 mA per slide. Non-specific precipitin lines were removed with 5% sodium citrate. 
(c) Gel Retardation Assay 
Gel retardation assay was performed for the visual detection of antigen-antibody inter-
action (Sanford et at., 1988). Constant amounts of nucleic acid samples were incubated with 
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varying amounts of IgG in PBS, pH 7.4 for 2 hr at 37°C and overnight at 4°C. One-tenth 
volume of'stop mix' dye was added to the mixture and electrophoresed on 0.8% agarose for 
2 hr at 30 mA in TAE buffer, pH 7.9. The gels were stained with ethidium bromide (0.5 ug/ml). 
visualized under LTV light and photographed. 
(d) Enzyme Linked Immunosorbent Assay 
ELISA was performed using polystyrene (96 well) flat bottom microtitre plates as 
described by Aotsuka et al. (1979). 
(i) Buffers and reagents 
Tris buffered saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 
7 m buffered saline-Tween 20 (TBS-T) 
20 mM Tris. 144 mM NaCl, 2.68 mM KC1, pH 7.4, containing 500 uL Tween 20/L 
Carbonate-bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6, containing 2 mM 
magnesium chloride 
Substrate 
500 ug p-nitropheuyl phosphate (PNPP)/ml of carbonate-bicarbonate buffer 
(ii) Procedure 
Polystyrene microtiter plates were coated with 100 ul of nucleic acid antigen (2 5 
ug/ml in TBS, pH 7.4) for 2 hr at room temperature and overnight at 4°C. The antigen coated 
wells were washed three times with TBS-T to remove unbound antigen and unoccupied sites in 
47 
test and control wells were blocked with 150 uL of 1.5% BSA in TBS for 4-6 hr at room 
temperature. The plates were washed with TBS-T and antibody (100 ul/well) to be tested, 
diluted in TBS was added to each well. After incubating plates for 2 hr at room temperature, 
the bound antibodies were assayed by an appropriate anti-immunoglobulin alkaline phosphatase 
using p-nitrophenyl phosphate substrate, respectively. The plates were incubated for 1-2 hr 
and the absorbauce was read at 4 10 mn. Each sample was coated in duplicate. Results were 
expressed as a mean of A - A 
r
 test control 
Competition ELISA 
The antigenic specificity of the antibodies was determined by inhibition experiments 
(Hasan et al., 1991). Varying amounts of inhibitors (0-20 ug/ml) were mixed with a 
constant amount of antiserum or IgG. The mixture was incubated at room temperature for 
2 hr and overnight at 4°C. The immune complex thus formed was coated in the wells 
instead of the serum. The remaining steps were the same as in direct binding ELISA. The 
results were expressed as percent inhibition. 
Percent inhibition = 1 ^ ^ x 100 
uninhibited 
Quantitative Precipitin Titration 
The immunointeraction between antigen and antibody was investigated by precipitin analy-
sis under equilibrium conditions. Increasing amounts of antigens (0-40 ug) were mixed with 
100 ug each of IgG in an assay volume of 0.2 ml. The mixture was incubated at 37°C for 2 hr 
and overnight at 4°C. The tubes were centrifuged at 10,000 rpm for 5 min. The precipitate 
was washed with cold PBS, pH 7.4 and dissolved in a fixed volume of 1 M NaCl. The amount 
of bound and unbound antigen and antibody in the dissociated immune complex supernatant 
was determined. For antigen, diphenylamine reagent (Burton, 1956) and for antibody, dye 
binding method (Bradford, 1976) was used. The binding data was analyzed and antibody 
affinity was calculated (Langmuir, 1918). 
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Isolation of DNA from Human Lymphocytes 
(a) Isolation of lymphocytes 
Blood was collected in EDTA from normal healthy individuals. Lymphocytes were 
harvested by first lysing erythrocytes using RBC lysing solution (155 mM NH4C1, lOmM 
NaHCOr 0.1 mM EDTA, pH 7.4). The blood samples were cooled to 4"C and 10 volumes 
of RBC lysis solution was added, swirled for 5-10 min. The sample was centrifuged at 
2000 rpm at 4"C for 10 min to harvest the lymphocytes. This process was repeated 3-4 
times, until a clear, white pellet of lymphocytes was obtained. 
(b) Exposure of lymphocytes to nitric oxide 
Lymphocytes were suspended in 1 ml PBS, pH 7.4 and exposed to varying amounts 
of sodium nitrite (2.5 mM, 5 mM, 10 mM) and sodium dithionite (in 1:100 molar excess) 
at 37°C for 3 hr under aerobic conditions. The cells were washed 3-4 times with PBS. pH 
7.4 to remove the excess salts. 
(c) Isolation of human DNA 
Human DNA was isolated from lymphocytes essentially as described by Baas et al. 
(1984). Lymphocytes were initially lysed by lymphocyte lysis buffer (19 mM Tris, 2 mM 
EDTA, 400 mM NaCl, containing 1% SDS and 1 mg/ml proteinase K, pH 7.4). The 
lymphocytes were resuspeuded in lymphocyte lysis buffer, incubated at 50°C for 1 hr and 
37°C overnight with constant shaking. To this, was added an equal volume of phenol-
chloroform- isoamyl alcohol(25:24:1), extracted for 15 min and allowed to stand for 15 min. 
The aqueous layer was removed carefully and the extraction step repeated 2 to 3 times. To the 
aqueous layer was added one-tenth volume of 3 N sodium acetate buffer, pH 5.2 and two 
volumes of cold absolute ethanol to precipitate DNA. The DNA was collected by centrifuga-
tion, washed once with 70% ethanol and allowed to dry. It was then dissolved in PBS, pH 7.4. 
The absorbance of DNA solution was read at 260 um and 280 nm to ascertain its purity and 
concentration. 
<^y\E±uL£ 
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Purification and Fragmentation of Calf Thymus DNA 
Native calf thymus DNA obtained commercially was digested with micrococcal 
nuclease to obtain fragments, separated by chromatography on Sepharose 4B column 
(Fig. 2). The size of DNA fragments were analyzed on 7.5% PAGE, using pBR322/Hinf III 
digest as DNA molecular weight markers (Fig. 3). Fragments of approximately 200 
bp were used for nitric oxide modification studies and will now be referred to as 
DNA and NO-DNA in case of nitric oxide modified 200 bp DNA fragments. 
Isolation of Plasmid Bluescript DH5a"KS" 
Plasmid DNA was purified from E. coli strain DH,a, using the alkali lysis method 
(Maniatis et al., 1989). The isolated DNA was subjected to agarose gel electrophoresis 
(Fig. 4) to assess its purity in terms of RNA. protein and chromosomal DNA 
contamination. 
Nitric Oxide Modification of 200 bp DNA Fragments 
Nitric oxide radical was generated by reduction of sodium nitrite with sodium 
dithionite. In order to optimise the dose of nitric oxide generation required for DNA 
modification, a standard reaction of the DNA (0.4 mg) with nitric oxide was performed 
for 3 hr at 37°C in 20 mM Tris-HCl buffer, pH 7.5. The amount of sodium nitrite 
and sodium dithionite was varied. The modified samples were dialyzed against 10 
mM Na-phosphate buffer, pH 7.5. Nitric oxide induced modification of 200 bp DNA 
at 100 mM sodium nitrite and 10 mM sodium dithionite concentrations, while no 
change was observed in the agarose gel electrophoretic pattern of the native and the 
DNA modified at other concentrations of sodium nitrite (100 fiM) with sodium 
dithionite (10 |.iM, 100 uM and ImM respectively). Low intensity of band in case of 
200 bp DNA modified with 100 mM sodium nitrite and 10 mM sodium dithionite is 
attributed to the modification of bases and formation of single strand breaks (Fig. 5). 
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Fig. 2. Fractionation ofmicrococcal nuclease digested calf thymus DNA on Sepharose 4B 
column. 
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Fig. 3. Polyacrylamide gel electrophoresis of calf thymus DNA fragments. Purified DNA 
was digested for 6 min with micrococcal nuclease followed by nuclease SI digestion. 
The fragments were seperated on a Sepharose 4B column. Lane 1. contained pBR 
322/Hinf III digest as a standard marker. Lane 9 shows DNA fragments of 200 bp 
approximately. Electrophoresis was performed on 7.5% polyacrylamide gel for 8 hr 
at 70 volts. 
S2 
Fig. 4. Agarose gel electrophoretic pattern of isolated plasmid Bluescript DNA. Lane 1 
contained the isolated sample showing low molecular weight RNA contamination. 
Lane 2 contained the RNase treated plasmid preparation. Electrophoresis was carried 
out on 1% agarose gel for 2 hr at 30 mA. 
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Fig. 5. Agarose gel electrophoretic pattern of uathe 200 bp DNA (lauel) and nitric oxide 
modified 200 bp DNA (lane2). Electrophoresis was carried out on 1% agarose gel 
for 2 hr at 30 mA. 
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The UV absorption spectra of nitric oxide modified 200 bp DNA (NO-DNA) 
showed hypochromicity at 260 nm( 13.2%) as compared to the native sample (Fig. 6). 
The spectral curve also exhibited shifts in the maxima and minima to the extent of 4 nm 
and 9 nm respectively for the modified 200 bp DNA relative to native 200 bp DNA. The 
maxima for native 200 bp DNA was observed at 260 nm which is shifted to 264 nm in 
case of modified DNA. Similarly, the minima of native 200 bp DNA at 230 nm shifted to 
239 nm. 
Thermally induced transitions were measured spectrophotometrically at 260 nm 
by heating nucleic acid samples at a rate of 1.5°C/niin. Melting curves were obtained 
at temperatures from 30°C to 95°C. The increase in absorbance at 260 nm was taken 
as a measure of denaturation. The process was characterised by determining the 
percent DNA in denatured state as a function of temperature. The melting temperature 
(Tm) of native DNA at which 50% of the double helical structure is lost was found to 
be 80°C, while in case of nitric oxide modified 200 bp DNA it was found to be 74"C 
(Fig. 7). The results exhibit a net decrease of 6"C in the Tm value for the modified 
DNA when compared to its unmodified native conformer. These findings indicate 
that the decrease in Tm to the extent of 6°C is primarily due to structural alterations 
of DNA which occur upon generation of single strand breaks and/or due to altered 
hydrogen bonding between base pairs. The UV absorption and thermal denaturation 
characteristics of native and nitric oxide modified 200 bp DNA are listed in Table 3 
Nitric oxide modified and unmodified native 200 bp DNA was digested with 
nuclease SI (20 units/ng DNA) and resolved by agarose gel electrophoresis (Fig. 8). 
The controls were the unmodified DNA samples with and without nuclease SI 
treatment. Nuclease S1 treated NO-DNA showed almost total digestion after 30 min 
of incubation, while native 200 bp DNA remained undigested. Nitric oxide, therefore, 
created sufficient structural alterations in DNA, to be a substrate for single strand 
specific nuclease SI. 
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Fig. 6. Ultraviolet absorption spectra of native 200 bp DNA ( 
DNA( ). 
)and NO200bp 
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Fig. 7. Thermal denaturation profile of native 200 bp DNA ( # ) and NO-200 bp DNA 
( O )• 
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TABLE 3 
UV Absorption and Thermal Denaturation Characteristics of 
Native and Nitric Oxide Modified 200 bp DNA 
Parameter Native 200 bp DNA NO-200 bp DNA 
Absorbance ratio 1.76 1.28 
Hyperchromicity 36.4 25.2 
at 95°C, (%) 
Melting temperature 80.0 74.0 
(Tm). °C 
Onset of duplex 62.0 50.0 
melting 
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Fig. 8. Nuclease SI digestibility of native and NO-200 bp DNA. Lane 1 contained native 
200 bp DNA, while lane 2 contained native 200 bp DNA treated with nuclease SI. 
Lane 3 contained NO-200 bp DNA, while lane 4 contained NO-200 bp DNA treated 
with nuclease S1 for 30 min. Electrophoresis was carried out on 1 % agarose gel for 
2 hr at 30 mA. 
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Nitric Oxide Modification of Plasmid DNA 
Plasmid DNA was modified with nitric oxide by the method of Sugiura and 
Matsumoto (1QQ5). The reaction sample contained DNA (0.4 ^g) . sodium nitrite 
( 100 nM) and sodium dithionite ( 10 mM) in 20 inM Tris-HCl buffer. pH 7.5. The 
mixture was incubated at 37"C for 3 hr, and thereafter nucleic acids were precipitated 
by cold ethanol. After two precipitations, the precipitate was disolved in TE buffer 
pH 8.0. 
Figure 9 shows UV absorption spectra of nitric oxide modified plasmid DNA 
(NO-plasmid DNA) with characteristic hypochromicity (16.9%). Furthermore, the 
spectral curves exhibited a change in the maxima and minima to the extent of 8 nm 
and 6 nm respectively, for modified DNA relative to native DNA. The maxima for 
native plasmid DNA was observed at 254 nm which shifted to 262 nm in case of 
modified DNA. Similarly, the minima of native plasmid DNA at 224 nm shifted to 
230 um. The perturbations incurred on plasmid DNA as a consequence of nitric oxide 
modification were also analysed by UV difference spectral scanning (Fig. 9 inset) 
Difference spectrum of nitric oxide modified plasmid DNA with respect to native 
plasmid DNA revealed an appreciable negative inversion in absorption between 23 0-
270 um, followed by increased absorption at around 300 nm. 
Circular Dichroism of Modified Plasmid DNA 
The circular dichroic spectra of the native and nitric oxide modified plasmid 
DNA showed characteristic changes in the ellipticity. Ln this study, native DNA showed 
a negative peak at 243 nm and positive peak at 267 um. Nitric oxide modified DNA 
when compared with native DNA showed a negative peak at 245 nm with a change in 
ellipticity from -10.0 mdeg to -12.8 mdeg and a positive peak at 269 nm with two 
small shoulders around 280 nm and a change in ellipticity from +15.6 mdeg to +10.0 
mdeg (Fig. 10). The result shows 35.8% decrease in ellipticity of native plasmid 
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Fig. 9. Ultraviolet absorption spectra of native plasmid DNA ( ) and nitric oxide 
modified plasmid DNA ( ). Inset: UV difference spectra of nitric oxide modified 
plasmid DNA. Native plasmid DNA served as control. 
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Fig. 10. Circular dichroic spectra of native plasmid DNA ( 
( )• 
) and NO-plasmid DNA 
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DNA after nitric oxide radical modification. 
Agarose Gel Electrophoresis 
The presence of strand breaks (both single and double) in nitric oxide modified 
plasmid DNA was ascertained by performing agarose gel electrophoresis of native 
and nitric oxide modified plasmid DNA in 1% agarose gel. As evident from Figure 
11, form I of modified plasmid DNA shows low fluorescence intensity while higher 
intensity was observed in form III compared to the native plasmid DNA. These changes 
in intensity can be attributed to the conversion of supercoiled form (form I) of plasmid 
to linear form (form III) due to the DNA cleavage activity of nitric oxide radical. In 
addition, form III seems to be diffused as compared to that of the native sample, 
probably indicating modification of bases and strand breaks as a consequence of 
modification by the nitric oxide radical. 
Nuclease SI Digestibility of Nitric Oxide Modified DNA 
Native and nitric oxide modified plasmid DNA were digested with nuclease S ! 
(20 units/ug DNA). The residual DNA was detected by agarose gel electrophoresis 
The controls were the unmodified DNA samples with and without nuclease SI 
treatment. The result showed complete disappearance of the supercoiled form and 
considerably low intensity of form III which appeared as diffused band. Nati\e 
DNA and nuclease SI treated native DNA showed almost identical electrophoretic 
migration pattern and fluorescence intensity (Fig. 12). 
Alkaline Sucrose Density Gradient Ultracentrifugation 
EcoRI linearised, nitric oxide modified and native plasmid DNA samples were 
subjected to sucrose density gradient ultracentrifugation under alkaline conditions to 
detect single strand breaks. Samples were denatured by the addition of 0.2 N NaOH, 
transferred to the top of 5-20% linear alkaline sucrose gradient and sedimented at 30,000 
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Fig. 11. Agarose gel electrophoresis of native plasmid DNA (laue 1) and NO-plasmid DNA 
(lane 2). Electrophoresis was carried out on 1% agarose gel for 2 hr at 30 mA. 
Form I-Supercoiled form; From II- Relaxed fonn; Fonn Ill-Linear form. 
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Fig. 12. Nuclease SI digestibility of native plasmid DNA and NO-plasmid. Lane 1 contained 
native plasmid DNA, while lane 2 contained native plasmid DNA treated with nuclease 
SI. Lane 3 contained NO-plasmid DNA, while lane 4 contained NO-plasmid DNA 
treated with nuclease SI for 30 min. Electrophoresis was carried out on 1% agarose 
gel for 2 hr at 30 mA. 
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rpm for one hour. The bottoms of the tubes were pierced, fractions collected, and moni-
tored at 260 nm and data plotted as absorbance at 260 nm against fraction number 
Figure 13 shows the sedimentation profile of native and nitric oxide modified plasmid 
DNA. Change in molecular weight of DNA due to single strand breaks by nitric oxide 
radicals can be observed as a change in the sedimentation rate. Native plasmid DNA 
banded as a sharp symmetrical peak, while nitric oxide modified plasmid DNA showed a 
diffused sedimentation profile indicating the generation of strand breaks. 
Isolation of DNA from Human Lymphocytes 
Lymphocytes from human blood obtained from clinically normal subjects were iso-
lated by RBC lysis. DNA was isolated from normal lymphocytes and lymphocytes ex-
posed to varying concentrations of sodium nitrite (2.5 mM 5.0 mM, 10 mM) and sodium 
dithionite ( in 1: 100 molar excess ). Figure 14 shows the UV absorption spectra of 
native and modified DNA. With the increasing dose of nitric oxide there is corresponding 
decrease in the absorbance at 260 nm. Native DNA and DNA modified with the highest 
concentration of nitric oxide were used as inhibitor in competitive assay. 
Immunogenicity of Nitric Oxide Modified DNA 
The antigenicity of the nitric oxide modified plasmid DNA was probed by 
inducing antibodies in rabbits. The antigenic specificity of the induced antibodies 
was assayed by direct binding and competition ELISA. The binding of these antibodies 
to the immunogen and native plasmid DNA was further substantiated by band shift 
assay. 
(a) Antibodies against nitric oxide modified DNA 
The antibodies raised against nitric oxide modified DNA was found to be non-
precipitating as observed by immunodiffusion and counterimmunoelectrophoresis. 
Direct binding ELISA on plates coated with nitric oxide modified plasmid DNA indicated 
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Fig. 13. Alkaline sucrose density gradient ultraceutrifugation of native plasmid DNA ( O ) 
and NO-plasmid DNA ( A ) 
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14. Ultraviolet absorption spectra of DNA from native lymphocytes ( ) and DNA 
from lymphocytes exposed to varying amounts of sodium nitrite ( ) 
and sodium dithionite (in 1:100 molar ratio). 
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high binding activity with different serum dilutions showing a titre of 1:12800 (Fig. 15) 
The antibodies against native plasmid DNA were also raised in rabbits. The result evalu-
ated by direct binding ELISA showed negligible antibodies induction (Fig. 16). Preimmune 
serum as control did not show appreciable binding with the iminunogen. The specificity 
of induced antibodies for antigenic determinants on modified DNA was evaluated b\ 
competitive binding assays. A maximum of 73% inhibition in antibody binding was re-
corded at an inhibitor (nitric oxide modified DNA) concentration of 20 ng/ml(Fig. 17) 
The concentration of the competitor required for 50% inhibition was 12.4 (.ig/ml. 
(b) Purification and binding characteristics of immune IgG 
Immunoglobulin G was isolated from preimmune and immune rabbit serum by 
affinity chromatography on Protein A-Sepharose CL-4B column (Fig. 18). The purity 
of the IgG was ascertained by SDS-polyacrylamide gel electrophoresis under non-
reducing conditions (Fig. 18 inset). The purified IgG migrated as a single baud 
Direct binding ELISA of the purified IgG showed a strong binding with the 
immunogen (Fig. 19). Preimmune IgG as negative control showed negligible binding 
to NO-modified DNA. The specificity of the purified IgG was evaluated by competitive 
inhibition assay. A maximum of 86.2% inhibition of anti-NO plasmid DNA IgG binding 
to immunogen was observed (Fig. 20). Fifty percent inhibition was achieved at an 
inhibitor concentration of 1.6 ug/ml. 
Immuno-crossreactivity of Anti-NO-PIasmid DNA Antibodies 
The antigenic specificity of the induced anti-NO-plasmid DNA antibodies was char-
acterised by competition inhibition assay. The anti-NO-plasmid DNA antibodies exhib-
ited a wide range of heterogeneity as demonstrated by inhibition assays, using the 
immunogen, nucleic acid polymers, synthetic polynucleotides and bases as inhibitors. A 
maximum of 86.2% inhibition of the anti-NO-plasmid DNA IgG with the immunogen as 
an inhibitor was observed (Fig. 20). Competition experiments with native DNA showed 
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Fig. 15. Level of induced antibodies against NO-plasmid DNA. Direct binding ELISA with 
preimmune serum ( 0 ). immune sera ( A , • ) and adjuvant immunized 
serum ( O ) The microtitre plate was coated with NO-plasmid DNA (2.5 |ng/ml) 
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Fig. 16. Level of induced antibodies against native plasmid DNA. Direct binding ELISA 
with preimmuue serum ( # ), immune sera ( A . • ) and adjuvant immunized 
serum ( O ). The microtitre plate was coated with native plasmid DNA(2.5 |.ig/ml). 
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7. Inhibition ELISA of immune sera against NO-plasmid DNA ( A , 0 ) with NO-
plasmid DNA as inhibitor. The microtitre plate was coated with NO-plasmid DNA 
(2.5 ng/ml). 
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Fig. 18. Elution profile ofanti-NOplasmid DNA IgG on Protein A-Sepharose CL-4B column. 
Inset: SDS-PAGE of purified IgG on 7.5°o acrylamide gel. 
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Fig. 19. Binding of affinity purified preimmime ( £\ ) and immune IgG ( JL ) to NO-
plasmid DNA Tlie microtitre plates were coated with NO-plasmid DNA (2.5 ng/ml). 
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20. Inhibition of anti-NO-plasmid DNA IgG binding to NO-plasniid DNA. The inhibitors 
were NO-plasuiid DNA ( O ) a»d native plasmid DNA ( A )• The microtitre 
plates were coated with NO-plasmid DNA (2.5 iig/ml). 
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considerable inhibition in antibody activity. Preincubation of immune antibody with na-
tive plasmid DNA inhibited its binding to modified DNA by 58.7% at 20 ug/ml (Fig. 20). 
whereas 50% inhibition was obtained at 16.4 ug/ml. Total DNA from human lymphocyte?* 
and 200 bp fragments of calf thymus DNA showed moderate inhibition of 48.5% and 
21.3% respectively (Fig. 21). whereas their NO modified conformers were inhibitory to 
the extent of 54.2% and 45 6% respectively. Fifty percent of inhibition of antigen-anti-
body interaction was obtained with 1 7.6 ug/ml of NO-lymphocyte DNA. 
The nitrogenous bases guanine, cytosine. adenine and their ROS-modified (hydrow 1 
radical) and NO-modified forms were used as inhibitors of antibody binding acti\ it \ 
Guanine showed a moderate inhibition of 43% (Fig. 22). In contrast. ROS and NO 
modified conformers of guanine were found to be potent inhibitors, showing maximum 
inhibitions of 6 1% and 69% respectively. The amount of ROS-guanine and NO-guanine 
required for 50% inhibition in antibody activity was 11.9 jig/ml and 8.7 ug/ml respec-
tively. Cytosine was non-inhibitory showing inhibition of 21% whereas its ROS modified 
form was a moderate inhibitor, showing 42% inhibition. In contrast, NO-modified form 
was found to be a potent inhibitor, showing maximum inhibition of 58.4% (Fig. 23). The 
amount of NO-cytosiue required for 50% inhibition was 13.2 ug/ml. On the other hand, 
adenine and its ROS-modified form showed negligible inhibition of 14% and 30% re-
spectively, whereas NO-adenine showed a moderate inhibition of 47% (Fig. 24). 
To further delineate the structural determinants recognised by anti-NO plasmid DNA 
antibodies, their interactions with various synthetic polymers were studied. Poly (dA-
dG).poly(dC-dT) showed a maximum inhibition of 4 1% at a concentration of 20 ug/ml. 
whereas poly(dA-dT).poly(dA-dT) showed negligible inhibition. Antibody recognition 
ofpoly(rG).poly(dC), a polymer known to attain A-/analogous conformation, resulted in 
38% elimination of antibody binding to the antigen (Fig. 25). The ribonucleotide polymer 
poly(G) and NO-poly(G) were also used as inhibitors. Poly(G) showed an inhibition of 
44% while NO-poly(G) inhibited antibody binding to an extent of 65% (Fig 26). The 
amount of NO-poIy(G) required for 50% inhibition was 15 ug/ml. In addition, catdiolipm 
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Fig. 21. Inhibition of anti-NO-plasmid DNA IgG binding to NO-plasmid DNA. The 
competitors were native 200 bp DNA ( O )- NO-200 bp DNA ( A ), native 
lymphocyte DNA ( A ) and NO-lymphocyte DNA ( # ). The microtitre plates 
were coated with NO-plasmid DNA (2.5 ng/ml). 
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Fig. 22. Inhibition of anti-NO-plasmid DNA IgG binding to NO-plasmid DNA. The 
competitors were native guanine ( O )- ROS-guanine ( A ) and NO-guanine 
( • ) The microtitre plates were coated with NO-plasmid DNA (2.5(.ig/ml). 
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Fig. 23. Inhibition of anti-NO-plasinid DNA IgG binding to NO-plasmid DNA. The 
competitors were native cytosine ( O )• ROS-cvlosine ( A ) and NO-cytosine 
( • ) Tlie microtitre plates were coated with NO-plasmid DNA (2.5 (.ig/ml). 
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Fig. 24. Inhibition of auti-NO-plasmid DNA IgG binding to NO-plasuiid DNA. The 
competitors were native adenine ( O). ROS-adenine ( A ) and NO-adenine ( A ) 
The microtitre plates were coated with NO-plasmid DNA (2.5 ug/ml). 
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Fig. 25. Inhibition of anti-NO-plasmid DNA IgG binding to NO-plasmid DNA. The 
competitors were poly(dA-dT).poly(dA-dT)(0 ), poly(dA-dG).poly(dC-dT) 
( A ) and poly(rG). poly(dC)( • ). The miciotitre plates were coated with NO-
plasmid DNA (2.5 ug/ml). 
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Fig. 26. Inhibition of anti-NO-plasmid DNA IgG binding to NO-plasmid DNA The 
competitors were cardiolipin ( O ). chondroitin sulphate ( A ). poly(G) ( A ) and 
NO-poly(G) ( # ). The miciotitre plates were coated with NO-plasmid DNA 
(2.5 ug/ml). 
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and chondroitin sulphate were also inhibitory to the antibody activity, showing an inhibi-
tion of 47% and 33%, respectively. Table 4 summarises the data of the binding charac-
teristics of auti-NO plasmid DNA IgG as determined by inhibition ELISA. 
Band Shift Assay 
The visual detection of binding of native and NO-plasmid DNA to the anti-NO-
plasmid DNA IgG was ascertained by band shift assay. Constant amounts of name 
and NO-plasmid DNA were incubated with varying amounts of immune IgG for 2 hi 
at room temperature and overnight at 4°C. The resulting immune complexes were 
then electrophoresed on 1% agarose for 2 hr at 30 mA. Figure 27 shows the binding 
of IgG to NO-plasmid DNA. As clearly evident, with an increase in the amount of 
IgG, there was an increase in the formation of high molecular weight immune 
complexes, which resulted in retarded mobility and increased fluorescence intensity 
of immune complex, whereas the unbound NO-plasmid DNA showed a proportional 
decrease in its intensity The recognition of native plasmid DNA by anti-NO-plasmid 
IgG was reiterated by the shift in electrophoretic mobility upon immune complex 
formation and loss in fluorescence intensity of unbound native plasmid DNA (Fig. 28). 
Quantitation of Anti-DNA Antibodies in SLE Sera 
Various SLE serum samples were tested for the presence of anti-DNA antibodies 
by direct binding ELISA. Out of the 30 serum samples tested, those (12 sera) showing 
high titer ranging from 1:1600 to 1:6400. of anti-DNA antibody binding are depicted 
in Figures 29-3 1. The same samples were subsequently employed for their binding 
to native and NO modified plasmid DNA. Normal human sera showed negligible 
binding with either of the antigens. 
Purification of SLE IgG 
Protein A binds IgG from most mammalian species through interactions with the Fc 
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TABLE 4 
Antigen Binding Specificity of Anti-NO-PIasmid DNA 
Antibodies 
Inhibitor Maximum % inhibition Concentration for 
at 20 jig/ml 50% inhibition 
( Hg/ml) 
Native plasmid DNA 
NO-plasmid DNA 
Native 200 bp DNA 
NO-200 bp DNA 
Native lymphocyte DNA 
NO-lymphocyte DNA 
Guanine 
ROS-guanine 
NO-guanine 
Cytosine 
ROS-cytosine 
NO-cytosine 
Adenine 
ROS-adeniue 
NO-adenine 
Cardiolipin 
Chondroitin sulphate 
Poby(G) 
NO-poly(G) 
Poly(dA-dG).poly(dC-dT) 
Poly (dA-dT).poly (dA-dT) 
Poly(rG).poly(dC) 
58.7 
86.2 
21.3 
45.6 
48.5 
54.2 
43.0 
61.0 
69.0 
21.0 
42.0 
58.4 
14.0 
30.0 
47.0 
47.0 
33.0 
44.0 
65.0 
41.0 
33.0 
38.0 
The microtitre plates were coated with NO-plasmid DNA (2.5 ng/ml) 
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Fig. 27. Band shift assay of anti-NO-plasmid DNA IgG binding to NO-plasmid DNA. NO-
plasmid DNA (0.5 |.ig each) was incubated with buffer (lanel) and 30, 40, 60 and 
80 [.ig IgG through lanes 2 to 5 respectively for 2hr at 37"C and overnight at 4"C. 
Electrophoresis was performed on 1 % agarose gel for 2 hr at 30 mA. 
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Fig. 28. Band sliift assay of anti-NO-plasmid DNA IgG binding to native plasmid. Native 
plasmid DNA (0.5 (.ig each) was incubated with 20. 30. 40. 60 and 80 (.ig IgG for 
2hr at 37"C and overnight at 4"C. Electrophoresis was performed on 1 °o agarose for 
2hr at 37"C. Lane 1, contained native plasmid DNA, while lane 2 to 6 contained 
native plasmid DNA with increasing concentrations of IgG. 
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Fig. 29. Evaluation of anti-DNA autoantibodies in SLE patients. The miciotitre plates were 
coated with native calf thymus DNA (2.5 f.ig/ml). Curves ( A ). ( A )- ( O ). ( • ) 
and ( V ) represent SLE serum 1. SLE serum 2, SLE semm 3. SLE serum 4 and 
normal human serum respectively. 
87 
1.50 
< 
u O 
z 
< 
00 
cc 
o 
CO 
GO 
< 
1.00 
0.50 
0.00 
2.0 2.3 2.6 2.9 3.2 3.5 
-LOG SERUM DILUTION 
3.8 4.1 
Fig. 30. Evaluation of anti-DNA autoantibodies in SLE patients. The microtitre plates were 
coated with native calfthymusDNA (2.5 ng/ml). Curves ( A ). ( O )-( A ), ( # ) 
and ( V ) represent SLE serum 5, SLE serum 6, SLE semm 7. SLE serum 8 and 
normal human serum respectively. 
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Fig. 31. Evaluation of anti-DNA autoantibodies in SLE patients. The microtitre plates were 
coated with native calf thymus DN A (2.5 ug/ml). Curves ( A ). ( O )-( A ). ( • ) 
and ( y ) represent SLE serum 9. SLE serum 10. SLE serum 11. SLE serum 12 and 
normal human serum respectively. 
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part of IgG molecules (Langone. 1978): SLE IgGs from 12 sera were purified by affinity 
chromatography on Protein A-Sepharose CL-4B column. The purified IgGs from normal 
and SLE sera were found to be eluted in a single symmetrical peak. The homogeniety of 
the IgG was checked by SDS-PAGE under non-denaturing conditions and was found to 
migrate as a single band. 
The binding of one of the purified IgGs with native and NO-plasmid DNA was 
studied by direct binding ELISA. High magnitude of binding was observed with NO-
plasmid DNA as compared to native plasmid DNA (Fig. 32). while normal human 
IgG showed negligible binding. The binding specificity was further ascertained by 
inhibition ELISA. 
Immuno-crossreactivity of Anti-DNA Autoantibodies 
The binding pattern of SLE anti-DNA autoantibodies to native and nitric oxide 
modified plasmid DNA was determined by direct binding ELISA. All the twelve sera 
showed appreciable binding to native and NO-plasmid DNA. Preferentially high binding 
was observed in case of NO-plasmid DNA. Figure 33 shows the enhanced binding of 
SLE anti-DNA autoantibodies (1:100 diluted) with NO-plasmid DNA as compared to 
native plasmid DNA. With normal human serum no appreciable binding was observed. 
The antigen binding specificity of isolated SLE IgGs against uative calf thymus DNA 
was ascertained by competition inhibition ELISA. Maximum inhibition ranging from 35% 
to 59% in twelve SLE IgG samples (Figs. 34-36) was observed. Table 5 shows the 
inhibition data of anti-DNA autoantibodies IgG binding to calf thymus DNA. 
Competition ELISA was also performed to further evaluate the specificity of each 
SLE IgG for native and NO-plasmid DNA (Figs. 37-42). In this case, IgG was first 
incubated with native or NO-plasmid DNA and then assayed for residual binding with 
native calf thymus DNA coated on microtiter plates. Native plasmid DNA showed maxi-
mum inhibitions ranging from 34% to 61% of twelve SLE IgG binding to uative calf thy-
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Fig. 32. Binding of affinity purified SLE IgG to native plasmid DNA ( A ) and NO-plasmid 
DNA ( A ). Normal human IgG ( O ) to either of the antigens coated on plates 
(2.5ng/ml). 
91 
1.50 
1.00 
< 
J J 
J 
Z 
< 
fl 
o 
0 
0.50 
0.00 
6 7 8 
SLE SERA 
10 11 12 NHS 
Fig.33. Direct bindmg ELISA of human SLE anti-DNA autoantibodies to native plasmid 
DNA (SS ) and NO-plasmid DNA ( ZH )• Microtitre plates were coated 2.5 ng/ml 
of respective antigens. 
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Fig. 34. Evaluation of SLE IgG binding specificity to native calf thymus DNA by inhibition 
ELISA. The inhibitor used was native calf thymus DNA. SLE IgG 1 ( A ) . SLE 
IgG 2 ( A ) . SLE IgG 3 ( # ) and SLE IgG 4 ( \7 ). The microtitre plates were 
coated with native calf thymus DNA (2.5 ng/ml). 
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Fig. 35. Evaluatiou of SLE IgG binding specificity to native calf thymus DNA by inhibition 
ELISA The inhibitor used was native calf thymus DNA. SLE IgG 5 ( A ) . 
SLE IgG 6 ( A ), SLE IgG 7 ( # ) and SLE IgG 8 ( V ) The microtitre plates 
were coated with native calf thymus DNA (2.5 |.ig/ml). 
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Fig. 36. Evaluation of SLE IgG binding specificity to native calf thymus DNA by inhibition 
ELISA. Tlie inhibitor used was native calf thymus DNA. SLE IgG 9 ( A ) . SLE 
IgG 10 ( A ). SLE IgG 11 ( • )and SLE IgG 12 ( O ) Tlie raicrotitre plates were 
coated with native calf thymus DNA (2.5 ng ml). 
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TABLE 5 
Inhibition of Binding of SLE IgG by Native Calf Thymus DNA 
SLE IgG Maximum % inhibition Concentration for 
at 20 ng/ml 50% inhibition 
( Hg/ml) 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
54.0 
49.0 
42.0 
55.0 
35.0 
55.0 
52.0 
39.0 
50.0 
48.0 
50.0 
58.0 
The microtitie plate was coated with native calf thymus DNA (2.5 ^g ml) 
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Fig. 37. Inhibition ELISA of SLE IgG from two SLE patients (1 and 2). The inhibitors used 
were name plasmid DNA ( A . # ) and NO-plasmid DNA ( A . V ) 
The mierotitre plate was coated with native calf thvmus DNA (2.5 (.ig/ml). 
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Fig. 38. Inliibition ELISA of SLE IgG from two SLE patients (3 and 4). Tlie inhibitors used 
were native plasmid DNA ( A . # ) and NO-plasmid DNA ( A - V ). 
Tlie niicrotitre plate was coated with native calf thymus DNA (2.5 ug/ml). 
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Fig. 39. Inhibition ELISA of SLE IgG from two SLE patients (5 and 6). The mhibitors used 
were native plasmid DNA ( A . • ) and NO-plasmid DNA ( A V )• 
The microtitre plate was coated with native calf thymus DNA (2.5 (.ig/ml). 
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Fig. 40. hihibitiou ELISA of SLE IgG from two SLE patients (7 and 8). Tlie inhibitors used 
were native plasmid DNA ( A , • ) and NO-plasmid DNA ( A . V ) 
Tlie microtitre plate was coated with native calf thymus DNA (2.5 ug/ml). 
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Fig. 41. Inhibition ELISA of SLE lgG from two SLE patients (9 and 10). Tlie inhibitor^ 
used were native plasmid DNA ( O • A ) and NO-plasmid DNA ( A - • ) 
Tlie microtitie plate was coated with native calf thymus DNA (2.5 f.ig ml). 
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Fig. 42. Inhibition ELISA of SLE IgG from two SLE patients (11 and 12). The inhibitors 
used were native plasmid DNA ( O • A ) and NO-plasmid DNA ( A - • ) 
The inicrotitre plate was coated with native calf thymus DNA (2.5 ng/ml). 
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mus DNA (Table 6). NO-plasmid DNA showed relatively high percent inhibition often 
SLE IgG binding to native calf thymus DNA. Binding of one of the SLE IgG's was 
inhibited to an extent of 71%. while the binding of two SLE IgGs was inhibited to an 
extent of 36% and 39% respectively. 
Band Shift Assay 
Band shift assay was employed to visualise and thus confirm the interaction of 
native and NO-plasmid DNA with SLE autoantibodies A constant amount of the 
antigen was incubated with increasing amounts (0-120 fig) of SLE IgG for 2 hr at 
37"C and overnight at 4"C. The immune complexes were then electrophoresed on 
1% agarose for 2 hr at 30 mA. Figures 43 and 44 show the binding of anti-DNA 
autoantibodies to native and NO-plasmid DNA. respectively. With increasing 
concentration of IgG there is a corresponding increase in the formation of high molecular 
weight immune complexes which resulted in retarded mobility and corresponding decrease 
in the fluorescence intensity of unbound antigen. Normal human IgG incubated under 
identical conditions did not show immune complex formation. 
Quantitative Precipitin Titration 
The antigen-antibody interaction was also characterized by quantitative precipitin 
titration. Varying amounts of modified, unmodified plasmid DNA and native calf 
thymus DNA (0-50 |.ig) were mixed with 100 ug of SLE IgG and incubated for 2 hr at 
37°C and 72 hr at 4°C. The results obtained were typical of precipitin titration curves 
(Figs. 45-47). NO-plasmid DNA showed maximum antibody binding at an antigen 
concentration of 20 (.tg while native plasmid DNA and native calf thymus DNA bind 
maximally at 30 ug. Estimation of protein in immune complexes showed that 
76.8 ug of SLE IgG bound to NO-plasmid DNA. 64 ug to native plasmid DNA and 
60 ug to native calf thymus DNA. Further analysis of precipitin data revealed that 
5 jo.g, 3 f.ig and 2.2 (.ig of SLE IgG/ f.ig of NO-plasmid, native plasmid and native calf 
103 
TABLE 6 
Competitive Inhibition Data of SLE IgG 
SLE IgG Maximum percent inhibition at 20 un/ml 
Native plasmid NO-plasmid 
1. 54.1 62.4 
2. 44.6 58.1 
3. 49.0 67.0 
4. 52.0 73.0 
5. 55.0 59.8 
6. 34.0 393 
7. 37.0 56.0 
8. 42.0 36.0 
9. 57.0 65.0 
10. 50.0 57.0 
U. 57.0 64.0 
12. 61.0 71.0 
The microtitre plate was coated with native calf thymus DNA (2.5 fig/ml) 
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Fig. 43. Band shift assay of SLE IgG binding to native plasniid DNA. Native plasmid DNA 
(0.5 f.tg each) was incubated with buffer (lane 1) and 30. 60, 90, and 120 jig IgG 
through lanes 2 to 5. respectK ely for 2 hr at 37"C and overnight at 4"C. Electrophoresis 
was performed on l°o agarose for 2 hr at 30 inA. 
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44. Baud shift assay of SLE IgG binding to NO-plasmid DNA. NO-plasmid DNA 
(0.5 ng each) was incubated with buffer (lane 1) and 30. 60. QO and 120 ng IgG 
througli lanes 2 to 5 respectively for 2 lir at 37"C and overnight at 4"C. Electrophoresis 
was performed on 1% agarose for 2 hr at 30 mA. 
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Fig. 45. Quantitative precipitin titration curves of NO-plasmid DN A with normal human 
IgG ( A ) and SLE IgG ( A ). 
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thymus DNA respectively were required for immune complex formation. The affinity 
constant of anti-native DNA antibodies was evaluated by Laugmuir analysis (Fig. 48) 
and apparent association constant was computed to be 1.8 x 107M. 1.3 x 10"M and 
1.0 x lO^M for NO-plasmid DNA. native calf thymus DNA and native plasmid DNA. 
respectively 
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Humans are exposed to a wide range of nitrogen-containing compounds and iiitrosating 
agents, such as nitrite, nitrate and nitrogen oxides, that can reactin vivo to form potentially 
carcinogenic N-nitroso compounds, as well as several carcinogenic C-nitro or reactive 
diazo compounds. Nitrosating agents can also be syuthesised endogenously by bacteria 
and activated macrophages via the nitric oxide synthase (NOS) pathway. Endogenous 
nitrosation can thus occur at many locations in the body, including sites of chronic 
inflammation or infection (Bartsch and Frank, 1996; Felley-Bosco. 1998). Nitric oxide, 
a multifaceted bioregulatory agent, shows an unusual divergence of action. It is demonstrated 
to play a major role as neurotransmitter and a regulator of blood pressure. Macrophages 
also use nitric oxide as a cytotoxic agent which may lead to DNA damage. The effects of 
nitric oxide at the DNA level are complex and involve formation of N-nitrosoamines. 
deamination of purines and pyrimidines, or damage induced by peroxynitrite Besides 
inducing DNA damage, nitric oxide may also inactivate DNA repair/replication enzymes 
(Delaney and Eizirik, 1996; Luperchio et al., 1996). 
In addition to the broad repertoire of regulatory functions, nitric oxide serves in 
mammalian physiology, the L-arginine: NO pathway is also involved in numerous patho-
physiological mechanisms. The role of nitric oxide in numerous disease states have generated 
considerable discussion over the past several years. Nitric oxide mediated cell injury may 
arise by a variety of mechanisms, including disruption of mitochondrial respiration, enzymes 
inhibition, lipid peroxidation and genetic mutation. Toxicity is largely mediated via 
intermediates such as N203 and peroxynitrite, arising from the reaction of nitric oxide with 
either molecular oxygen or reactive oxygen species. In general, such reactions become 
significant only when high concentrations of nitric oxide are generated by the induction of 
NOS (Gordge, 1998; Wink et al., 1998a and b). Nitric oxide is an important mediator of 
the inflammatory response. Over expression of NOS2 and overproduction of nitric oxide 
are parallel with the development of an autoimmune syndrome with a variety of inflammatory 
manifestations (Gilkeson et al., 1997). Nitric oxide is involved in a number of 
immunopathologies, including diabetes, graft-vs-host reaction, rheumatoid arthritis, SLE 
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and multiple sclerosis (Cook and Cattell. 1996; Parkinson et al.. 1997; Kuhn etal.. 1998) 
Nitric oxide is a paramagnetic diatomic, uncharged molecule with an unpaired electron 
These characteristics make it highly reactive, having a half life of 2 to 30 seconds (Halliwell 
and Gutteridge. 1989; Lowenstein etui.. 1994). Saturated solutions of nitric oxide ha\e 
been demonstrated to deaminate deoxyribonucleosides. deoxyribonucleotides and intaci 
DNA under aerobic conditions/// vitro (Keefer eta/., 1991). Nitric oxide and its progenitor 
have been shown to be mutagenic to Salmonella typhi murium (Keefer et al., 199 I; Arrovo 
et a/., 1992), rat lung cells following /// vivo exposure (Isomura et al.. 1984) and human 
TK6 lymphoblastic! cells in culture (Nguyen et al.. 1992). Purines are more readiU 
deaminated than pyi i m i d i n e s . H o w e v e r , s o m e u n e x p e c t e d b a s e s like 8-
hydroxyaden ine and 8-liydiox\guanine are also found (Lin et al.. 1993a). TheGC-->AI 
transitions predominate in molecular mechanisms of mutagenesis in cells exposed to nitric oxide 
Nitric oxide damages DNA by diazotisation of primary arylamines in an oxidising environment 
(JiandBellocher. 1988; Rait e tal.. 1988; Kosakac/a/. , 1989). Xanthine and hvpoxanthine 
from deamination of guanine and adenine respectively leads to mispairing( Duncan and Millei 
1980; Eritja et al.. 1986). and the instability of hvpoxanthine and xanthine in DNA leads io 
depuriuatiou and subsequent strand breakage (Lindahl and Anderson. 1972). Both of these 
pheuomenan have been observed in calf thymus DNA and in intact cells and potentially contribute 
to both cytotoxicity and mutagenicity (Loeb and Preston. 1986; Nguyen etal.. 1992). A third 
possibility is the formation of intrastrand crosslinks via attack of the aryl diazonium ion of one 
purine on die free amino group of a second purine in the matching strand (Singer and Gnuibergei. 
1983; Kirchner and Hopkins. 1991). 
Nitric oxide dearninates guanine faster thau other bases (Nguyen et al., 1992). Extreme 
instability of xanthine in DNA leads to its rapid depurination (Shapiro and Chargaff, I960. 
Moschel and Keefer, 1989). Nitric oxide attacks guanine bases as the most preferential 
cleaving sites and the frequency of nitric oxide induced cutting decreases in the order 
G>OA>T. The preferred cleavage at GC sequences by nitric oxide may correlate to predominant 
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mutagenicity at GC sites by nitric oxide (Sugiura and Matsumoto, 1995). Nitric oxide producing 
systems may abstract hydrogen atoms from the deoxyribose moiety of DNA, a process that 
can lead to DNA nicks (Kapp and Smith. 1970). Exposure to eudogenously and exogenously 
produced nitric oxide is extensive, and in the presence of oxygen nitric oxide can cause a 
variety of damages to DNA as well as mutatious in various cell hues in culture. Therefore, the 
cytotoxicity and mutagenicity associated with the inflammatory process may result from nitric 
oxide radicals in addition to the better known reactions of oxygen radicals. 
Systemic lupus erythematosus is a multisystem, immune complex disease of unknown 
etiology, characterised by the elevated levels of anti-DNA antibodies of multiple specificities 
to numerous self components which include nuclear and cytoplasmic antigens (Tan. 198^; 
Pisetsky, 1994). Amongst various autoantibodies, antibodies reactive with double stranded 
DNA (dsDNA) are diagnostic of the disease and contribute to renal pathology. The marked 
heterogeneity of SLE autoantibodies has been one of the impediments in understanding 
the disease. The immune abnormalities contributing to the development of systemic 
autoimmune disease in mice and humans are now being defined at the single cell and 
molecular levels. It has been suggested that while neither exogenous polyclonal B or T cell 
activators nor imrnunoregulatory disturbances appear to be satisfactory explanation, it is 
clear that the development of overt autoimmune disease is highly dependent on a permissive 
genetic constitution (Theofilopoulos, 1995). Antibodies to DNA in SLE have been 
extensively studied and may be specific for ssDNA, reactive with both ssDNA and dsDNA. 
or specific for dsDNA (Stollar, 1979; Worrall etai, 1990). It is the antibodies to native 
dsDNA that represent a characteristic serological finding in these patients and are of 
important diagnostic and clinical value. DNA alone has generally been found not to be 
immunogenic. Repeated attempts to specifically induce anti-DNA antibody with 
characteristics similar to those produced in autoimmune mice have met with limited success 
(Stollar, 1989). 
The binding diversity of lupus autoantibodies to a whole spectrum of modified nuleic 
acidconformers(Ali«?/a/., 1991; AJam and Ali, 1992; Mametal., 1992; 1993; Arif etal 
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1994; Arjumand and Ali, 1994; Klinman etal., 1994; Moinuddin and Ali. 1994; Arjumand «v 
ai, 1995; Ahmad etal., 1997; Garg and Ali, 1998) seems to be enormous. The efforts to 
understand the origin and consequence of anti-DNA autoantibodies are still elusive. For these 
reasons, it was thought desirable to investigate the damage induced by nitric oxide on 200 bp 
DNA fragments of native calf thymus DNA and study the immunogenicity of nitric oxide modified 
plasmid Bluescript DNA and its possible role in SLE. 
In the present study, 200 bp fragments of native calf thymus DNA were modified by 
nitric oxide radicals (NO), generated by the reduction of sodium nitrite with sodium 
dithionite. Nitric oxide caused extensive damage to DNA, leading to single strand breaks 
and base modifications. The 200 bp DNA showed hypochromicity after NO modification 
compared to the native double stranded analogue. The spectral curves of NO-modified 
DNA exhibited shifts in the A. and X . These are indicative of an appreciable proportion 
mix mm * * " * 
of nitric oxide induced damage of both bases aud sugar phosphate backbone. The thermal 
denaturation profile of native and NO-200 bp DNA showed a net decrease of 6"C in the 
Tm value for the modified DNA as compared to its unmodified couformer. indicating the 
presence of single stranded regions in the modified DNA and also a partial destruction in 
its secondary structure. Base stacking as well as hydrogen bonding are involved in stabilising 
the native structure of DNA aud their disruption by high temperature favours denaturation 
(Casperson and Voss, 1983; Thomas, 1993). The lowered Tm of NO-200 bp DNA . 
therefore, points towards the destabilizatiou of these interactions and consequently helix 
disruption. Structural alterations are caused in NO-200 bp DNA due to simultaneous 
strand scission, generation of single-stranded regions and disruption of hydrogen bonding. 
Earlier studies demonstrate that the structural alteration in DNA, following damage 
by various agents, may at times be large enough to act as substrate for single strand specific 
nucleases (Kato and Fraser, 1973; Slor and Lev, 1973; Shishido and Ando, 1974; Yamasaki 
etal., 1977). Native and NO-200 bp DNA were subjected to nuclease S1 digestion, in order 
to confirm the generation of single strand breaks. The data shows almost total digestion of 
NO-200 bp DNA on treatment with nuclease Si, while native 200 bp DNA remain undigested 
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These observations clearly demonstrate that sufficient distortions are caused in the helical 
structure of DNA by nitric oxide radical, rendering it susceptible to digestions by single-strand 
specific nuclease SI. 
Nitric oxide radical caused extensive damage to plasmid DNA. pBS DH,a"KS" 
Nitric oxide modification of the plasmid DNA resulted in the decrease in hypochromicity 
as well as shifts in k and k . of spectral curve of NO-plasmid DNA as compared to the 
inax nun r i • 
native plasmid DNA. This could be attributed to the single strand breaks and modification 
of the nitrogenous bases which result in the destruction of the chromophoric groups as 
revealed by the hypochromicity of NO-plasmid DNA. The chemically predominant reaction 
was breakage of sugar phosphate backbone. 
The UV difference spectral curves exhibited appreciable perturbation in the plasmid 
DNA as a consequence of nitric oxide modification. The spectral curve of NO-plasmid 
DNA with respect to native plasmid DNA revealed a negative inversion in absorption 
between 230-270 nm. followed by increased absorption at around 300 nm. These are 
indicative of an appreciable proportion of nitric oxide induced damage of both bases, as 
well as sugar phosphate backbone. 
The CD spectra of uative plasmid DNA consist of a positive and negative band of 
nearly equal magnitude with intersection point at the absorption maxima. The decrease in 
ellipticity and slight change in peaks of DNA after NO modification may be due to unstacking 
of bases as a result of strand breaks. 
Appreciable evidence for the generation of strand breaks (single and double) in the 
plasmid DNA as a consequence of nitric oxide modification was resolved by agarose gel 
electrophoresis. The results clearly suggest that nitric oxide modifiy plasmid DNA, resulting in 
the formation of strand breaks as evident from the decrease in fluorescence intensity of the 
supercoiled form (form 1) of the NO-plasmid DNA. The data is compatible with earlier reports 
indicating nitric oxide radicals result in strand breakage (Kolb et al., 1993; Sugiura and 
Matsumoto, 1995). 
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The presence of single strand regions in linearised form of theplasmid DNA following 
modification with nitric oxide radical, was further ascertained by alkaline sucrose density 
gradient ultracentrifugatiou. The sedimentation profile of NO-plasmid DNA was distinct 
from that of native plasmid DNA, which banded as a sharp symmetrical peak. In contrast, 
the modified plasmid DNA appeared as a broader peak indicating the generation of single 
strand breaks which causes decrease in the molecular weight and hence the diffused pattern. 
Native DNA per se is known to be a poor immunogen (Madio et al.. 1984; Stollar. 
1986). whereas some synthetic homopolynucleotides. chemically modified DNA. helical 
synthetic polynucleotides and denatured DNA are immunogenic. Effective helical 
immunogen inducing antibodies in this form have been double-stranded RNA-DNA hybrid, 
left handed Z-DNA. triple helical RNA and DNA analogues, double helical 
polydeoxyribonucleotides, DNA modified with drugs, hormones, chromatin or DNA in 
complexes with DNA binding proteins (Stollar. 1973; 1975; 1986; Anderson et al.. 1988a; 
Desai et al., 1993; Moinuddin and AH, 1994; Hasan et al.. 1995; Theofilopoulos. 1995; 
Arif and Ali, 1996; Aijumand et al.. 1995; 1997; ). Evidences suggest that DNA from 
various species differ in their immunological activity and that bacterial DNA can induce 
the in vitro proliferation of normal murine B cells (Messina et al., 1993). The autogenic 
activity of DNA is dependent on sequence specific determinants that can be presented by 
synthetic duplexes (GC-rich region) as well as bacterial single stranded and double stranded 
DNA, suggesting that DNA regions enriched in GC content have enhanced immunological 
activity. Reactive oxygen species modified DNA have been implicated in the pathogenesis 
of SLE (Ara and Ali, 1992; 1993; 1995; Ahmad et al., 1997; Cooke et al.. 1997). 
Conformational variance from the B-form appears to be a prerequisite for the induction of 
antibody response (Burlingame e/ al., 1993; Mohan etal., 1993). 
Antibodies against nitric oxide modified plasmid DNA were induced in rabbits by 
immunizing with NO-plasmid DNA complexed with methylated bovine serum albumin 
The nitric oxide modified plasmid DNA was a potent immunizing stimulus, inducing high 
titre antibodies. The antigenic specificity of anti-NO-plasmid DNA-IgG was ascertained by 
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competition binding assay. A maximum of 86% inhibition was observed with the immunogen 
The concentration of immunogen required for 50% inhibition of IgG binding to immunogen \sa> 
observed at 1.6 ng/nil. In addition, the induced antibodies showed considerable binding to the 
native plasmid DNA. This crossreactivity may be due to the recognition of an antigenic 
determinant common to both NO-plasmid DNA and native plasmid DNA and could possibly 
be the sugar phosphate backbone (Later tV al , 1981; Rauch era/., 1985). The data indicates 
the higher specificity of the immune IgG towards nitric oxide modified epitopes. Modification 
of DNA by NO might have generated potential epitopes against which the antibodies are raised 
In order to facilitate the detection of interaction between immune IgG and immunogen. 
gel retardation assay was carried out. The results revealed a high affinity of anti-NO-
plasmid DNA IgG for its immunogen. Besides, the specific binding of anti-NO-plasmid 
DNA IgG was also observed with native plasmid DNA. These results further reiterated 
that induced antibodies react with antigenic deteminants common to both native and NO-
plasmid DNA. 
Total DNA from human lymphocytes and 200 bp fragments of calf thymus DNA 
showed inhibitions of 49% and 21% respectively, whereas their NO-modified forms showed 
higher inhibition of 54% and 45.6% respectively. Tliese results demonstrate the preferential 
recognition of NO-modified epitopes by immune IgG. Competition immunoassay using 
guanine, cytosine. adenine. poly(G) showed inhibitions of 43%. 21%. 14% and 44% 
respectively. In contrast, their NO modified forms showed higher inhibition (69%. 58%. 47% 
and 65%) than their ROS modified forms of IgG binding to immunogen. The data clearly 
indicates that the immune IgG is more specific to guauine, cytosine and poly(G) after NO-
modification. Earlier reports demonstrated guanine, cytosine and adenine moiety to be 
particularly susceptible to NO-modification (Nguyen etal., 1992; Lin etai, 1993; Sugiura 
and Matsumoto, 1995). 
To further define the structural determinant recognised by the anti-NO-plasmid DNA 
antibodies, their interaction with various synthetic polynucleotides was studied. Tliese 
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compounds present a more limited set of determinants than natural DNA and can be used as 
probe for specificity analysis. Poly(dA-dG).poly(dC-dT) which are stable as B-DNA at low 
salt concentration, inhibited the antibody binding. However, 50% inhibition could not be achieved. 
Besides, binding to various nucleic acids and synthetic polynucleotides, the anti-NO-plasmid 
DNA IgG also showed crossreactivity towards chondroitin sulphate and cardiolipin. It has 
been suggested that phosphate-sugar-phosphate moiety of cardiolipin mimics the backbone of 
DNA. thus explaining the cross-reactivity of immune IgG (Rauch et al., 1984). Analysis of the 
data indicates that anti-NO-plasmid DNA IgG is polyspecific and the various crossreacting 
inhibitors with which it reacts, share a common antigenic determinant or epitope. 
Systemic lupus is a multisystem, highly variegated andpleoomorphic autoimmune disease 
of unknown etiology (Andrzejeweski et al., 1980). Sera of SLE patients contain a variety of 
autoantibodies of which a subset may be responsible for the array of clinical symptoms 
(Chastagner et al.. 1994). Antibodies to dsDNA serve as an immunochemical marker for the 
diaguosis of SLE. The polyspecific behaviour exhibited by SLE anti-DNA autoantibodies 
suggests that native DNA itself may not be the immunogen responsible for their production and 
the binding of these autoantibodies to dsDNA may be a non-specific crossreactive event (Zack 
et al.. 1995). Thus, the precise antigen responsible for anti-DNA autoantibody production in 
SLE patients remains an enigma. Efforts are underway to generate antibodies against antigens, 
which cross-react with native DNA thereby mimicking the SLE autoantibodies (HalUwell and 
Gutteridge, 1984; Sundquist et al., 1987; Ames, 1989; Desai et al, 1993; Blount et al.. 
1994; Ara and Ali, 1995). 
There is an evidence for a pathological role of nitric oxide in inflammatory diseases 
(Bagasra et al., 1995; Buttery et al., 1996; Parkinson et al., 1997; van deer Veen et al.. 
1997). Lowenstein et al. (1994) postulated that DNA damage by nitric oxide may affect 
the development of autoimmune diseases. Subsequent release of altered DNA during 
apoptosis may enable it to act as an antigen inducing antibodies cross-reacting with nDNA 
(Herrmann et al., 1996; Casciola-Rosen and Rosen, 1997). Apoptosis is an important 
mechanism of cell destruction by nitric oxide (Bukart e/ al., l994;Zett\et a/., 1997). Further 
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evidences of the role of nitric oxide in SLE are provided by various other studies ( Belmont tv 
al., 1997;Gilkesont>fa/., 1997 ;Wigand etal., 1997 ). 
In the present study, the possible involvement of NO-modified and the unmodified 
plasmid DNA in SLE was also probed. A group of patients with SLE were used to studv 
the possible role of nitric oxide induced damage to DNA in inflammation. High titie anti-
DNA autoantibodies were observed in sera of SLE patients, collected for the present studv 
Of these, 12 SLE sera IgG were found to show an inhibition ranging from 35% to 59%. 
thus, showing the specificities of these SLE IgGs towards native calf thymus DNA. When 
reactivity of native and NO-plasmid DNA with SLE IgG, was probed, competition ELISA 
results showed the preferential binding of NO-plasmid DNA over native plasmid DNA 
Native plasmid DNA as an inhibitor showed an inhibition ranging from 32% to 6 1 % while 
NO-plasmid DNA showed in the range of 39% to 71%. These results indicate that the 
modified DNA is an effective inhibitor, showing substantial difference in the recognition 
of NO-plasmid DNA over native plasmid DNA. Band shift assay further substantiated 
the binding of native and NO-plasmid DNA with SLE auti-uative DNA autoantibodies 
To have a better insight into the recognition of anti-native DNA autoantibodies in 
SLE sera with native and NO-plasmid DNA. quantitative precipitin titration was also performed 
The data was analysed by Laugmuir plots and antibody affinity was calculated. In case of NO-
plasmid DNA the apparent association constant was computed to be 1.8 x l0 7 M. for native 
plasmid DNA 1.0 xlO"*M and for native calf thymus DNA 1.3 x 10*M. The affinity 
constants clearly indicate the better recognition of NO-plasmid DNA as compared to native 
calf thymus DNA and native plasmid DNA by SLE autoantibodies. The data obtained bv 
various immunological techniques clearly demonstrates a substantial increase in recognition 
and binding of NO-modified plasmid DNA over native calf thymus DNA by circulating anti-
DNA autoantibodies. 
The findings of Caspersou and Voss (1983) are that plasmid DNA (pBR322) is a 
more effective inhibitor of dsDNA binding activity than native calf thymus DNA, suggesting 
12 0 
that nucleotide bases might be involved in antibody binding since plasmid DNA has a higher 
GC content (54%) than calf thymus DNA (39%). The data is in accordance with our result that 
plasmid pBS (50%GC content) is an effective inhibitor of dsDNA biuding activity. The strong 
binding potential of anti-DNA IgG towards NO-modified plasmid DNA demonstrates the 
possible participation of modified nucleotide in SLE patliogenesis. as it has already been reported 
that nitric oxide modifies DNA bases and nucleosides /// vivo (Reefer et al.. 1991). These 
results demonstrate the high susceptibility of the bases in DNA to nitric oxide modification in 
inflammatory diseases, like SLE. Modified DNA bases and nucleosides have been detected in 
urine of humans (Halliw ell and Aruoma. 1991; Lin et al.. 1993a). The spontaneous production 
of anti-DNA autoantibodies in SLE might arise as a consequence of antigenic change in DNA 
Therefore, it could be possible that nitric oxide modified bases of DNA might be contributing 
towards die production of autoantibodies. Based on the above studies, the following conclusions 
can be drawn: 
1 Nitric oxide modification of DNA resulted in the formation of strand breaks and 
base modifications. 
2. Thermal transition studies showed that modified conforraers are less stable as 
compared to native form. 
3. NO-modified plasmid DNA is highly immunogenic in experimental animals. 
4. Induced antibodies are highly specific for immunogen and also show substantial 
crossreactivity with native plasmid DNA. 
5. The induced antibodies show polyspecificity. These antibodies show significant 
binding with various synthetic nucleic acid polymers. 
6. Anti-NO-plasmid DNA recognizes the NO-modified conformers better than native 
conformers of the polynucleotides. 
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7. The multiple binding characteristics of anti-NO-plasmid DNA antibodies towards various 
nucleic acids polymers resembles the binding characteristics of SLE anti-DNA 
autoantibodies. 
8. The binding affinity of NO-plasmid DNA for SLE IgG is maximum, followed by native 
calf thymus DNA and native plasmid DNA respectively. 
9. NO-plasmid DNA presents discriminating antigen for the binding of SLE autoantibodies 
It is suggested that nitric oxide modified nucleic acids might be challenging the immune 
system, leading to autoantibody production. 
<*tf> EXEnCE^L 
122 
Adams, LB., Franzblau, S.G., Vavrin, Z., Hibbs, J.B. Jr. and KrahenbuhL J.L. (1991) J. Immunol 
147, 1642-1646. 
Adams. R.L.P.. Budon. R.H., Campbell AM., Leader, DP and Smellie. R M S . (1981) In: The 
Biochemistry ofthe Nuleic Acids, 9th edition, pp.24. Chapman and HalL London. 
Adorim;L (1993) The Immunologist 1, 185-190. 
Ahmad, J., Ashok B.T. and Ali, R. (1997) Immunol. Lett. 58,69-74. 
Alam, K.. AIL A. and Ali. R. (1993) FEBS Lett. 319. 66-70. 
AlamK. and Ali. R.( 1992) Biochem. Int. 26.597-605. 
Alam, K . Islam N.. Hasan. R.. AIL A. and Ali. R. (1992) Microbiol. Immunol. 36, 1003-1007 
AIL R. DerSimonian. H. and Stollar, B.D. (1985) Mol. Immunol. 22, 1415-1422. 
Ali, A.. Hasan. R. and AIL R. (1991) Biochem. Int. 23, 111-118. 
Ah, R- and Sauerbier, W. (1978) Biophys. J. 22, 393-411. 
Alspaugh. J.A. and Granger, D.L. (1991) Infect. Immun. 59,2291-2296. 
Ames, B.N. (1989) Free Rad. Res. Commun. 7, 121-128. 
Amezcua, J.L., Palmer, R.M., de Souza, B.M. and Moncada, S. (1989) Br. J. Pharmacol. 97. 
. 1119-1124. 
Anderson, W.F.. Cygler. M.. Braun. R. P. and Lee, J.S. (1988a) BioEssays8, 69-74. 
Anderson. R.E.. Rosenblum M.K.. Grauss. F. Willy, R.G. and Pesner, J. B. (1988 b) Neurology 
38, 1391-1398 
Andres, G.A., Accini, L., Beiser, S.M., Christian, C.L., Cinothi, G.A., Erlanger, B.F., Hsu, K.C 
and Segal, B.L. (1970) J. Cliu Invest. 49, 2106-2118. 
Andrews, B.S., Eisenberg, R.A., Theofilopoulos, A.N., IzuL S., Wilson, C.B., McConahey, P.J . 
Murphy, ED.. Roths, J.B. and DLxou, F.J. (1978) J. Exp. Med. 148, 1198-1215. 
Andrzejewski, C. Rausch, J., Lafer, E., Stollar, B.D. and Schwartz, R.S. (1981) J. Immunol. 26. 
226-231. 
Aotsuka, S., Okawa, M., Ikebe, K. and Yokohari, R. (1979) J. Immunol. Methods 28, 149-162 
Ara, J., Ah, A. and Ah. R. (1992) Immunol. Invest. 27, 553-563. 
Ara, J. and Ah, R. (1992) Immunol. Lett. 34, 195-200. 
Ara. J. and Ah, R. (1993) Clin. Exp. Immunol. 94,134-139. 
Ara, J. and Ali, R. (1995) Biochem. Mol. Biol. Int. 35,213-222. 
Aru\Z. and Ah, R. (1996) Arch. Biochem. Biophys. 329, 191-198. 
Arif Z., Arjumand, S, Ah., A. and Ah, R. (1994) Autoimmunity 19, 7-14. 
12 3 
Arjumand, S. and AH, A. (1994) Microbiol. Immunol. 38, 239-243. 
Arjumand, S., Aril Z , Ali, A. and All R. (1995) Immunol. Lett. 48,215-219. 
Arjumand, S., Moinuddiu, and Ali, A. (1997) Biochem. Mol. Biol. Int. 43,643-653. 
Arnett, EC. (1992) Clin. Immunol. Immunopathol. 63,4-6. 
Aniett, EC , Edworthy, S.M., Bloch, DA., McShane, D.J., Fries, J.E, Cooper, N.S., Healy, 
LA., Kaplan, S.R., Liang, M R , Lutlira, H.S., Medsagar, T.A. Jr., Mitchell DM., Neustadt, 
D.H., Finals, R.S., Schaller, J.G., Sharp. J.T., Wilser. R.L. and Hunder, G.G. (1988) Arth 
Rheum. 31,315-324. 
Amett, F. C. and Moulds, J.M. (1991) Clin. Exp. Rheumatol. 9,289. 
Arroyo,PL., Hatch-Pigott, V, Mower, HE andCooner, R.V.(1992)Mutat. Res. 281,193-202 
Aston-Rickardt, P.G. and Tonegawa, S. (1994) Immunol. Today 15,362-366. 
Baas, E, Bikker, H., van Ommen, G.J.B. and de Vijlder, J.J. M. (1984) Hum. Genet. 67, 301-305 
Bagasra, O., Michaels, F.H., Mu, Z.Y., Bobroski, L.E., Spitsin, S.V., Fang, F.Z., Tawadros, R 
and KoprowsklH. (1995)Proc. Natl. Acad. Sci.(U.S.A.)92, 12041-12045. 
Bartsch, H. and Frank, N. (1996) LARC Sci. Publ. 139, 189-201. 
Baumann, J.E., Persson, P.B., Ehmke, H.. Nafi, B. and Kirchheim, H.R. (1992) Am J. Physiol 
263,208-213. 
Beckerman, K.P., Rogers, H.W., Corbett, J.A., Schreiber, R.D., McDaniel ML. and Unanue 
E.R. (1993) J. Immunol. 150,888-895. 
Beckman, J.S., Beckman, T.W., Chen, J., Maishall, PA. and Freeman, B.A. (1990) Proc. Natl 
Acad. Sci.(U.S.A.)87, 1620-1624. 
Bekmont, KM., Levartovsky, D., Goel A., Amin, A., Giorno, R., Rediske, J., Skovron, ML. and 
Abramson, SB. (1997) Arthritis. Rheum. 40,1810-1816. 
Bessho,T, Tano, K., Kasal H., Ohtsuka, E. and Nishimura, S. (1993)J. Biol. Chem 268, 19416-
19421. 
Bianco, F.J., Ochs, R.L., Schwar, H. and Lotj, M. (1995)Am. J. Pathol. 146, 75-80. 
Bias, W.B., Reveille, J.D., Beaty, T.H., Meyers, DA. and Amett, EC. (1986) Am. J. Human 
Genet. 39, 584-602. 
Bittrich, H., Matzig, A.K., Kraker, I. and Appel K. E. (1993) Chemico-Biol. Interact. 86, 199-
211. 
Blount, S., Griffiths, H.R., Emery, P. and Lunec, J. (1990) Clin. Exp. Immunol. 81, 384-389. 
Blount, S., Griffiths, H.R. and Lunec, J. (1989) FEBS Lett. 245, 100-104. 
Blount, S., Lunec, J., Griffiths, FLR., Herbert, K. and Isenberg, D. (1994) Immunol Lett 41 135-
138. 
12 4 
Bohme. G.A.. Bon. C. Stutzmann. J.M.. Doble, A. and Blanchard. J.C. (1991) Eur. J. Pharmacol 
199,379-381. 
Bohr. V.A., Tuffe, B.G. and Larminat. F. (1995) In: Oxidative Stress and Ageing. Cutler. R.G.. 
Pecker. L.. Bertram. J.. Mori. A. (Eds), Birkhauser Verlag. BaseL 
Boiteux, S., Gajeswski. E.. Lax al. J. and Dizdaroglu, M. (1992) Biochemistry 31. 106-110. 
Bolanos. J.P. Almeida, A.. Stewart. Y. Peucheu. S., Land. J.M.. Clark. J.B.. and Heales. S.J 
(1997) J. Neurochem. 68.2227-2240. 
Bortland. C. and Higenbottam. T. (1987) Int. J. Epidermiol. 16. 31-34. 
Bowen. R. and Haslam. R.J. ( 199 1) J. Cardiovasc. Pharmacol. 17.424-433. 
Bradford. M M . (1976) Anal. Biocliem. 72.248-254. 
Braun. R.P. and Lee. J.S. (1988) J ImmunoL 141,2084-2089. 
Braun, R.P and Zachary, A. (1988) In: Autoimmune Diseases. Clinics in Laboratory Medicine 
Deodhar, S.D. (Ed) . Vol. 8. pp. 35 1-372. W.B. Saunders. Philadelphia. 
Bredt, D.S.. Hwang. P.M.. Glatt. C.E . Lowenstein, C , Reed. R.R. and Snyder. S.H.. (1991) 
Nature 351.714-718. 
Bredt. D.S., Hwang, P.M. and Suyder. S.H. (1990) Nature 347. 768-770. 
Breer. H. and Shepherd. G.M. (1993) Trends Neurosci. 16. 5-9. 
Brosnan. C.F.. Bomstein. M B . and Bloom. BR. (1981) J. Immunol. 126,614-620. 
Broten. T.P.. Miyashiro. J.K.. Moncada. S. and Feigi, E.O. (1992) Am. J. Physiol. 262. 157^'-
1584. 
Bnuie. B., Molina, Y., Vedia, L. and Lapetina, E.G. (1990) Proc. Natl. Acad. Sci. (U.S.A.)87. 
3304-3308. 
Buga. G.M., Gold, M.E.. Fukuto, J.M. andlgnarro L. J. (1991) Hypertension 17, 187-193. 
Buh, FL. Boeckxstaens. G.E.. Peickmans. P A . Jordaens. F.H.. Van Maercke. Y.M. and Herman. 
A.G. (1990) Nature 345. 346-347. 
Burkart, V . Kroucke. K. D.. Kolb-Bachofen, V. and Kolb, H. (1994). Clin. Immunother. 2,233-
239. 
Burlingame, R.W., Rubin, R.L., Balderas. R.S. andTheofilopoulos. A.N. (1993) J. Clin. Invest 
91. 1687-1696. 
Burnet, F.M. (1959) In: The Clonal Selection Theory of Acquired Immunity. Cambridge University 
Press, London. 
Burton. K. (1956) Biochem. J. 62. 315-323. 
Buttery, L.D.K., SpringalL DR., Giester, A H , Evans, T.J.. Standfield. N.. Panuns. D.V. Yacoub. 
M R , and Polak. J.H. (1996) Lab. Invest. 75, 77-85. 
12 5 
Calabrese, L.H. (1988) In: Autoimmune Diseases, Clinics in Laboratory Medicine. Deodhar. SI) 
(Ed.), V0L8, pp.269-279. W.B. Saunders. Philadelphia. 
Camerini-Otero, R.D. and Hseih. P (1993) CeU 73,217-223. 
Cantanzaro, O.L., Marinaprendes, M.G.. Hope, S.I., Zuccollo. A. and Dominguez. A. (1994) 
Braz. J. Med. Biol. Res. 27. 2043-2047. 
Casciola-Rosen. L. and Rosen, A. (1997) Lupus 6. 175-180. 
Casperson. G.F. and Voss. E.W.Jr.( 1983) Mol. Immunol. 20, 573-580. 
Cepellini, R., Polli, C. and Celada, F. (1957) Proc. Soc. Exp. Biol. Med. 96, 572-574. 
Chan. T.M. Yu. P.M.. Tsang K.L. and Cheng. I.K. (1995) Clin. Exp. Immunol. 100. 506-513. 
Chastagner. P.. Demaison. C, Theze, J. andZouali. M. (1994)Scand. J. Immunol. 39, 165-178 
Chu. A., Chambers. D.E . Lin. C.C , Kuehl, WD. and Cobb, F.R. (1990) Am. J. physiol. 258. 
1250-1254. 
Clancy, R.M. and Abramson. SB. (1995) Proc. Soc. Exp. Biol. Med. 210. 93-101. 
Cohen, P.I. and Eisenberg. R.A. (1991) Ann. Rev. Immunol. 9,243-269. 
Cohen, PI. and Eisenberg. R.A. (1992) Immunol. Today 13,427-428. 
Collier, J. and Vallance. P. (1991) Br. Med. J. 302, 1289-1290. 
Connor, J.R., Manning, P.T.. Settle. S.L., Moore, W.M.. Jerome. G.M.. Webber. R.K.. Tjoeng. 
. F.S. and Cunrie, M.G. (1995) Eur. J. Pharmacol. 273, 15-74. 
Cook. H. T. and Cattell, V. (1996) Clin. Sci. 91, 375-384. 
Cooke, M.S.. Mistry. N.. Wood, C, Herbert, K.E. aud Lunec, J. (1997) Free Rad. Biol. Med. 22. 
151-159. 
Cookson, MR., Ince, PG. and Shaw, P.J. (1998) J. Neurochem. 70, 501-508. 
Cooper, D.N. and Krawczak. M. (1990) Hum. Genet. 85. 55. 
Corbett, J.A., Sweetlaud, MA, Wang, J.L., Lancaster, JR., Jr. and McDanieL M.L. (1993) Proc 
Natl. Acad. Sci. (U.S.A.) 90, 1731-1735. 
Counihan, K.A., Vertosic, FT. and Kelly, R.H. (1991) Immunol. Invest. 20,317-331. 
Croen, K.D. (1993) J. Clin. Invest. 91, 2446-2452. 
Cross, A.H., Misko, T.P., Lin, RE, Hickey, W.F., Trotter, J.L. and Tilton, R.G. (1994) J. Clin. 
. Invest. 93, 2684-2690. 
Crystal R.G. (1995) Nature. Med. 1, 15 
Cuzzocrea, S., Caputi. A.P. aud Zingarelli, B. (1998) Immunology 93,96-101. 
Dang-Vu, A.P., Pisetsky, D.S. and Weinberg, J.B. (1987) J. Immunol. 138, 1757-1761. 
12 6 
Dawson, V.L., Dawson. T.M., Loudon. ED., Bredt, D.S. and Snyder. S.H. (1991) Proc. NatLAcad. 
Sci.(U.S.A)88. 6368-6371. 
de Belder. A.J. and RadomskL M.W.( 1993) Laucet 341. 84-85. 
deGraaf. J .C. Banga. J.D.. Moucada, S.. Palmer. R.M., de Groof. P.G. and Sixma. J.J. (1992) 
Circulation 85, 2284-2290. 
Delaney. C.A. and Eizirik. D.L. (1996) Braz. J. Med. Biol. Res. 29. 569-579. 
Deniple. B. and Harrison. L. (1994) Ann. Rev. Biochem. 63.915-948. 
Deng. A. andBaylis, C. (1993) Am. J. Physiol. 264, 212-215. 
Denis. M. (1991a) J. Leukoc. Biol. 49. 380-387. 
Denis. M. (199 lb) Cell. Immunol. 132, 150-157. 
Deodhar. S.D. (1992) Clin. Biochem 25. 181-185. 
Desat D.D.. Krishnan. M l , Swindle, J.T. and Marion. T. N. (1993) J. Immunol. 151. 1614-
1626. 
Desai. K.M.. Sessa. W. C. aud Vaue. J. R. (1991) Nature 351, 477-479. 
Devlin, J.. Palmer. R.M.J.. Christopher. E.G., CTGrady, J.. Tan, K.C., Martin. J.F.. Moucada. S 
and Willis. R. (1994) Transplantation 58. 592-595. 
Ding. M.. Wong. J.L.. Rogers. N.E.. Ignano. L.J. and VoskuhL R.R. (1997) J. Neuroimmunol. 77, 
99-106. 
Ding, M., Zhang. M.. Wong. J.L., Rogers, N.E., Iguarro, L.J. and Voskuhl R.R. (1998) J. Immunol. 
160, 2560-2564. 
Dipple. A.. Wiiik DA.. Keefer, K.A., Srinivasan, A., Kehnan, D.J. and Clmstodoulou, D. (1997) 
Carcinogenesis 18, 1045-1048. 
Donnelly, J.J., Ulmer, J.B. and Liu, M A . (1994) J. Immunol. Methods 176, 145-152. 
Duarte, LD.G., Loreuzetti. B.B. and Ferriera, S.H In: Nitric oxide fromL-argiuine: a bioregulatory 
system: proceedings of the Symposium ou Biological Importance of Nitric Oxide, London. 
(1989), Moucada, S.audHiggs, E.A. (eds). 14-15. Amsterdam: Excerpta Medica,(I990): 
165-170. 
Duncan. B.K. and Miller. J.H. (1980) Nature 287, 560-561. 
Durante, W. KrolL M.H.. Vauhoutte, P.M. and Schafer, A.I. (1992) Blood 79, 110-116. 
DziarskL R. (1988) Immunol. Today 9, 340-342. 
Ehrenstein. M l , Loughurst, C M . and Iseuberg, DA. (1993) Clin. Exp. Immunol. 93,39-45. 
Eliassou, M.J., Sampei, K., Maudir, A.S., Hum, P.D., Traystman, R.J., Bao, J., Pieper, A., Wang, 
Z.Q., Dawson, T.M.. Snyder, S.H. and Dawson, V.L. (1997) Nat. Med. 3, 1089-1095. 
12 7 
Emlen. W.. Neibur. J. and Kadera, R. (1994) J. Immunol. 152, 3685-3692. 
Emlen, W. Pisetsky, D.S. and Taylor, R.P. (1986) Artli. Rlieum. 29, 1417-1426. 
Eritja, R.. Horowitz, DM., Walker, PA, Ziehler, Martin. J.P., Boosalis, M.S., Goodman. M.F 
Itakura. K. and Kaplan , B.E. (1986) Nucleic Acids Res. 14. 8135-8153. 
Erlanger. B.F. and Beiser, S.M. (1964) Proc. Natl. Acad. Sci. (U.S.A.) 52. 68-74. 
Faraci. F.M. and Breese, K.R. (1993) Circ. Res. 72, 476-480. 
Faraci. F.M. and Heistad, D.D. (1992) J. Cereb. Blood. Flow Metab. 12. 500-506. 
Farrell. A.J.. Blake. DR., Palmer. R.M. and Moncada. S. (1992) Ann. Rlieum. Dis. 51. 1219-
1222. 
Felley-Bosco. E. (1998) Cancer Metastasis Rev. 17.25-37. 
Fenyk-Melody. J.E.. Ganison. J.E.. Bnumert. S.R.. Weidnes. JR., Shen, F., Shelton. B.A. and 
Mudgett, J.S.(1998)J. Immunol. 160.2940-2946. 
Fineman, J. R.. Heymann, M.A.. and Solfer, S.J. (1991) Am. J. Physiol. 260. 1299-1306. 
Floyd. R.A.. West, M.S., Eneff, K.L., Hogsett. W.E. and Tingey, D.T. (1988) Arch. Biochem 
Biophys. 262. 266-272. 
Forstemiann, V, Gorsky, L.D., PoUack, J.S., Schmidt, H.H., Heller, M. and Murad, F. (1990) 
Biochem. Biophys. Res. Commun. 168, 727-732. 
Fortier. A.. H., PolsineilL T., Green, S. J. and Nacy, C. A. (1992) Infect. Immun.60. 817-825. 
Foster, M.H.. Kieber-Emmons, R.K., Ohliger, M. and Madaio, M.P (1994) Immunol. Res. 13. 
186-206. 
Fredriksen. K.. Osei, A., Sundsrjord, A., Traavik, T. and Rekvig, OP. (1994) Eur. J. Immunol. 24. 
66-70. 
Freidberg, E.C. (1985) DNA Repair. Freeman Press, New York. 
Fukunaga, W., Brannan, R.C.I., Copeland, N .G, Tenkins. N.A. and Nagata, S. (1992) Nature 
356,314-317. 
Furchgott, R.F. and Zawadski, J.V. (1980) Nature 288,373-376. 
Garg, D.K. and Ali, R. (1998) J. Autoimmunity 11,371-378. 
Gavalchin, J. and Datta, S.K. (1987) J. Immunol. 138,138-162. 
Gazzinelli, R.T., Oswald, LP, James, S.L. and Sher, A. (1992), J. Immunol. 148, 1792-1795. 
Gilkeson, G.S. , Bloom, D.D., Pisetsky, D.S. and Clarke, S.H. (1993) J.Immunol. 151, 1353-
1364. 
Gilkeson, G.S., Grudier, J.P, Karounos, D.G. and Pisetsky, D.S. (1989) J. Immunol. 142, 1482-
1486. 
12 8 
Gilkeson. G.S.. Mudgett, J.S., Seldin. M.F.. Ruiz. P.. Alexander. A., Misukonis. M.A.. Pisetsky. 
D.S. and Weinberg^ J.B. (1997) J. Exp. Med. 186, 365-373. 
Gilkeson. G.S.. Pippen. A.M. and Pisetsky D.S. (1995) J. Clin. Invest. 95, 1398-1402. 
Gilkeson. G.S.. Pritohard, J.P. and Pisetsky. D.S. (1991) Clin. Immunol. ImmunopathoL 59, 288-
300. 
Godden. J. W. Turley, S., Teller, D.C.. Adam. E.T.. Liu. M Y . Payne, W.J. and LeGall. J. (1991) 
Science 253, 438-442. 
Goding. J.W.(1978)J. Immunol. Metliods 20. 241-254. 
Goldstein. R. and Aniett, FC. (1987) Rheum. Dis. Clin. North Am. 13.487. 
Goodnovv, C.C. (1992) Annu. Rev. Immunol. 10.489-5 18. 
Gordge. M.P. (1998) Exp. Nephrol. 6. 12-16. 
Gordon. C , Blount, S.. Lunec. J. and Emery. P. (1990) Br. J. Rheumatol. 39,42. 
Gorsdorf. S , Appel. K.E., Engeholm, C. audObe. G. (1990) Carcinogenesis 11,37-41. 
Gourley. M.F., Kisch. W.J., Mojcik. C.F.. King. L.B.. Kreig. A.M. and Steinberg. A.D. (1992 > 
DNA and Cell Biol. 11,253-257. 
Graziewicz, M., Wink, DA. and Laval, F. (1996) Carcinogenesis 17,2501-2505. 
Green. S.J.. Meltzer, M.S., Hibbs. J.B. Jr. and Nacy. C.A. (1990) J. Immunol. 144. 278-383 
GrifantiuL R.. Finco. O.. Bartoliui, E., Draghi. M.. Giudice. G.D.. Kockai, C.Thomas. A.. AbnguaiiL 
S. andGrandi, G. (1998) Eur. J. Immunol. 28, 1225-1232. 
Grygleswski, R. J., Korbut, R., Trabka-Janik, E., Zembowicz, A. and Trybulec. M. (1989a) J 
Cardiovasc. Pharmacol. 14, 124-128. 
Gryglewski, R. J., Korbut, R., Kalecinska, A. and Zembowicz, A. (1989b) Int. J. Tissue. React. 
11, 269-275. 
Gustafsson, L.E., Wiklund, C.U., Wikhind, N. P., Perssou. M.G. and Moncada, S. (1990) Biochem 
Biophys. Res. Commun. 173, 106-110. 
Hahn, B.H. andTsao, B.P. (1993) In: Antibodies to DNA. Dubois Lupus Erythematosus. Wallace, 
D.J. and Hahn, B.H. (Eds). Lea and Febiger, Philadelphia. 
HalliwelL B. and Aruoma, O.I. (1991) FEBS Lett. 281,9-19. 
HaUiwelL B. and Gutteridge, J.M.C. (1984) Biochem. J. 219, 1-14. 
HalliwelL B. and Gutteridge, J.M.C. (1989) In: Free Radicals in Biology and Medicine, 2nd edition. 
Clarendon Press, Oxford, London. 
Halloran, M.J. and Parker, C.W. (1966) J. Immunol. 96. 379. 
Hanenberg, HL, Kolb-Bachofeu, V, Kaurwerk-Funke, G. and Kolb, H. (1989)Diabetologia 32, 
126-134. 
12 9 
Harada, T . Suziki. N., Muzushima, Y. and Sakane. T. (1994) J. Immunol. 153. 4806-4815. 
Hardin, J.A. (1986) Arth. Rheum. 29, 457-460. 
Hasan, R. and Ali. R. (1990) Biochem. Int. 20, 1077-1088. 
Hasan, R., Ali, A. and AIL R. (1991) Biochim. Biophys. Acta 1073. 507-5 13. 
Hasan, R., Moinuddin, Alam, K. and AIL R (1995) FEBS Lett. 368. 27-30. 
Herrmann, M. Z . Zoller. O.M., Hagenhofer. M. VoH. R. and Kalden. JR. (1996) Mol. Biol. Rep 
23, 265-270. 
Hewett, S.J.. Corbett, J.A.. McDanieL M L . and Choi. D.W. (1993) Neurosei. Lett. 164. 229-
232. 
Hibbs. J.B. Jr.. Tahitor, R R , Vavrin, Z. and Rachihi. EM. (1988) Biochem Biophys. Res. Conimun. 
157, 87-94. 
Hibbs, J.B., Jr., Tahitor, R R and Vavrin. Z. (1989): In: Nitric oxide from L-arginine: a bioregulatoiy 
system: proceedings of die symposium on Biological Importance ofNitric Oxide. Loudon (1989) 
Moucada. S. audHiggs, E.A. (eds.) 14-15. Amsterdam; Excerpta Medica. (1990) 189-223 
Hirschbora, R , TzalL S. and Elleubogen, A. (1990) Proc. Natl. Acad. Sci.( U. S. A.) 87.6171 
Hochberg, M.C. (1987) J. RheumatoL 14. 867-869. 
Hoopper, D.C., Olmishi S T . Kean. R.. NumagamL Y.M.. Dietzschold. B. and Koprovvski. H 
(1995) Proc. Natl. Acad. Sci. (U.S.A.) 92. 53 12-5316. 
Hortelano, S.. Dallapoita, B., ZamzamL N.. Hirsch, T . Sushi, S.A., Marzo, I. and Bosca. L. (1997) 
FEBS Lett. 410, 373-377. 
Huang, F.P., Feng, G.J., Lindop, G., Scott. D.I. and Liew, FY. (1996) J.Exp. Med. 183, 144^-
1459. 
Huang, Y.P., Perrin., L.H., Miescher, PA. andZubler. R.H. (1988) J. Immunol. 141. 827-833 
Ialenti A., Moncada, S. and Di Rosa, M. (1993) Br. J. Pharmacol. 110. 701-706. 
Ignarro, L.J. (1990) Annu. Rev. Pharmacol. Toxicol. 30, 535-560. 
Ignarro, L.J. (1991) Blood Vessels 28,67-73. 
Inoue, S. and Kawanishi S. (1995) FEBS Lett. 371,86-88. 
Ischiropoulos, R , Zhu, L. and Beckman, J.S. (1992) Arch. Biochem. Biophys. 298,446-451 
Isenberg, D A (1997) J. Rehumatol. BioL (Supl). 48,62-66. 
Isenberg, D.A., Stehier, G. and Smolen, J.S. (1994) J. Rheumatol. 21, 1260-1263. 
Isomura, K., Chikahira, M., TeranishL K. and Hamada, K. (1984) Mutat. Res. 136, 119-125 
Ivanova, K., Schaefer, M., Drummer, C. and Gerzer, R (1993) Eur. J. Pharmacol. 244,37-47 
130 
Ivvata, F , Joh, T., Kawal, T. and Itoh, M. (1992) Am. J. Physiol. 263, 149-154. 
Jackson, S.P. (1996) Curr. Opin. Genet and Dev. 6, 19-25. 
Jacob, L., Lety, M.A., Bach, J.F. and Louvard, D. (1986) Proc. Natl. Acad. Sci.(U.S.A) 83, 
6970-6974. 
Janssens. S.P. Shimouchi, A., Quertermous, T., Bloch, D.B. and Bloch K.D. (1992) J. Biol. Chein 
267,14519-14522. 
Ji. X. B. and Bellocher, T.C. (1988) Appl. Environ. Microbiol. 54, 1791. 
Jonhson, C , Henshaw. J. and Mclnnes, G. (1992) Nature 355. 69-72. 
Jones, L.F. and Brody, M.J. (1992) J. Pharmacol. Exp. Ther. 260. 627-631. 
Kalden, JR. and Marion, T.N. (1997) Lupus 6,324-329. 
Kaplan, S.S., Billar, T.R., Curran, R.D., Zdziarski, U.E., Simmons, RL. and Basford, RE. (1989) 
Blood 74, 1885-1887. 
Kapp, D.S and Smith, K.C. (1970) Radiat. Res. 42, 34-49. 
Karonous, D.G., Grudier, J.P. and Pisetsky, D.S. (1988) J. Immunol. 140,451-455. 
Karupiah, G., Xie, Q , Buller, R.M.L., Nathan, C , Duarte, C. and MacMicking, J.D. (1993) 
Science 261, 1445-1448. 
Kasai. H., Crain, P.F., Kuchino, Y , Nishimura, S., Ootsuvama, A. and Tanooka.H. (I9<s<i) 
Carcinogenesis 7, 1849-1851. 
Kashihara, N. Kirakawa, S., Mino, Y , Makino, H. and Ota, Z. (1993) Acta Med. Okayama 47. 
255-259. 
Kato, AC. and Fraser, M.J. (1973) Biochim. Biophys. Acta 312, 645-655. 
Kay, R.A., Wood, K.J., Bernstein, R.M., Holt, P.J.L. and Pumphrey, R.S.PL (1988) Ann. Rheum 
Dis. 47, 536-541. 
Keefer, L.K., Wink, D.A., Kasprazak, K.S., Marages, CM., Elespuru, R.K., Misra, M., Dunaim, 
T.M., Cebula, T.A., Koch, W.H., Andrews A. W. and Allen, J.S. (1991) Science 254, 1001-
1003. 
Kelm, M., Feelisch, M , Deussen, A., Strauer,B.E. andSchrader, J. (1991)Cardiovasc. Res. 25. 
831-836. 
Kennedy, M., Dennenberg, A.G., Szabo, C. and Salzman, A.L. (1998) Gastroenterology 114. 
601-603. 
Kieber-Emmons, T.K., Foster, K.R, Williams, W.V. and Madaio, M.P. (1994) ImmunoL Res. 13, 
186-206. 
KiechJe, F. L. and Malinski, T. (1993) Am. J. Clin. Pathol. 100, 567-575. 
131 
Kilbourn, R.G, Jubran, A., Gross, S.S., Griffith, O.W., Levi R. and Adanis J. (1990a) Biochem. 
Biophys. Res. Commun. 172,1132-1138. 
KUbourn, R.G, Jubran, A., Gross, S.S., Adams, J., Griffith, O.W. and Levi R. (1990b) Proc. 
. Natl. Acad. Sci.(U.S.A.)87, 8629-8632. 
Kirchner. J.J. and Hopkins, P.B. (1991) J. Am. Chem Soc. 113.4681-4682. 
Kirk, S.J, Regan, M.C. and Barbul, A. (1990) Biochem. Biophys. Res. Commun. 173. 660-665 
Kleemann. R, Rothe. H, Kolb-Bachofen, V, Xie, Q.W.. Nathan. C , Martin. S. and Kolb. H 
(1993) FEBS Lett. 328.9-12. 
Klinman, D M , Eisenberg, R.A. and Steinberg, A.D. (1990) J. Immunol. 144. 506-5 11. 
Klinman, D M , Shirai. A, Conover. J. and Steinberg, AD. (1994) Eur. J. Immunol. 24. 53-58 
Klinman. DM. and Steinberg, A.D. (1987) J. Exp. Med. 165, 1755-1760. 
Klinman. D. M, Yamschchikov, G. and Ishigatsubo, Y. (1997) J. Immunol. 158. 3635-3639. 
Klippel, J.H. (1997) J. Rheumatol. Suppl. 48,67-71. 
Koffler, D. (1974) Ann. Rev. Med. 25, 147-164. 
Kolb, H, Burkart. V, Appels, B , Hanenberg, H, Kantwerk-Funke. G, Kiesel, U , Funda. J , 
Schraermeyer, U. and Kolb-Bachofen, V. (1990) J. Autoimmun. 3, 117-120. 
Kolb, H.. Fehsel. K.. Jalowy, A, Qi, S., Burkart, V and Hartmann, B. (1993) Diabetes 42.496-
500. 
Kolb, H., Kiesel. U, Kroncke, K.D. and Kolb-Bachofen. V. (1991) Life Sci. 49, 213-217. 
Kolb, H. and Kolb-Bachofen, V. (1992) Immunol. Today 13, 157-160. 
Koppenol, W.H, Moreno, J.J, Pryor, W.A., Ischiropoulos, H. and Beckman, J.S. (1992) Chem. 
Res. Toxicol. 5. 834-842. 
Koprowski. H, Zyeug. Y.M., Heber-Katz, E., Fraser, N , Rorke, L, Fu, Z.F, Hanlon. C. and 
Dietzschold, B. (1993) Proc. Natl. Acad. Sci.(U.S.A.) 90,3024-3027. 
Kosaka, H., Wishnok, J.S, Miwa, M , Leaf, CD. and Tannenbaum, S.R. (1989) Carcinogenesis 
• 10,563. 
Krakauer, S.R, Sundeen. J., Saunder, D.N. and Scherbel, A. (1981) Arch. Dermato, 117,80-82. 
Krieg, A.M., Gause, W.C, Gourley, M.F. and Steinberg, A.D. (1989) J. Immunol. 143, 2448-
2451. 
Krieg, A M , Gourley, M.F. and Steinberg, A.D. (1991) J. Immunol. 146, 3002-3005. 
Krieg, A.M. and Steinberg, A.D. (1990) J. Clin. Invest. 86,809-816. 
Krieg, A.M., Yi, A., Matson, S., Waldschmidt, T.J., Bishop, G.A, Teasdale, R, Koretzky, G.A 
and Klinman DM. (1995) Nature 374, 546-549. 
132 
Krislmau. M l and Marion. T.N. (1993) J. Immunol. 150.4948-4957. 
Kroemer. G. and Martinez, A.C. (1991) Clin. Immunol. ImmunopathoL 61, 275-295. 
Kroucke, K.D. Kolb- Bachofeu, V, Berschick, B., Burkart, V. and Kolb, H. (1991) Biochem 
Biophys. Res. Commim. 175, 752-758. 
Kuchino, Y. Mori, F.. Kasai, H., Inoue, H., Iwai, S., Miura, K.. Ohtsuka. E. and Nishimare. S 
(1987) Nature 327. 77-79. 
Kulm. A.. Fehsel. K., Lehman. P., Krulman. J.. Ruzicka. T. and Kolb-Bachofen. V. (1998) J 
Invest. Dermatol. I l l , 149-153. 
Kurata. N. and Tan, E.M. (1976) Arthritis. Rheum. 19, 574-580. 
Kwon. N.S.. Stuehr. D.J. and Nathan, C.F. (1991) J. Exp. Med. 174. 761-768. 
LaemmlL U.K. (1970) Nature 227, 680-685. 
Lafer. EM.. Rauch. J., Andrzejewski C , Mudd, D., Furie. B.C.. Furie, B., Schwartz. R.S. and 
Stollar, B.D. (1981) J. Exp. Med. 153, 897-909. 
Lahita. R.G. (1992) Clin. Immunol. ImmunopathoL 63, 12-18. 
Lauder, H.M., SehajpaL P., Leviue, DM. and Novogrodsky, A. (1993) J. Immunol. 150, 1509-
1516. 
Langridge, R.. Maniin. DA., Seeds. W.E., Wilson. H.R.. Cooper, C.W., Wilkins, M.G.F., and 
Hamilton; L.D. (1960) J. Mol. Biol. 2. 38. 
Langmuir, I. (1918) J. Am. Chem. Soc. 40, 1361. 
Langoue, J.J. (1978) J. Immunol Methods 24, 2o9-285. 
Laval F. and Wink, DA. (1994) Carcinogenesis 15, 443-447. 
Lee K.U. (1994) Diabetes 43, 1218-1220. 
Lee, K.U., Amano, K. and Yoon, J.W. (1988b) Diabetes 37. 989-991. 
Lee, K. U., Kim, M.K.. Amano, K., Pak, C.Y., Jaworski, M.A., Mehta, J.G. and Yoon, J.W 
(1988a) Diabetes 37, 1053-1058. 
Lepoivre, M., Fieschi, F., Coves, J., Thelander, L. and Foutecave, M. (1991) Biochem. Biophys. 
Res. Commun. 179,442-448. 
Levine, L., Murakami, W. T, van Vunakis, H. and Grossman, I. (I960) Proc. NatL Acad. Sci 
(U.S.A.) 46, 1038-1043. 
Levinson, S.S. (1994) J. Clin. Immunoassay 17,72-84. 
Lewis, R.S., Taiinenbaum, S.R. and Deen, W.M. (1995)J. Am. Chem. Soc. 117, 3933-3939 
Liew, F.Y. (1994) Ann. N.Y. Acad. Sci. 741, 39-45. 
Liew, F. Y, Li, Y and Millott, S. (1990) Immunology 71, 556-559. 
133 
Lilly, D.M.J. (1980) Proc. Natl Acad. Sci.(U.S.A.) 77,6468-6472. 
Lin, J.K., Wang, J.M. and Lin-Shiau, S.Y. (1993a) Biochemical Pharmacology 45, 819-825. 
Lin, J. Y. and Chadee. K. (1992) J. Immunol. 148, 3999-4005. 
Lin, R E , Lin. T.S.. Tilton, R.G. and Cross, AH. (1993b) J. Exp. Med. 178. 643-648. 
LindahL T. and Anderson. A. (1972) Biochemistry 11, 3618-3623. 
Liu, R.H. and Hotchkiss. J.H. (1995) Mutat. Res. Rev Genet. Toxicol. 339. 73-89. 
Loeb, L.A. and Preston, B.D. (1986) Annu. Rev. Genet. 20,201-230. 
Lowenstein, C.J.. Dinerman, J.L. and Snyder, SH. (1994) Ann. Intern. Med. 120, 227-237. 
Lowenstein. C.J. and Snyder. S.H. (1992) Cell 70. 705-707. 
Lovvry. O R , Rosenberg, N.J., Farr. A.L. and Randall RJ. (1951) J. Biol. Chem. 193, 265-275. 
Ludowyk, P A , Hughes, W.. Hugh. A., Willenborg, DO., Rockett, K.A. and Parish, C.R. (1993) 
J. Neuroimmunol. 48. 121-134. 
Lukic. M.L., Stosic-Griijicic, N., Ostojic. N. Chan, L. and Liew, FY. (1991) Biochem. Biophys. 
Res. Commun. 178, 913-920. 
Lundberg, J.O.N.. Hellstrom, P.M., Lundberg J.M. and Alving, K. (1994) Lancet 344, 1673-
1674. 
Luperchio, S., Tamir. S.. and Tannenbauux S.R. (1996) Free Radic. Biol. Med. 21, 513-519. 
Luscher, T.F. (1990) Clin. Exp. Hypertens. 12,897-902. 
Luscher, T.F. (1992) Br. J. Clin. Pharmacol. 34,29-35. 
MacMicking. J.D.. Willenborg, DO. , Weidemann, M.J., Rockett, K.A. and Cowden, W.B. (1992) 
J. Exp. Med. 176, 303-307. 
Madaio, M P , Hodder, S., Schwartz, R.S. and Stollar, B.D. (1984) J. Immunol 132,872-876. 
Maniatis. T., Fritsch, E.F, and Sambrook, J. (1989) Molecular Cloning: A Laboratory Manual, 
2nd ed.. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. New York. 
Margrinat, G., Mason, S.N., Shami, P. J. and Weinberg, J.B. (1992) Blood 80, 1880-1884. 
Marietta, MA. (1989) Trends Biochem. Sci. 14,488-492. 
Marion, T.N., BothweU, A.L. M., Briles, D.E. and Janeway, C.A. Jr. (1989) J. Immunol. 142. 
4269. 
Marsden, P.A., Schapperl, K.T., Chen, H.S., Flowers, M., Sundeli, C.L. and Wilcox, J.N. (1992) 
FEBS Lett. 307, 287-293. 
Maruyama, W., Takahashi, T. and Naoi, M. (1998) J. Neurochem. 70, 2510-2515. 
134 
Matheis. G.. Shennan. M P , Buckberg. G.D.. Haybron. DM.. Young. H.H. aud Ignarro. L.J 
(1992) Am. J. Physiol. 262.616-620 
Matsuo, N. and Ross. P.M. (1987) Biochemistry 26.2001-2009. 
MaueL J.. Rausijn. A. and Buclimuller-Rouiller. Y. (1991) J. Leukoc. Biol. 49. 73-83 
Maurice, D.H. and HaslamR.J. (1990) Mol. Pharmacol. 37. 671-681. 
Mayer. J.. Woods. ML. . Vavrin. Z. and Hibbs. I B . Jr. (1993) Infect. Immunol. 61. 491-497 
Mayhan. W.G. (19Q2) Inflammation 16. 295-305. 
McCartney. F.N., Allen. J.B., Mizel. D L . Albina. J.E., Xie. Q , Nathan. C.F. and WaliL S.M 
(1993) J. Exp. Med. 178. 749-754. 
McMillan. K.. Bredt. D.S.. Hirsch. D.J.. Snyder. S.H., Clark. J.E. and Masters. B.S. (1992) Proc 
Natl. Acad. Sei.(U.S.A) 89. 11141-11145. 
Meischer. P. and Strassie. R. (1957) Vox Sanguins 2. 283. 
Messina. J.P.Gilkeson.G.S. and Pisetsky. D.S. (1993)Cell. Immunol. 147. 148-157. 
Messmer. U.K.. Ankarcrona, M.. Nicotera. P. and Brune. B. (1994) FEBS Lett. 355, 23-26. 
Mills, CD. . Stevens. R.B. and Sutherland. D.E.R. (1994) Transplantation Proceedings 6, 3348. 
Miossec, P. (1993) Eur. Cytokine Netw 4. 245-251. 
Mohan, C . Adams. S.. Satnik. V. and Datta. S.K. (1993) J. Exp. Med. 177. 1367-1381. 
Mohan IK. and Das. U.N. (1997) Prostaglandins Leukot. Esseut. Fatty Acids56. 193-198. 
Moinuddin and All A. (1994) Lupus 3. 43-46. 
Mollace, V. Bagetta. G. andNistico. G. (1991). Neuroreport 2,269-272. 
Moucada, S. (1992) Acta Physiol. Scand. 145, 201-227. 
Moncada, S.. Herman. A.G. and Vanhoutte, P.M. (1987) Trends Pharmacol. Sci. 8.365-368 
Moncada, S., Palmer, R.M.J. and Higgs. E.A. (1991) Pharmacol. Rev. 43. 109-142. 
Moore, P.K., Oluyoml A.O.. Babbedge. R.C.. WaUace. P. aud Hart. S.L. (1991) Br. J. Pharmocol. 
102, 198-202. 
Moreno, J.J. and Pryor, W.A. (1992) Chem Res. Toxicol 5, 425-431. 
Morley, J.E. and Rood. J.F. (1991) Life Sci. 49, 707-711. 
MoscheL R. C. and Keefer, K.K. (1989) Tetrahdron Lett. 30. 1467-1468. 
Mullingan, M.S.. HeveL J.M., Marietta. M.A. and Ward, PA. (1991) Proc. Natl. Acad Sci(U.S.A ) 
88, 6338-6342. 
Munoz-Fernandez, M.A., Fernandez, M.A. and Fresno, M. (1992) Eur. J. Immunol. 22,301-307 
Nagata, S. and Suda, T. (1995) Immunol. Today 16,39-43. 
135 
Nathan. C. (1992) FASEB J. 6, 3051-3064. 
Neparstek. Y. and Madaio, M.P (1997) Lupus 6,307-309. 
Nguyen. T. Brunson. D., Crespi, C.L., Penman. B.W., Wishnok, J.S. and Tannenbaum. S.R. (1992) 
Proc. Natl. Acad. Sci.(U.S.A) 89, 3030-3034. 
Nishiya. K. and Hashimoto, K. (1997) Clin. Exp. Rheumatol. 15. 39-44. 
Nolte, C . Eigenthaler. M. Schanzenbacher. P and Waher. U. (1991) J. Biol Chem. 266. 14808 
14812. 
Nossal, G.J.V. (19Q4) CeU 76. 229-239. 
Nowicki. J.P.. DuvaL D.. Poignet. H. and Scatton, B. (1991) Eur. J. Pharmacol. 204. 339-340. 
Nussler, A.K. and Billiar. T.R. (1993) J. Leukocyte. Biol. 54, 171-178. 
Oates. J.C., Ruiz. P., Alexander, A., Pippen, A.M.M. and Gilkeson, G.S. (1997) Clin. Immunol 
Immunopathol. 83.86-92. 
ODell. T.J., Hawkins, R.D., KandeL E.R. and Arancio, O. (1991) Proc. Natl Acad. Sci.(U.S.A ) 
88,11285-11289. 
Ohnishi. K. Ebling. F.M.. Mitchell B.. Singh, R.R. Hahn. B.H. and Tsao. B.P. (1994) Int. Immunol 
6,817-830. 
Ohshima, H. and Yoshie, Y. (1997) Carcinogenesis 18.1359-1363. 
Okuda. Y. Sakoda. S., Fujimura, H. and Yanagihara, T. (1998) J. Neuroimmunol. 81.201-210. 
Oudker, P. M.. Bouma, G.. Visser, J.J.. Kolkman, J.J.. Tran, D.D.. Meuwisseu. S.G. and Pena. 
, A.S. (1995) Scand. J. Gastroenterol. 30, 784-788. 
Palmer, R.M., Ferrige, AG. and Moncada, S. (1987) Nature 327, 524-526. 
PardolLD.M. and Beckonleg, A.M. (1995) Immunity 3, 165. 
Park, S.H. and Aust. A:E. (1998) Cancer Res. 58, 1144-1148. 
Parkinson, J.F., Mitrovic, B. and Merrill, J.E. (1997) J. Mol. Med. 75, 174-186. 
Pasqui. A.L., Capecchi, PL., Ceccatelli, L., Mazza, S., Gistri, A. and Laghi-Pasini, F. (1991) 
Throm. Res. 61, 113-122. 
Perutz, M.F. (1990) Biophys. Chem. 37,25. 
Pires, M., Rossi, M.J. and Ross, D.S. (1994) Int. J. Chem. Kinetics 26, 1207-1227. 
Pisetsky, D.S. (1992) Rheum Dis. Clin. North Am. 18,437. 
Pisetsky, D.S. (1993) Structure of Antigens. Vol. 2, pp. 129. van Regenmorel M.H. V. (Ed.), CRC 
' Press, Boca Raton, Florida. 
Pisetsky, D.S. (1994) Immunol. Allergy Clin. North Am. 14,371-385. 
136 
Pisetsky, D.S. (19%) J. Immunol. 156,421-423. 
Pisetsky, D.S. (1997) Methods 11,55-61. 
Pisetsky, D.S. and Drayton. DM. (1997) Proc. Assoc. Am. Physicians(U.S.A.) 109.237-244. 
Pisetsky. D.S.. Gnidier. J.P andGilkeson. G.S. (1990) Arthritis Rheum. $5. 153-159. 
Pisetsky. D.S.. Hoch. SO.. Klatt. C.L.. O'Demiel. MA. and Keene. J.D. (1985) J. Immunol 
150. 1579-1590. 
Plescia. O. Braun. W. and Palczuk. N. (1964) Proc. Natl. Acad. Sci. (U.S.A.) 52. 279-285 
Privalle. C.T., Keng. T., Gilkeson. G.S. and Weinberg. J.B. (1996) In: The Biology ofNkric Oxide 
Vol.5. Stamler, J., Gross, S.S. andMoucada, S. (Eds. ), Portland Press, London. 
Pryor. W.A., Dooley, MM. and Church, D.F. (1985)Chemico-Biol. Interact. 54, 171-183. 
Pryor. W.A.. Jin. X. and Squadrito. G.L. (T994) Proc. Natl. Acad. Sci.(U.S.A.) 91. 1173-1177 
Pryor. W.A., Saigo. M.G, Stone, K.. Squadrito, G.L. and Battista. JR. (1995) Biochem. Biophys 
Res. Commun. 210, 1025-1030. 
Puttermann, C . Lunpanasithikul. W., Edelman. M. and Diamond, B. (1996) J. Clin. Invest. 97. 
2251-2259. 
Radi. R., Beckman. J.S., Bush, K. M. and Freeman, B.A. (1991) Arch. Biochem. Biophys 288. 
481-487. 
Radomski. M.W.. Palmer, R. M. and Moncada, S. (1987a) Biochem. Biophys. Res. Commun 
148, 1482-1489. 
Radomski, M.W.. Palmer, R.M. and Moncada, S. (1987b) Lancet 2. 1057-1058. 
Radomski, M.W., Palmer, R.M. and Moncada, S. (1987c) Br. J. Pharmacol. 92, 639-646. 
Radomski, M.W., Palmer, R.M. and Mancada, S. (1990a) Proc. Natl. Acad. Sci. (U.S.A.) 87. 
5193-5197. 
Radomski, M.W., Palmer, R.M. and Moncada. S. (1990b) Br. J. Pharmacol. 101, 325-328. 
Rait, D., Wishnok, J.S., Fitts, R. and Tannenbaum, S.R. (1988) J. Bacteriol. 170,359. 
Ramotar, D. and Demple, B. (1993) In: DNA and Free Radicals, HalliweU, B. and Aruoma, O.I. 
(Eds.), Harwood Academic Publishers, Chichester. 
Rand, M.J. (1992) Clin. Exp. Phamacol. Physiol. 19, 147-169. 
Rauch, J , Massicotte, H. and Tannenbaum, H. (1985) J. Immunol. 134, 180-186. 
Rauch, J., Tannenbaum, R, Stollar, B.D. and Schwartz. RS. (1984) Eur. J. Immunol. 14, 529-534 
Rekvig, OR, Fredriksen, K., Hokland, K., Moeus, U., Travik, T, Krishnan, M l and Mario, T 
(1995) Scand. J. Immnol. 41, 593-602. 
Ribeiro, M.O., Aotunes, E., deNucci, G.. Lovisolo, G.M. andZatz. R (1992) Hypertension 20. 
137 
298-303. 
Rich. A. (1958) Biochim. Biophys. Acta 29, 502-509. 
Rich, D , Nordheim. A. and Wang, A.J.H. (1984) Aiinu. Rev. Biochem. 53. 791-846. 
Richard. V. Berdeaux. A.. La Rochelle. CD. and Giudicelh. J.F. (1991) Br. J. Pharmacol. 104. 
59-64. 
Robbins, W.C.. Helmann. H.R.. Deicher. H. and Kimkel. H.G. (1957) Proc. Soc. Mol. Med. 96. 
• 575-579. 
Robertson. C.R.. Gilkeson. G.S., Ward. MM. and Pisetsky. D.S. (1992) Clin. Immunol, 
luimunopatliol. 62. 25-32 
Rockett. K.A.. Awbuni. MM.. Aggarwal. B. B., Covvden. W. B. and Clark, L A (1992) Infect 
Immun. 60. 3725-3730. 
Rockett, K.A.. Awbuni, M.A., Rockett. E.J.. Cowdeu. W.B. and Clark. I.A. (1994) Parasite 
Immunology 16. 243-249 
Rose, E. and Pittsbury, D.M. (1994) Ann. Int. Med. 21. 1022-1034. 
Routledge. M.N.. Wink. DA.. Keefer. L.K. aud Dipple. A. (1993) Carcinogenesis 14. 125 I-
1254. 
Routledge. M.N.. Wink. DA.. Keefer. L.K. and Dipple, A. (1994) Chem. Res. Toxicol. 7. 628-
632. 
Saenger, W. (1984) Priuciples of Nucleic Acid Structure, pp. 315-320. Spriuger-Verlag, New 
York. 
Safifrey. M.J.. Hassall. C.J.. Hoyle. C.R. BelaL A. Moss. J. aud Schmidt. R R (1992)Neuroreport 
. J J J - J J 6 . 
Sagawa. A. (1992) Hikkaido Igaku Zasshi (Japan) 67,67-80. 
Sahrbacher. U.C.. Lechner, F. Eugster. R P , FreL K.. Lassmaou, R aud Foutana, A. (1998) Eur. 
J. Lmmuuol. 28. 1332-1338. 
Sakurai, R , Kohsaka. R , Liu., M.F., Higasbiyama, R , Rirata, Y, Kanno. K.. Saito, I. and 
Miyasaka, N. (1995) J. Cliu. Invest. 96, 2357-2363. 
Sandau, K., Pfeilschifler, J. and Brune, B. (1997) J. ImmimoL 158,4938-4946. 
Sanders, K.M., Ward, S.M., Thombury, K.D., DaLael, R, WestfaH, D.P. and Carl, A. (1992) Jpn. 
. J. Pharmacol. 58, 220-225. 
Sanford, D.G., Kotkow, K.J. aud Stollar, B.D. (1988) Nucleic Acids Res. 16, 10643-10655. 
Sano, R, Imokawa, M., Steinberg, AD. and Morimoto, C. (1983) J. lmmuuol. 130, 187-190. 
Sato, Y, Roman, M„ Tiglie, R, Lee, D., Corr, M., Nguyeu. M., Carsou, D A aud Raz, E. (1996) 
Science 273, 352-354. 
13R 
Satoh, M , Kumar, A., Kanwar, Y.S. and Reeves, W.H. (1995) Proc. Natl Acad. Sci. (U.S.A.) 
21, 10934-10938. 
Schlomchik, M.J., Marshak-Rotbstein, A., Wolfowicz, C.B., Rotlistein, T.L. and Weigert, M.G. 
(1987) Nature 328, 805-811. 
Schneenmann, M., Schoeldon, G., Hoefer, S., Blau, N., Guerrero, I. and Schafrher, A. (1993) J. 
Infect. Dis. 167, 1358-1363. 
Schror, K., Woditsch, I., Strobach, H. and Schroder, H. (1991) Basic Res. Cardiol. 86,117-125. 
Schulz, R., Nava, E. and Moncada, S. (1992)Br. J. Pharmacol. 105, 575-580. 
Schuman, E.M. and Madison, D.V. (1991) Science 254,1503-1506. 
Schwartz, R. S. (1997) Lupus 6,344-345. 
Sqhwartz, R.S. and Stollar, B.D. (1985) J. Clin. Invest. 75,321-327. 
Sehgal, V. and Ah, R. (1990) Ind. J. Med. Res. (B) 92, 158-162. 
Seligmann, M. (1957) C.R. Acad. Sci (Paris) 245.243. 
Sessa. W.C. Harrison, J.K., Barber, CM.. Zeng. D., Durieux. M.E. andD'Angelo, D.D. (1992) 
J. Biol. Chem. 267, 15274-15276. 
Setlow. P. (1992) Mol. Microbiol. 6. 563-567. 
Shapiro, H.S. and Chargaff,E. (1966)Biochemistry 5.3012-3018. 
Sherman, M P , Loro,M.L, Wong, V.Z. andTashkin.D.P.(1991)J. Protozool. 38,234-236. 
Shibuki, K. and Okada, D. (1991) Nature 349, 326-328. 
Shishido, K. and Ando,T. (1974)Biochem. Biophys. Res. Commuii. 59. 1380-1388. 
Shoenfeld, Y. and Isenberg,D. (1989) Immunol. Today 10. 123-126. 
Siney. L. and Lewis. M.J. (1992) Eur. J. Pharmacol. 229, 223-226. 
Singer, B. and Grunberger, D. (1983) In: Molecular Biology ofMutagens and Carcinogens, pp.4748. 
Plenum. New York. 
Slor, H. and Lev.. T. (1973) Biochim. Biophys. Acta 312, 637-644. 
Smith. H. R. and Sternberg, A.D. (1983) Annu. Rev. Immunol. 1. 175-210. 
Sneddon. J.M. and Vane, J.R. (1988) Proc. Natl. Acad. Sci.(U.S.A.) 85. 2800-2804. 
Springall DR.. Riveros-Moreno. V and Buttery. L. (1992) Histochemistry 98.259-266. 
Spronk. P.E., Horst, G., van derGun, B.T., Limburg. P C and Kallenberg. CG. (1996) Clin. Exp 
Immunol. 104. 446-453. 
St. Clair, E.W., Wilkinson, W.E., Lang, T. Sanders. L.. Misukonis, M A . Gilkeson, G.S., Pisetsky. 
139 
D.S., Granger, D.L. and Weinberg, J.B. (1996) J. Exp. Med. 184, 1173-1178. 
Stadler, J., Billiar, T.R., Curran, R.D., Sruehr, D.J., Ochoa. J.B. and Simmons, RL. (1991) Am J 
Physiol. 260, 901-916. 
Stamler, J.S., SingeL D.J. and LoscaLzo, J. (1992) Science 258, 1898-1902. 
Steinberg, A.D. (1992)Cecil Textbook of Medicine, 19th Edition, Wyngaarden, J.B., Smith, L. H. 
Jr. and Benett. J.C. (Eds), pp. 1522-1530. W.B. Saunders, Philadelphia. 
Steinberg, A.D., Gourley, M.F., Klinman, D.M., Tsokos, G.C., Scott, D.E. and Kreig, A.M. (1991) 
Ann. Intern. Med. 115, 548-559. 
Steinberg. A.D.. Krieg, A.M., Gourley, M.F. and Klinman, DM. (1990) Immunol. Rev. 118. 12l>-
1163. 
Steinman, L. (1993) Scientific American 269, 106-115. 
Stevens, R.B., Ansite, J.D., Sutherland, D.F.R., Coulter, C.F, Wotus, C. and Mills, CD. (1994) 
FASEBJ. 8, 771. 
Stollar. B.D. (1973) In: The Antigen. Sela. M. (Ed), pp. 1-85. Academic Press, New York. 
StoUar. B.D. (1975)CRC Crit. Rev. Biochem. 3,45-69. 
Stollar, B.D. (1979) Trends Biochem Sci. 4, 5. 
Stollar. B.D. (1981) Anti DNA Antibodies, Clinics in Immunology and Allergy. 1,243-260. 
Stollar, B.D. (1986) CRC Crit. Rev. Biochem. 20, 1-36. 
Stollar, B.D. (1989) Intern. Rev. Immunol. 5, 1-22. 
StoUar. B.D.. Zon, G. and Paster, RW. (1986) Proc. Natl. Acad. Sci. (USA) 83, 4469-4473 
Suarez-Pinzon, W.L., Strynadka, K, Schulz, R. and Rabinovhch, A. (1994)Endrocrinology 134. 
1006-1010. 
Sugiura, Y. and Matsumoto,T. (1995)Biochem. Biophys.Res.Commun. 211, 748-753. 
Sundquist, W.I., Lippard, S.J. and StoUar, B.D. (1987) Proc. Natl Acad. Sci. (U.S.A.) 84, 8225-
8229. 
Suzuki, N.,Mihara,S. and Sakane, T. (1997) FASEB. J. 11, 1033-1038. 
Swanson, P C , Yung, R.L., Blatt, N.B., Eagan, M.A., Richardson, B.C., Johson, K.J. and Glick, 
G.D.(1996)J. Clin. Invest. 97, 1748-1760. 
Szabo, C. (1996) Free Radic. Biol. Med. 21, 855-869. 
Tajiri, T, Maki, H. and Sekiguchi, M. (1995) Mutat. Res. 336, 257-267. 
Talal N.( 1989) Clin. Immunol. ImmunopathoL 53,1-3. 
Tamir, S., Derojaswalker, T, Gal, A., WeUer, A.H., Li, X.T., Fox, J.G., Wogan, G.N. and 
140 
Tannenbaum. S.R. (1995) Cancer Res. 55. 4391-4397. 
Tamir. S. and Tannenbaum, S.R (1996) Biochim. Biophys. Acta 1288, 31-36. 
Tan, EM. (1985) Aitliritis and Allied Conditions. McCarty, D.J. (Ed.), Lea and Febiger, Philadelphia 
Tan, E.M. (1989) Adv. Immunol. 44, 93-151. 
Tan, E.M., Carr. R.I., Schur, P.H. and KunkeL H.G. (1966)J. Clin. Invest. 45, 1732-1740. 
Tanaka, K... Gotoh, F., Gomi. S.. Takashima, S., Mihara, B. and Shirai. (1991) Neurosci. Lett 
127, 129-132. 
Tannenbaum, S.R.. Tamir. S.. Derojas-Walker. T and Wishnok. J.S. (1994) ACS Symp. Ser. 553. 
120-135. 
Taylor-Robinson. A., Phillips. R.S., Steven, A., Moncada, S. and Liew. F.Y. (1993) Science 260. 
1931-1934. 
Tews, D.S. and Goebel. H.H. (1998) Clin. Immunol. Immunopathol. 87,240-247. 
Theofilopoulos, A.N. (1993) In: The Molecular Pathology of Autoimmune Diseases. Bona, C 
Siniinovitca, K.A.. Zanetti. M. and Theofilopoulos, A.N. (Eds.), pp. 1-12. Harwood Academic 
Publishers. Chichester. 
Theofilopoulos, A.N. (1995) Immunol. Today 16, 90-98. 
Theofilopoulos, A.N. and Dixon, F.J. (1985) Adv. Immunol. 37,269-390. 
Thomas. R. (1993) Gene 135, 77-79. 
Thomas, S., Lowe, J.E.. Knowles, R.G., Green, I.C. and Green, M.H.L. (1998) Mutat. Res. 402, 
• 77-84. 
Tiikkainen, U., Wangel, A., Appleton, S.L. and Arthur, D. (1991) Scand. J. Immunol. 34,265-
271. 
Toda, N. and Okamura; T. (1990) Am. J. Physiol. 259, 1511-1517. 
Tottrup,A..Glavind, E.B. and Svane, D. (1992) Gastroenterology 102,409-415. 
Tsujimura, M.. Tokana, Y. Takasaki, Y. and Hashimoto, H. (1997) Nihon Rinsho Meneki Gakkai 
Kaishi20, 8-13 
Tsuzaka, K., Leu. A.K., Frank, M B . , Movafagh, B.F., Kosec, M., Winkler, T.H., Kalden, JR., 
and Reichlin, M. (1996) J. Immunol. 156, 1668-1675. 
Turpaev, K.T., Amchenkova, A.M. andNarovlyansky, AN. (1997)Biochem. Mol. Biol. Int. 41, 
1025-1033. 
Ulfvarson, U., Alexandersson, R., Dahlqvist, M., Ekholm, U. and Bergstrom, B. (1991) Am. J. 
Indust. Med. 19, 283-289. 
Vallance, P., Benjamin, N. and Collier, J. (1992) Eur. J. Clin. Pharmacol. 42, 37-41. 
141 
VaUance. P. and Moncada, S. (1991) Lancet 337, 776-778. 
Vdllance. P. and Moncada, S. (1993) New Horiz. 1, 77-86. 
van Bruggen, M.C., Kramers, C. and Berden, J.H. (1996) Ann. Intern. Med. 147, 485-489. 
Van der Veen. R.C., Hinton. DR.. Incardonna. F. and Hofman. F.M. (1997) J. Neuroimmunol. 77. 
1-7. 
Van Dervort. A.L.. Yan. L., Madara. P.J. Cobb, J.P.. Wesley, R.A.. Corriveau. C.C.. Tropea. 
MM. and Danner. R.L. (1994) J. Immunol. 152,4102-4109. 
Vander-Vliet. A.. Smith, D., O'Neill, C.A., Kaur, K, Darley-Usmar, V and Cross. C.E. (1994) 
Biochem. J. 303. 295-301. 
Varela. A.F.. Runge. A.. Ignarro, L.J. and Chaudhuri, G. (1992) Am. J. Obstet Gynecol. 167 
1599-1604. 
Veuturi. CM.. Knowles. R.G.. Palmer, R.M.J, and Moncada. S. (1991) Biochem. Biophys. Res 
Commun. 180.920-925. 
Viereck. R.A.. Murad, E., Green, B.D., Joshi, P., Pike, C.P, Hieb, R. and Harbaugh, G. (1991) 
Nature 354. 48-50. 
Vincendeau, P. and Daulouede, S. (1991) J. Immunol. 146,4338-4343. 
von Boehmer. H. A. (1994) Am. J. Soc. Nephrol. 2,1345-1354. 
Wallace, D.J., Halm. B.H. and KlippeL J. (1993) In: Lupus Nephritis, Dubois Lupus Erythematosus 
Wallace. D.J. and Halm, B.H. (Eds), Lea Febiger, Philadelphia. 
Wang, J. Koraaror, P.. Sies H. and De Groot, H. (1991) Biochem J. 279,311-314. 
Watson. J.D. and Crick, F.H.C. (1953) Nature 171,737-738. 
Weetruan, A.P and Borysiewicz, L.K. (1990) Autoimmunity 5,277-292. 
Weinberg, J.B.. Granger, D.L., Pisestsky. D.S., Seldin, M.A., Misukonis. M.S., Mason, A.M.. 
Pippen, P., Ruiz. P., Wood, E.R. and Gilkeson, G.S. (1994) J. Exp. Med. 179,651-660. 
Welsh, W. and Sandler, S. (1992) Biochem. Biophys. Res. Commun. 182,333-340. 
Wennmalm, A.. Lanne,B. andPetersson, A.S.( 1990) Anal. Biochem. 187,359-363. 
White. K.A. and Marietta, M A (1992) Biochemistry 31,6627-6631. 
Wigand, R., Meyer, J., Busse, R. and Hecker, M. (1997) Ann. Rheum. Dis. 56, 330-332. 
Wink, D.A. Feelisch, M.. Fukoto, J., Chistodoulou, D., Jourd'heuU, D., Grishani MB., Vodovotz 
Y. Cook. J.A., Krishna, M., DeGraff, W.G., Kim, S., Gamson, J. and Mitchell, IB . (1998a) 
Arch. Biochem. Biophys. 351,66-74. 
Wink, D.A. and Ford, PC. (1995) Methods 7, 14-20. 
Wink, D.A. and Laval, J. (1994) Carcinogenesis 15,2125-2129. 
142 
Wink. DA.. Vodovotz. Y, Laval. J.. Laval. F, Dewhirst. M.W. and Mitchell. J.B. (1998b) 
Carcinogenesis 19. 711-721. 
Winlavv. D.S.. Smythe. G.A., Keogh. A.M., Schyvens, C.G.. Spratt. P.M. and Macdonald, PS 
(1994) Lancet 344, 373-374. 
Wong. A.L..Stempnaik,M„ French. C. andWeisbart, R.H. (1995) J. Immunol. 154. 1987-1994 
Woolfsou. R G . Qasim. F.J., Tliiru. S., Oliveiia, D.B.G.. Neild. G.H. and Matlueson P.W. (1995) 
Biochem. Biophys. Res. Cornmun. 217. 515-521. 
Worrall. J.G.. Snaith, M.L.,Batchelor. JR. and Isenberg. DA. (1990) Quart. J.Med. 74,319. 
Xie. Q.W.. Cho. H.J.. Calaycay J.. Mumford. RA., SwidereL K.M. and Lee. T.D. (1992) Science 
256, 225-228. 
Yamakado. T.. Nishkawa. M. and Hidaka, H. (1982)Thromb. Res. 26. 135-140. 
Yamasaki. H.. Pulkrabek, P., Grunberger, D. and Weinstein, IB. (1977) Cancer Res. 37, 3756-
3760. 
Yanase, K.. Smith, R.M.. Cizman. B.. Foster, M.H., Peachey. L.D.. Jarett, L. and Madaio, M.P 
(1994) Lab. Invest. 71, 52-60. 
Yoshie, Y. and Ohshima, H. (1997)Chem Res. Toxicol 10, 1015-1022. 
Young. H.M., Fumess, J.B., Shuttleworth. C.W., Bredt, D.S. and Snyder, S.H (1992) Histochemistry 
. 97. 375-378. 
Yukimura. T. Yamasliita. Y. Miura. K... Okumura, M., Yamanaku S. and Yamamoto. K_( 1992) 
Am. J. Hypertetis. 5,484-487. 
Zack, D.J.. Yamamoto, K., Wong, A.L., Stempnick, M., Frend, C. and Weisbart, R.H. (1995) J 
Immunol. 154. 1987-1994. 
Zarling, D.A., Arndt-Jovin, D.J., Robert-Nicoud, M., Mcintosh, L.P., Tliomae. R. and Jovin, T.M 
(1984) J. Mol. Biol. 176,369-415. 
Zettl U.K., Mix, E., Zielasek, J., StangeL M, Harling, H. and Gold, R. (1997) CelL ImmunoL 178, 
1-8. 
Zhang, J. Dawson, V.L. and Snyder, S.H. (1994) Science 263, 687-689. 
Zhao, W.. Tilton, RG., CorbelL J.A., McDanieL M.C., Misko, LP., Wilhamson, JR., Cross, A.H. 
and Hickey, W.F. (1996) J. NeuroimmunoL 64, 123-133. 
Zielasek, J.. Tauseh, M., Toyka, K.V. and Hartung, H.R (1992) CeU. Immunol. 141, 111-120. 
Zingarelli, B., Squadrito, F, Altavilla, D., Calapai, G., Campo, G.M., Calo, M., Saitta, M. and 
Caputi, A.P. (1992) J. Cardiovasc. Pharmcol. 19,982-986. 
Zouali, M. (1992) Immunol. Rev. 128, 73-99. 
Zouali, M., Jefferies, R. and Eyguem, A. (1984) Immunology 51,595-600. 
